Therapy of CF-Patients with Amitriptyline and Placebo Placebo-Controlled Phase IIb Multicenter, Cohort-Study

Cellular Physiology and Biochemistry

31, 505-512

DOI: 10.1159/000350071

Citation Report

#	Article	IF	Citations
1	Multiple forms of casein kinase from rabbit erythrocytes. Biochimica Et Biophysica Acta - Biomembranes, 1975, 410, 87-98.	1.4	59
2	Cystic fibrosis: after the gene.. Journal of Medical Genetics, 1989, 26, 737-738.	1.5	0
3	The cystic fibrosis gene.. Archives of Disease in Childhood, 1989, 64, 1647-1648.	1.0	4
5	Polymerase chain reaction. Journal of Clinical Immunology, 1989, 9, 437-447.	2.0	68
6	Screening for carriers of cystic fibrosis among partners of people heterozygous for the disease.. BMJ: British Medical Journal, 1990, 301, 1081-1081.	2.4	2
7	Identification of the cystic fibrosis gene.. BMJ: British Medical Journal, 1990, 300, 345-346.	2.4	118
8	Biochemical neonatal screening.. BMJ: British Medical Journal, 1990, 300, 1667-1668.	2.4	2
9	Additional polymorphisms at marker loci D9S5 and D9S15 generate extended haplotypes in linkage disequilibrium with Friedreich ataxia.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 1796-1800.	3.3	59
10	Meiotic recombination between yeast artificial chromosomes yields a single clone containing the entire BCL2 protooncogene.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 9913-9917.	3.3	42
11	Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 1968-1972.	3.3	291
12	Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2264-2268.	3.3	1,400
13	Dual modulation of chloride conductance by nucleotides in pancreatic and parotid zymogen granules. Biochemical Journal, 1990, 272, 119-126.	1.7	30
14	Molecular mechanisms of drug resistance. Biochemical Journal, 1990, 272, 281-295.	1.7	273
15	A Genotype-Phenotype Research Strategy for Schizophrenia[*]. Canadian Journal of Psychiatry, 1990, 35, 776-783.	0.9	5
16	Ligand-gated ion channels. Molecular Neurobiology, 1990, 4, 129-169.	1.9	61
17	Common denominators in the etiology and pathology of visceral lesions of cystic fibrosis and Keshan disease. Biological Trace Element Research, 1990, 24, 189-205.	1.9	4
18	Prenatal screening. Journal of General Internal Medicine, 1990, 5, S42-S46.	1.3	1
19	Gradient of distribution in Europe of the major CF mutation and of its associated haplotype. Human Genetics, 1990, 85, 436-445.	1.8	123

#	Article	IF	Citations
20	Three point mutations in the CFTR gene in French cystic fibrosis patients: Identification by denaturing gradient gel electrophoresis. Human Genetics, 1990, 85, 446-449.	1.8	131
21	A 3â€² splice site consensus sequence mutation in the cystic fibrosis gene. Human Genetics, 1990, 85, 450-453.	1.8	63
22	The cystic fibrosis defect approached from different angles â€” new perspectives on the gene, the chloride channel, diagnosis and therapy. European Journal of Pediatrics, 1990, 149, 670-677.	1.3	11
23	Transport systems encoded by bacterial plasmids. Journal of Bioenergetics and Biomembranes, 1990, 22, 493-507.	1.0	41
24	Proton-linked sugar transport systems in bacteria. Journal of Bioenergetics and Biomembranes, 1990, 22, 525-569.	1.0	159
25	Binding protein-dependent transport systems. Journal of Bioenergetics and Biomembranes, 1990, 22, 571-592.	1.0	277
26	Genetic basis of multidrug resistance of tumor cells. Journal of Bioenergetics and Biomembranes, 1990, 22, 593-618.	1.0	129
27	The mechanism of secretion of hemolysin and other polypeptides from Gram-negative bacteria. Journal of Bioenergetics and Biomembranes, 1990, 22, 473-491.	1.0	85
28	Application of the polymerase chain reaction to the diagnosis of human genetic disease. Human Genetics, 1990, 85, 1-8.	1.8	31
29	Patterns of organellar and nuclear inheritance among progeny of two geographically isolated strains of Volvox carteri. Current Genetics, 1990, 18, 141-153.	0.8	66
30	Identification of sequences of chromosome 7 that are expressed in sweat gland epithelial cells. Human Genetics, 1990, 85, 151-6.	1.8	1
31	Localization of the gene for amiloride binding protein on chromosome 7 and RFLP analysis in cystic fibrosis families. Human Genetics, 1990, 85, 587-589.	1.8	13
32	Crossovers within a short DNA sequence indicate a long evolutionary history of the APRT*J mutation. Human Genetics, 1990, 85, 600-4.	1.8	23
33	Studies of RFLP closely linked to the cystic fibrosis locus throughout Europe lead to new considerations in populations genetics. Human Genetics, 1990, 84, 449-54.	1.8	86
34	The major cystic fibrosis mutation in a British population. Human Genetics, 1990, 86, 236-7.	1.8	2
35	Prenatal diagnosis and linkage disequilibrium with cystic fibrosis for markers surrounding D7S8. Human Genetics, 1990, 85, 275-8.	1.8	3
36	DNA sequence analysis of the KM19 locus linked to cystic fibrosis. Human Genetics, 1990, 85, 319-23.	1.8	12
37	The amplified H circle of methotrexate-resistant leishmania tarentolae contains a novel P-glycoprotein gene.. EMBO Journal, 1990, 9, 1027-1033.	3.5	239

#	Article	IF	Citations
38	Protease secretion by Erwinia chrysanthemi: the specific secretion functions are analogous to those of Escherichia coli alpha-haemolysin.. EMBO Journal, 1990, 9, 1375-1382.	3.5	228
39	Genetic analysis of an MDR-like export system: the secretion of colicin V.. EMBO Journal, 1990, 9, 3875-3884.	3.5	214
40	Exon trapping: a genetic screen to identify candidate transcribed sequences in cloned mammalian genomic DNA.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8995-8999.	3.3	192
41	DNA markers near the cystic fibrosis locus: further analysis of the British population.. Journal of Medical Genetics, 1990, 27, 39-41.	1.5	3
42	Haplotyping the human T-cell receptor beta-chain gene complex by use of restriction fragment length polymorphisms.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4823-4827.	3.3	47
43	Molecular characterization and functional expression of the human cardiac gap junction channel.. Journal of Cell Biology, 1990, 111, 589-598.	2.3	203
44	Sequence of a cDNA from theDrosophila melanogaster whitegene. Nucleic Acids Research, 1990, 18, 1633-1633.	6.5	70
45	The genetics of deafness.. Archives of Disease in Childhood, 1990, 65, 1196-1197.	1.0	11
46	A cystic fibrosis pancreatic adenocarcinoma cell line.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4012-4016.	3.3	231
47	Molecular biology and respiratory disease. I– Basic principles.. Thorax, 1990, 45, 52-56.	2.7	0
48	The human genome: a prospect for paediatrics.. Archives of Disease in Childhood, 1990, 65, 457-461.	1.0	6
49	Cystic fibrosis screening and community genetics.. Journal of Medical Genetics, 1990, 27, 475-479.	1.5	41
50	Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8923-8927.	3.3	285
51	Haplotype of multiple polymorphisms resolved by enzymatic amplification of single DNA molecules.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 6296-6300.	3.3	156
52	Regulation of Cl- transport in T84 cell clones expressing a mutant regulatory subunit of cAMP-dependent protein kinase.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8975-8979.	3.3	34
53	A child, homozygous for a stop codon in exon 11, shows milder cystic fibrosis symptoms than her heterozygous nephew. Journal of Medical Genetics, 1990, 27, 717-719.	1.5	44
54	Derivation of clones from the choroideremia locus by preparative field inversion gel electrophoresis. Nucleic Acids Research, 1990, 18, 725-731.	6.5	19
55	Isolation of cDNA clones using yeast artificial chromosome probes. Nucleic Acids Research, 1990, 18, 3913-3917.	6.5	95

#	Article	IF	Citations
56	Approaches to localizing disease genes as applied to cystic fibrosis. Nucleic Acids Research, 1990, 18, 345-350.	6.5	24
57	Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 9188-9192.	3.3	648
58	Aetiology and Pathophysiology of Chronic Liver Disorders. Drugs, 1990, 40, 3-22.	4.9	20
59	Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8447-8451.	3.3	417
60	Pancreatic function and gene deletion F508 in cystic fibrosis.. Journal of Medical Genetics, 1990, 27, 665-669.	1.5	46
61	Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium. British Journal of Pharmacology, 1991, 103, 1649-1656.	2.7	290
62	Ion transport in cultured epithelia from human sweat glands: comparison of normal and cystic fibrosis tissues. British Journal of Pharmacology, 1991, 102, 57-64.	2.7	14
63	Isolation of molecular markers from specific chromosomal intervals using DNA pools from existing mapping populations. Nucleic Acids Research, 1991, 19, 6553-6568.	6.5	381
64	cDNA selection: efficient PCR approach for the selection of cDNAs encoded in large chromosomal DNA fragments.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 9623-9627.	3.3	236
65	A P-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole.. Journal of Cell Biology, 1991, 113, 1033-1042.	2.3	275
66	Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Research, 1991, 19, 5417-5423.	6.5	168
67	Amino acid substitution matrices from an information theoretic perspective. Journal of Molecular Biology, 1991, 219, 555-565.	2.0	538
68	Therapeutic Flexibility in the Post Disaster Response. Journal of the Royal Society of Medicine, 1991, 84, 2-3.	1.1	11
69	Mutational analysis of the yeast a-factor transporter STE6, a member of the ATP binding cassette (ABC) protein superfamily.. EMBO Journal, 1991, 10, 3777-3785.	3.5	177
70	Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium.. EMBO Journal, 1991, 10, 1355-1363.	3.5	126
71	Energetically distinct early and late stages of HlyB/HlyD-dependent secretion across both Escherichia coli membranes.. EMBO Journal, 1991, 10, 3263-3272.	3.5	97
72	Genetic transformation in Streptococcus pneumoniae: nucleotide sequence analysis shows comA, a gene required for competence induction, to be a member of the bacterial ATP-dependent transport protein family. Journal of Bacteriology, 1991, 173, 372-381.	1.0	162
73	Functional complementation between bacterial MDR-like export systems: colicin V, alpha-hemolysin, and Erwinia protease. Journal of Bacteriology, 1991, 173, 7549-7556.	1.0	78

#	Article	IF	Citations
74	Frequency of carriers of cystic fibrosis gene among patients with myeloid malignancy and melanoma.. BMJ: British Medical Journal, 1991, 302, 760-761.	2.4	20
75	Genetics and lung disease.. BMJ: British Medical Journal, 1991, 302, 1222-1223.	2.4	5
76	Screening for carriers of cystic fibrosis through primary health care services.. BMJ: British Medical Journal, 1991, 303, 504-507.	2.4	135
77	Antisense oligodeoxynucleotide to the cystic fibrosis gene inhibits anion transport in normal cultured sweat duct cells.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7759-7762.	3.3	27
78	Calcium and cAMP activate different chloride channels in the apical membrane of normal and cystic fibrosis epithelia.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 6003-6007.	3.3	373
79	cAMP-inducible chloride conductance in mouse fibroblast lines stably expressing the human cystic fibrosis transmembrane conductance regulator.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7500-7504.	3.3	106
80	Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 8725-8729.	3.3	226
81	Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 10094-10098.	3.3	164
82	Reconstitution of tracheal grafts with a genetically modified epithelium.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 11192-11196.	3.3	64
83	Locating protein-coding regions in human DNA sequences by a multiple sensor-neural network approach.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 11261-11265.	3.3	623
84	Identification of two genes, kpsM and kpsT, in region 3 of the polysialic acid gene cluster of Escherichia coli K1. Journal of Bacteriology, 1991, 173, 4603-4610.	1.0	116
85	Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.. BMJ: British Medical Journal, 1991, 302, 1237-1240.	2.4	71
86	Structure of two sulphated oligosaccharides from respiratory mucins of a patient suffering from cystic fibrosis. A fast-atom-bombardment m.s. and 1H-n.m.r. spectroscopic study. Biochemical Journal, 1991, 275, 199-206.	1.7	51
87	Mucus glycoproteins from cystic fibrotic sputum. Macromolecular properties and structural â€˜architectureâ€™. Biochemical Journal, 1991, 276, 667-675.	1.7	69
88	Effects of media buffer systems on growth and electrophysiologic characteristics of cultured sweat duct cells. In Vitro Cellular & Developmental Biology, 1991, 27, 47-54.	1.0	21
89	Cystic fibrosis and control nasal epithelial cells harvested by a brushing procedure. In Vitro Cellular & Developmental Biology, 1991, 27, 684-686.	1.0	29
90	Chromosome-specific recombinant DNA libraries from the fungusAspergillus nidulans. Nucleic Acids Research, 1991, 19, 3105-3109.	6.5	231
91	Disease resistance in farm animals. Experientia, 1991, 47, 923-934.	1.2	51

#	Article	IF	Citations
92	Small-intestinal abnormalities in cystic fibrosis patients. European Journal of Pediatrics, 1991, 150, 824-828.	1.3	43
94	Sequence analysis of the cystic fibrosis gene in patients with disseminated bronchiectatic lung disease. Klinische Wochenschrift, 1991, 69, 657-663.	0.6	25
95	Glutathione and inflammatory disorders of the lung. Lung, 1991, 169, 123-138.	1.4	81
96	DNA-and classical genetic markers in schizophrenia. European Archives of Psychiatry and Neurological Sciences, 1991, 240, 197-203.	0.9	12
97	Reliability of gender determination using the polymerase chain reaction (PCR) for single cells. Journal of in Vitro Fertilization and Embryo Transfer: IVF, 1991, 8, 225-229.	0.8	42
98	Iron(III) hydroxamate transport across the cytoplasmic membrane ofEscherichia coli. Biology of Metals, 1991, 4, 23-32.	1.1	52
99	Frequency of the F508 deletion in cystic fibrosis patients from the European part of the USSR. Human Genetics, 1991, 87, 61-64.	1.8	9
100	Localisation of the myotonic dystrophy locus to 19q13.2?19q13.3 and its relationship to twelve polymorphic loci on 19q. Human Genetics, 1991, 87, 73-80.	1.8	34
101	Inhibition of epithelial chloride channels by cytosol. Pflugers Archiv European Journal of Physiology, 1991, 418, 479-490.	1.3	58
102	Evidence for a cytosolic inhibitor of epithelial chloride channels. Pflugers Archiv European Journal of Physiology, 1991, 418, 491-499.	1.3	44
103	The adenylyl cyclase family. Molecular and Cellular Biochemistry, 1991, 104, 73-9.	1.4	50
104	Construction of physical maps of the Hor1 locus of two barley cultivars by pulsed field gel electrophoresis. Molecular Genetics and Genomics, 1991, 226-226, 177-181.	2.4	32
105	Acid phosphatase-11, a tightly linked molecular marker for root-knot nematode resistance in tomato: from protein to gene, using PCR and degenerate primers containing deoxyinosine. Plant Molecular Biology, 1991, 16, 647-661.	2.0	47
106	Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Human Genetics, 1991, 86, 425-41.	1.8	438
107	The human aldose reductase gene maps to chromosome region 7q35. Human Genetics, 1991, 86, 509-14.	1.8	40
108	Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene. Human Genetics, 1991, 87, 441-6.	1.8	97
109	Discrimination between recurrent mutation and identity by descent: application to point mutations in exon 11 of the cystic fibrosis (CFTR) gene. Human Genetics, 1991, 87, 457-61.	1.8	25
110	Molecular analysis of cystic fibrosis in the Hungarian population. Human Genetics, 1991, 87, 511-2.	1.8	5

#	Article	IF	Citations
111	The ?F508 mutation and RFLP-linked loci in Spanish cystic fibrosis families. Human Genetics, 1991, 87, 516-7.	1.8	1
112	A tetranucleotide repeat polymorphism in the cystic fibrosis gene. Human Genetics, 1991, 86, 625.	1.8	35
113	Cystic fibrosis allele frequency, sex ratio anomalies and fertility: a new theory for the dissemination of mutant alleles. Human Genetics, 1991, 87, 671-6.	1.8	13
114	Analysis of 14 cystic fibrosis mutations in five South European populations. Human Genetics, 1991, 87, 737-8.	1.8	52
115	Frequency of the cystic fibrosis mutation ?F508 in Algeria. Human Genetics, 1991, 87, 759.	1.8	2
116	Identification of a cystic fibros is mutation: deletion of isoleucine506. Human Genetics, 1991, 86, 391-3.	1.8	8
117	A pooling strategy for heterozygote screening of the ?F508 cystic fibrosis mutation. Human Genetics, 1991, 86, 289-91.	1.8	14
118	Frequency of the cystic fibrosis mutation ?F508 in Poland. Human Genetics, 1991, 86, 329.	1.8	4
119	Methods for analysis of multiple cystic fibrosis mutations. Human Genetics, 1991, 87, 613-7.	1.8	45
120	Molecular mapping of obesity genes. Mammalian Genome, 1991, 1, 130-144.	1.0	65
121	A Hinfl polymorphism in the cystic fibrosis gene CFTR. Nucleic Acids Research, 1991, 19, 2517-2517.	6.5	17
122	Mspl restriction fragment length polymorphism near exon 10 of cystic fibrosis (CFTR) gene. Nucleic Acids Research, 1991, 19, 1719-1719.	6.5	0
123	Cystic fibrosis. 7. Management of cystic fibrosis in different countries. Cystic fibrosis in Copenhagen.. Thorax, 1991, 46, 385-390.	2.7	6
124	Direct PCR from CVS and blood lysates for detection of cystic fibrosis and Duchenne muscular dystrophy deletions. Nucleic Acids Research, 1991, 19, 1155-1155.	6.5	35
125	A cystic fibrosis patient with the nonsense mutation G542X and the splice site mutation 1717-1.. Journal of Medical Genetics, 1991, 28, 878-880.	1.5	8
126	Failure of cholinergic stimulation to induce a secretory response from the rectal mucosa in cystic fibrosis.. Gut, 1991, 32, 1035-1039.	6.1	42
127	The incidence of different cystic fibrosis mutations in the Scottish population: effects on prenatal diagnosis and genetic counselling.. Journal of Medical Genetics, 1991, 28, 317-321.	1.5	40
128	Cystic fibrosis. 6. Gastrointestinal and nutritional aspects.. Thorax, 1991, 46, 261-267.	2.7	21

#	Article	IF	Citations
129	Genetic analysis in cystic fibrosis using the amplification refractory mutation system (ARMS): the J3.11 MspI polymorphism.. Journal of Medical Genetics, 1991, 28, 248-251.	1.5	6
130	Medical genetics.. Postgraduate Medical Journal, 1991, 67, 613-631.	0.9	1
131	Leukaemia mortality among relatives of cystic fibrosis patients.. Archives of Disease in Childhood, 1991, 66, 317-319.	1.0	1
132	A fertile male with cystic fibrosis: molecular genetic analysis.. Journal of Medical Genetics, 1991, 28, 420-421.	1.5	23
133	Association of less common cystic fibrosis mutations with a mild phenotype.. Journal of Medical Genetics, 1991, 28, 34-37.	1.5	18
134	Cystic fibrosis: current survival and population estimates to the year 2000.. Thorax, 1991, 46, 881-885.	2.7	322
135	Exon amplification: a strategy to isolate mammalian genes based on RNA splicing.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 4005-4009.	3.3	448
136	Measurement of intracellular mediators in enterocytes isolated from jejunal biopsy specimens of control and cystic fibrosis patients.. Gut, 1991, 32, 893-899.	6.1	15
137	Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening.. Archives of Disease in Childhood, 1991, 66, 29-33.	1.0	152
138	Cystic fibrosis. 3. Cloning the cystic fibrosis gene: implications for diagnosis and treatment.. Thorax, 1991, 46, 46-55.	2.7	4
139	What do young people think about screening for cystic fibrosis?. Journal of Medical Genetics, 1991, 28, 322-324.	1.5	26
140	Identification of markers linked to disease-resistance genes by bulked segregant analysis: a rapid method to detect markers in specific genomic regions by using segregating populations.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 9828-9832.	3.3	4,074
141	A simple technique for generating probes for RNA in situ hybridization: an adjunct to genome mapping exemplified by the RAG-1/RAG-2 gene cluster.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 3927-3931.	3.3	29
142	Molecular basis of galactosemia: mutations and polymorphisms in the gene encoding human galactose-1-phosphate uridylyltransferase.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2633-2637.	3.3	106
143	Rapid identification of markers linked to a Pseudomonas resistance gene in tomato by using random primers and near-isogenic lines.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2336-2340.	3.3	437
144	New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up.. Archives of Disease in Childhood, 1991, 66, 1339-1345.	1.0	99
145	Single nucleotide primer extension to detect genetic diseases: experimental application to hemophilia B (factor IX) and cystic fibrosis genes.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 1143-1147.	3.3	172
146	A genetic study of neurofibromatosis 1 in south-western Ontario. I. Population, familial segregation of phenotype, and molecular linkage.. Journal of Medical Genetics, 1991, 28, 746-751.	1.5	9

#	Article	IF	Citations
147	Immunocytochemical localization of the cystic fibrosis gene product CFTR.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 9262-9266.	3.3	431
148	Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 6565-6569.	3.3	224
149	Cystic fibrosis. 4. Abnormalities of airway epithelial function and the implications of the discovery of the cystic fibrosis gene.. Thorax, 1991, 46, 124-130.	2.7	11
150	Polygenic susceptibility in rheumatoid arthritis.. Annals of the Rheumatic Diseases, 1991, 50, 343-346.	0.5	124
151	Mutation and linkage disequilibrium analysis in genetic counselling of Spanish cystic fibrosis families.. Journal of Medical Genetics, 1991, 28, 771-776.	1.5	11
152	Lymphocyte mRNA as a resource for detection of mutations and polymorphisms in the CF gene.. Journal of Medical Genetics, 1991, 28, 777-780.	1.5	39
153	A cystic fibrosis patient who is homozygous for the G85E mutation has very mild disease.. Journal of Medical Genetics, 1991, 28, 875-877.	1.5	16
154	Cystic fibrosis gene expression is not correlated with rectifying Cl- channels.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5277-5281.	3.3	58
155	SSCP-polymorphism in intron 12 of the CFTR gene recognized by Bcll. Nucleic Acids Research, 1991, 19, 6343-6343.	6.5	14
156	Rescue of end fragments of yeast artificial chromosomes by homologous recombination in yeast. Nucleic Acids Research, 1991, 19, 4943-4948.	6.5	59
157	A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7289-7293.	3.3	201
158	Direct selection: a method for the isolation of cDNAs encoded by large genomic regions.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 9628-9632.	3.3	302
159	A cystic fibrosis patient homozygous for the nonsense mutation R553X.. Journal of Medical Genetics, 1991, 28, 715-717.	1.5	21
160	Intracellular pH and its relationship to regulation of ion transport in normal and cystic fibrosis human nasal epithelia.. Journal of Physiology, 1992, 455, 247-269.	1.3	35
161	Targeted integration of neomycin into yeast artificial chromosomes (YACs) for transfection into mammalian cells. Nucleic Acids Research, 1992, 20, 2971-2976.	6.5	26
162	Genetic and clinical studies in autosomal dominant polycystic kidney disease type 1 (ADPKD1).. Journal of Medical Genetics, 1992, 29, 243-246.	1.5	10
163	A mutation in exon 7 of the CFTR gene is common in the western part of France.. Journal of Medical Genetics, 1992, 29, 679-679.	1.5	3
164	UK clinicians' knowledge of and attitudes to the prenatal diagnosis of single gene disorders.. Journal of Medical Genetics, 1992, 29, 20-23.	1.5	29

#	Article	IF	Citations
165	Molecular biology in medicine.. Postgraduate Medical Journal, 1992, 68, 251-262.	0.9	1
166	Effects of genetic screening on perceptions of health: a pilot study.. Journal of Medical Genetics, 1992, 29, 24-26.	1.5	86
167	Sequence specific generation of a DNA panhardle permits PCR amplication of unknown flanking DNA. Nucleic Acids Research, 1992, 20, 595-600.	6.5	98
168	Severity of chest disease in cystic fibrosis patients in relation to their genotypes.. Journal of Medical Genetics, 1992, 29, 883-887.	1.5	21
169	Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4564-4568.	3.3	137
170	Cystic fibrosis mutations delta F508 and G542X in Jewish patients.. Journal of Medical Genetics, 1992, 29, 131-133.	1.5	13
171	Nine cystic fibrosis patients homozygous for the CFTR nonsense mutation R1162X have mild or moderate lung disease.. Journal of Medical Genetics, 1992, 29, 558-562.	1.5	37
172	Cystic fibrosis in a 70 year old woman.. Thorax, 1992, 47, 202-203.	2.7	11
173	The molecular revolution--coming your way soon.. Gut, 1992, 33, 1-3.	6.1	25
174	Evidence for linkage disequilibrium between D16S94 and the adult onset polycystic kidney disease (PKD1) gene.. Journal of Medical Genetics, 1992, 29, 247-248.	1.5	13
175	Principles and practicalities of carrier screening: attitudes of recent parents.. Journal of Medical Genetics, 1992, 29, 313-319.	1.5	40
176	Expression of the human cystic fibrosis transmembrane conductance regulator gene in the mouse lung afterin vivointratracheal plasmid-mediated gene transfer. Nucleic Acids Research, 1992, 20, 3233-3240.	6.5	181
177	Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia.. Journal of Cell Biology, 1992, 118, 551-559.	2.3	175
178	Cloning and characterization of a sixth adenylyl cyclase isoform: types V and VI constitute a subgroup within the mammalian adenylyl cyclase family.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 8774-8778.	3.3	209
179	Mutation analysis of 184 cystic fibrosis families in Wales.. Journal of Medical Genetics, 1992, 29, 642-646.	1.5	9
180	Intrinsic anion channel activity of the recombinant first nucleotide binding fold domain of the cystic fibrosis transmembrane regulator protein.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 1539-1543.	3.3	66
181	Linkage investigation of three putative tuberous sclerosis determining loci on chromosomes 9q, 11q, and 12q. The Tuberous Sclerosis Collaborative Group.. Journal of Medical Genetics, 1992, 29, 861-866.	1.5	28
182	Sequence of the complete cDNA and the 5â€² structure of the human sucrase-isomaltase gene. Possible homology with a yeast glucoamylase. Biochemical Journal, 1992, 285, 915-923.	1.7	77

#	Article	IF	Citations
183	Isolation of a candidate gene for choroideremia.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2135-2139.	3.3	66
184	Attitudes toward genetic testing of Amish, Mennonite, and Hutterite families with cystic fibrosis.. American Journal of Public Health, 1992, 82, 236-242.	1.5	26
185	Antisense oligodeoxynucleotides to the cystic fibrosis transmembrane conductance regulator inhibit cAMP-activated but not calcium-activated chloride currents.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6785-6789.	3.3	71
186	Polymorphism in a second ABC transporter gene located within the class II region of the human major histocompatibility complex.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 1463-1467.	3.3	180
187	Delineation of the dystonia-parkinsonism syndrome locus in Xq13.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 8245-8248.	3.3	53
188	GTP-binding proteins inhibit cAMP activation of chloride channels in cystic fibrosis airway epithelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 10623-10627.	3.3	50
189	Global and local genome mapping in Arabidopsis thaliana by using recombinant inbred lines and random amplified polymorphic DNAs.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 1477-1481.	3.3	381
190	Characterization of the cystic fibrosis transmembrane conductance regulator in a colonocyte cell line.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2340-2344.	3.3	79
191	Management and Survival of Meconium Ileus A 30-year Review. Annals of Surgery, 1992, 215, 179-185.	2.1	68
192	High-resolution mapping of mammalian genes by in situ hybridization to free chromatin.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 9509-9513.	3.3	515
193	Drug Therapy in the 1990s. Drugs, 1992, 43, 431-439.	4.9	18
194	Adenosine receptors on human airway epithelia and their relationship to chloride secretion. British Journal of Pharmacology, 1992, 106, 774-782.	2.7	60
195	The cystic fibrosis transmembrane conductance regulator chloride channel. Iodide block and permeation. Biophysical Journal, 1992, 62, 1-4.	0.2	70
196	Primary structure and functional expression of the Na/Ca,K-exchanger from bovine rod photoreceptors.. EMBO Journal, 1992, 11, 1689-1695.	3.5	182
197	CFTR protein expression in primary and cultured epithelia.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 344-347.	3.3	75
198	Delineation of DNA replication time zones by fluorescence in situ hybridization.. EMBO Journal, 1992, 11, 1217-1225.	3.5	281
199	Regulation of CFTR expression and function during differentiation of intestinal epithelial cells.. EMBO Journal, 1992, 11, 2487-2494.	3.5	65
200	Cystic fibrosis transmembrane conductance regulator (CFTR) gene transcripts.. EMBO Journal, 1992, 11, 379-380.	3.5	1

#	Article	IF	Citations
201	Transfection of wild-type CFTR into cystic fibrosis lymphocytes restores chloride conductance at G1 of the cell cycle.. EMBO Journal, 1992, 11, 875-883.	3.5	40
202	Characterization of immortal cystic fibrosis tracheobronchial gland epithelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 5171-5175.	3.3	85
203	Heavy metal tolerance in the fission yeast requires an ATP-binding cassette-type vacuolar membrane transporter.. EMBO Journal, 1992, 11, 3491-3499.	3.5	358
204	Marfan phenotype variability in a family segregating a missense mutation in the epidermal growth factor-like motif of the fibrillin gene.. Journal of Clinical Investigation, 1992, 89, 1674-1680.	3.9	142
205	Factors affecting chloride conductance in apical membrane vesicles from human placenta. Journal of Membrane Biology, 1992, 130, 227-39.	1.0	13
206	Localised mutagenesis of the fts YEX operon conditionally lethal missense substitutions in the FtsE cell division protein of Escherichia coli are similar to those found in the cystic fibrosis transmembrane conductance regulator protein (CFTR) of human patients. Molecular Genetics and Genomics, 1992, 234, 121-128.	2.4	32
207	Genetic and physical analysis of the rice bacterial blight disease resistance locus, Xa21. Molecular Genetics and Genomics, 1992, 236, 113-120.	2.4	275
208	Correlation of genetic and physical structure in the region surrounding the I 2 Fusarium oxysporum resistance locus in tomato. Molecular Genetics and Genomics, 1992, 231, 179-185.	2.4	80
209	NPPB block of Ca++-activated Cl? currents in Xenopus oocytes. Pflugers Archiv European Journal of Physiology, 1992, 420, 227-229.	1.3	37
210	A mouse genomic library in the bacteriophage P1 cloning system: organization and characterization. Mammalian Genome, 1992, 3, 550-558.	1.0	82
211	Long-range walking techniques in positional cloning strategies. Mammalian Genome, 1992, 3, 127-142.	1.0	15
212	P-glycoprotein expression in brain tumors. Journal of Neuro-Oncology, 1992, 14, 37-43.	1.4	68
213	Molecular aspects of Alport's syndrome. The Clinical Investigator, 1992, 70, 809-15.	0.6	4
214	Frequency of ?F508 and haplotype association in Austrian cystic fibrosis families. Human Genetics, 1992, 89, 437-8.	1.8	7
215	Frequency of ?F508 mutation and haplotype analysis in Austrian cystic fibrosis families. Human Genetics, 1992, 89, 464-5.	1.8	2
216	A point mutation changes the polymorphisms pattern in a cystic fibrosis carrier family. Human Genetics, 1992, 89, 465-6.	1.8	1
217	Genetic analysis of susceptibility to Type 1 diabetes. Seminars in Immunopathology, 1992, 14, 33-58.	4.0	13
218	The immunogenetics of rheumatoid arthritis. Seminars in Immunopathology, 1992, 14, 59-78.	4.0	55

#	Article	IF	Citations
219	Single-strand conformation polymorphism (SSCP) analysis of exon 11 of the CFTR gene reliably detects more than one third of non-?F508 mutations in German cystic fibrosis patients. Human Genetics, 1992, 88, 283-7.	1.8	13
220	Intra- and extragenic marker haplotypes of CFTR mutations in cystic fibrosis families. Human Genetics, 1992, 88, 417-425.	1.8	73
221	Carrier detection and prenatal diagnosis of cystic fibrosis using an intragenic TA-repeat polymorphism. Human Genetics, 1992, 88, 479-481.	1.8	6
222	Detection of multiple cystic fibrosis mutations by reverse dot blot hybridization: a technology for carrier screening. Human Genetics, 1992, 89, 163-8.	1.8	78
223	The occurrence of various non-?F508 CFTR gene mutations among Hungarian cystic fibrosis patients. Human Genetics, 1992, 89, 245-6.	1.8	9
224	CFTR illegitimate transcription in lymphoid cells: quantification and applications to the investigation of pathological transcripts. Human Genetics, 1992, 88, 508-512.	1.8	34
225	Screening for cystic fibrosis gene mutations by multiplex DNA amplification. Human Genetics, 1992, 88, 552-556.	1.8	13
226	The spectrum of CFTR mutations in south-west German cystic fibrosis patients. Human Genetics, 1992, 90, 267-9.	1.8	8
227	A termination mutation (2143delT) in the CFTR gene of German cystic fibrosis patients. Human Genetics, 1992, 90, 279-84.	1.8	15
228	A novel CFTR mutation, 4035delA, detected by non-radioactive SSCP analysis. Human Genetics, 1992, 90, 303-4.	1.8	5
229	Non-radioactive detection of the most common mutations in the cystic fibrosis transmembrane conductance regulator gene by multiplex allele-specific polymerase chain reaction. Human Genetics, 1992, 90, 375-8.	1.8	10
230	Analysis of 30 known cystic fibrosis mutations: 10 mutations account for 27% of non-?F508 chromosomes in Southern France. Human Genetics, 1992, 90, 464-6.	1.8	6
231	A rare DNA variant in exon 15 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Human Genetics, 1992, 90, 474.	1.8	6
232	Deletion Î”F508 and haplotype analysis of CFTR gene region in Slovak CF patients. Human Genetics, 1992, 89, 305-306.	1.8	2
233	Identification of crossovers in Wilson disease families as reference points for a genetic localization of the gene. Human Genetics, 1992, 89, 607-11.	1.8	6
234	Omission of exon 12 in cystic fibrosis transmembrane conductance regulator (CFTR) gene transcripts. Human Genetics, 1992, 89, 615-9.	1.8	37
235	Incidence and expression of the N1303K mutation of the cystic fibrosis (CFTR) gene. Human Genetics, 1992, 89, 653-658.	1.8	69
236	Diagnostic approaches to renal genetic disorders using DNA analysis. Pediatric Nephrology, 1992, 6, 113-118.	0.9	0

#	Article	IF	Citations
237	Construction of a yeast artificial chromosome library of tomato and identification of cloned segments linked to two disease resistance loci. Molecular Genetics and Genomics, 1992, 233, 25-32.	2.4	124
238	Attitudes toward genetic testing for cystic fibrosis among college students. Journal of Genetic Counseling, 1992, 1, 219-226.	0.9	5
239	Mapping quantitative trait loci for behavioral traits in the mouse. Behavior Genetics, 1992, 22, 635-653.	1.4	69
240	A transformed human epithelial cell line that retains tight junctions post crisis. In Vitro Cellular & Developmental Biology, 1992, 28, 735-744.	1.0	92
241	Lung involvement, the Î”F508 mutation and DNA haplotype analysis in cystic fibrosis. Human Genetics, 1992, 88, 639-641.	1.8	6
242	Successful targeting of the mouse cystic fibrosis transmembrane conductance regulator gene in embryonal stem cells. Transgenic Research, 1992, 1, 101-105.	1.3	22
243	Disruption of the cystic fibrosis transmembrane conductance regulator gene in embryonic stem cells by gene targeting. Transgenic Research, 1992, 1, 177-181.	1.3	18
244	Isolation of cDNA sequences around the chromosomal breakpoint in a female with lowe syndrome by direct screening of cDNA libraries with yeast artificial chromosomes. Journal of Inherited Metabolic Disease, 1992, 15, 526-531.	1.7	8
245	Molecular genetics of mineral metabolic disorders. Journal of Inherited Metabolic Disease, 1992, 15, 592-609.	1.7	7
246	Mutations of the cystic fibrosis gene locus within the population of the Northwest of England. European Journal of Pediatrics, 1992, 151, 108-111.	1.3	20
247	Congenital bilateral absence of the vas deferens and cystic fibrosis. World Journal of Urology, 1993, 11, 82-8.	1.2	29
248	HLA-E is the only class I gene that escapes CpG methylation and is transcriptionally active in the trophoblast-derived human cell line JAR. Immunogenetics, 1993, 38, 117-130.	1.2	64
249	CF2603/4delT, a new frameshift mutation in exon 13 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Human Genetics, 1993, 91, 614-5.	1.8	2
250	A novel mutation in exon 3 of the CFTR gene. Human Genetics, 1993, 91, 233-5.	1.8	13
251	Analysis of 160 CF chromosomes: detection of a novel mutation in exon 20. Human Genetics, 1993, 91, 254-256.	1.8	3
252	Cystic fibrosis in Spain: high frequency of mutation G542X in the Mediterranean coastal area. Human Genetics, 1993, 91, 66-70.	1.8	35
253	Two cystic fibrosis patients with the genotype G542X/G551D. Human Genetics, 1993, 91, 78-9.	1.8	2
254	Extended haplotype analysis of cystic fibrosis mutations and its implications for the selective advantage hypothesis. Human Genetics, 1993, 92, 289-95.	1.8	25

#	Article	IF	Citations
255	Construction of a basic genetic map for alfalfa using RFLP, RAPD, isozyme and morphological markers. Molecular Genetics and Genomics, 1993, 238-238, 129-137.	2.4	118
256	Long-range physical maps of two loci (Aps-1 and GP79) flanking the root-knot nematode resistance gene (Mi) near the centromere of tomato chromosome 6. Plant Molecular Biology, 1993, 23, 185-192.	2.0	37
257	Characterisation of volume-activated ion transport across epithelial monolayers of human intestinal T84 cells. Pflugers Archiv European Journal of Physiology, 1993, 423, 213-220.	1.3	12
258	Phosphorylation-regulated low-conductance Cl? channels in a human pancreatic duct cell line. Pflugers Archiv European Journal of Physiology, 1993, 425, 1-8.	1.3	25
259	Synergistic activation of non-rectifying small-conductance chloride channels by forskolin and phorbol esters in cell-attached patches of the human colon carcinoma cell line HT-29cl.19A. Pflugers Archiv European Journal of Physiology, 1993, 425, 100-108.	1.3	33
260	Inactivation of the murine cftr gene abolishes cAMP-mediated but not Ca2+-mediated secretagogue-induced volume decrease in small-intestinal crypts. Pflugers Archiv European Journal of Physiology, 1993, 425, 434-438.	1.3	39
261	Co-expression of an anion conductance pathway with Na+-glucose cotransport in rat renal brush-border membrane vesicles. Pflugers Archiv European Journal of Physiology, 1993, 423, 406-410.	1.3	9
262	Generation of a chromosome-22-specific c-DNA library as confirmed by FISH analysis. Human Genetics, 1993, 92, 623-626.	1.8	8
263	Microdissection of proximal mouse Chromosome 6: identification of RFLPs tightly linked to the ob mutation. Mammalian Genome, 1993, 4, 511-515.	1.0	18
264	Spectrum of mutations in cystic fibrosis. Journal of Bioenergetics and Biomembranes, 1993, 25, 7-10.	1.0	21
265	Effects of the ?F508 mutation on the structure, function, and folding of the first nucleotide-binding domain of CFTR. Journal of Bioenergetics and Biomembranes, 1993, 25, 11-19.	1.0	39
266	CFTR targeting in epithelial cells. Journal of Bioenergetics and Biomembranes, 1993, 25, 21-26.	1.0	6
267	Outwardly rectifying chloride channels and CF: A divorce and remarriage. Journal of Bioenergetics and Biomembranes, 1993, 25, 27-35.	1.0	52
268	Prospects for virus-based gene therapy for cystic fibrosis. Journal of Bioenergetics and Biomembranes, 1993, 25, 37-42.	1.0	36
269	Modes of DAPI banding and simultaneous in situ hybridization. Chromosoma, 1993, 102, 325-332.	1.0	402
270	Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer. Breast Cancer Research and Treatment, 1993, 28, 121-135.	1.1	18
271	Why there is no gene for alcoholism. Behavior Genetics, 1993, 23, 145-151.	1.4	14
272	Sequence and structural homology among membrane-associated domains of CFTR and certain transporter proteins. The Protein Journal, 1993, 12, 279-290.	1.1	20

#	Article	IF	Citations
273	Chronic obstructive pulmonary disease: Less common causes. Journal of General Internal Medicine, 1993, 8, 564-572.	1.3	3
274	Contemporary management of meconium ileus. World Journal of Surgery, 1993, 17, 318-325.	0.8	86
275	Myocardial fibrosis â€" a rare complication in patients with cystic fibrosis. European Journal of Pediatrics, 1993, 152, 694-696.	1.3	19
276	Cystic fibrosis: The Î"F508 mutation does not lead to an exceptionally severe phenotype. A cohort study. European Journal of Pediatrics, 1993, 152, 1006-1011.	1.3	19
277	Mutation analysis in the diagnosis of cystic fibrosis. European Journal of Pediatrics, 1993, 152, 909-911.	1.3	7
278	Gene SNQ2 of Saccharomyces cerevislae, which confers resistance to 4-nitroquinoline-N-oxide and other chemicals, encodes a 169 kDa protein homologous to ATP-dependent permeases. Molecular Genetics and Genomics, 1993, 236-236, 214-218.	2.4	192
279	The human genome project.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 4338-4344.	3.3	84
280	Bridging the gap between anomalous sodium channel molecules and aberrant physiology. Biophysical Journal, 1993, 65, 13-14.	0.2	1
281	CFTR transcripts are undetectable in lymphocytes and respiratory epithelial cells of a CF patient homozygous for the nonsense mutation R553X.. Journal of Medical Genetics, 1993, 30, 833-837.	1.5	17
282	Absence of cystic fibrosis mutations in a large Asian population sample and occurrence of a homozygous S549N mutation in an inbred Pakistani family.. Journal of Medical Genetics, 1993, 30, 164-166.	1.5	22
283	Allelic discrimination by nick-translation PCR with fluorgenic probes. Nucleic Acids Research, 1993, 21, 3761-3766.	6.5	695
284	Gene therapy for cystic fibrosis.. Archives of Disease in Childhood, 1993, 68, 437-440.	1.0	27
285	An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 4601-4605.	3.3	140
286	Genetic risk: women's understanding of carrier risks in Duchenne muscular dystrophy.. Journal of Medical Genetics, 1993, 30, 562-566.	1.5	31
287	Cystic fibrosis identified by neonatal screening: incidence, genotype, and early natural history.. Archives of Disease in Childhood, 1993, 68, 464-467.	1.0	38
288	The production of PCR products with 5â€² single-stranded tails using primers that incorporate novel phosphoramidite intermediates. Nucleic Acids Research, 1993, 21, 1155-1162.	6.5	21
289	Single gene disorders affecting the gastrointestinal tract.. Gut, 1993, 34, 433-436.	6.1	1
290	Functionally distinct phospho-forms underlie incremental activation of protein kinase-regulated Cl- conductance in mammalian heart.. Journal of General Physiology, 1993, 101, 629-650.	0.9	111

#	Article	IF	Citations
291	Frequency of delta F508 in a Mexican sample of cystic fibrosis patients.. Journal of Medical Genetics, 1993, 30, 501-502.	1.5	15
292	Male infertility as the only presenting sign of cystic fibrosis when homozygous for the mild mutation R117H.. Journal of Medical Genetics, 1993, 30, 797-797.	1.5	18
293	Trinitrophenyl-ATP blocks colonic Cl- channels in planar phospholipid bilayers. Evidence for two nucleotide binding sites.. Journal of General Physiology, 1993, 101, 545-569.	0.9	16
294	Cystic fibrosis in Asians.. Archives of Disease in Childhood, 1993, 68, 120-122.	1.0	49
295	The a-factor transporter (STE6 gene product) and cell polarity in the yeast Saccharomyces cerevisiae.. Journal of Cell Biology, 1993, 120, 1203-1215.	2.3	104
296	Resting energy expenditure and substrate oxidation rates in cystic fibrosis.. Archives of Disease in Childhood, 1993, 68, 754-759.	1.0	15
297	Screening for carriers of cystic fibrosis–a general practitioner's perspective.. BMJ: British Medical Journal, 1993, 307, 849-852.	2.4	22
298	Cystic fibrosis carrier testing in early pregnancy by general practitioners.. BMJ: British Medical Journal, 1993, 306, 1580-1583.	2.4	76
299	Uptake of cystic fibrosis testing in primary care: supply push or demand pull?. BMJ: British Medical Journal, 1993, 306, 1584-1586.	2.4	172
300	Independently gated multiple substates of an epithelial chloride-channel protein.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 5691-5694.	3.3	6
301	Recombination walking: genetic selection of clones from pooled libraries of yeast artificial chromosomes by homologous recombination.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 8118-8122.	3.3	2
302	Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 10613-10617.	3.3	480
303	Accessory cholera enterotoxin (Ace), the third toxin of a Vibrio cholerae virulence cassette.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 5267-5271.	3.3	275
304	The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9480-9484.	3.3	332
305	The gene for congenital chloride diarrhea maps close to but is distinct from the gene for cystic fibrosis transmembrane conductance regulator.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 10686-10689.	3.3	40
306	Functional expression of P-glycoprotein encoded by the mouse mdr3 gene in yeast cells.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 11588-11592.	3.3	61
307	Functional roles of the nucleotide-binding folds in the activation of the cystic fibrosis transmembrane conductance regulator.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9963-9967.	3.3	97
308	Molecular genetic analysis of a locus required for resistance to antimicrobial peptides in Salmonella typhimurium.. EMBO Journal, 1993, 12, 4053-4062.	3.5	191

#	Article	IF	Citations
309	The role of airway mucus in pulmonary toxicology.. Environmental Health Perspectives, 1994, 102, 89-103.	2.8	61
310	Requirement for metabolic activation of acetylaminofluorene to induce multidrug gene expression.. Environmental Health Perspectives, 1994, 102, 209-212.	2.8	15
311	A novel exon in the cystic fibrosis transmembrane conductance regulator gene activated by the nonsense mutation E92X in airway epithelial cells of patients with cystic fibrosis.. Journal of Clinical Investigation, 1994, 93, 1852-1859.	3.9	31
312	Multimeric structure of ClC-1 chloride channel revealed by mutations in dominant myotonia congenita (Thomsen).. EMBO Journal, 1994, 13, 737-743.	3.5	203
313	Activation of intestinal CFTR Cl- channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase.. EMBO Journal, 1994, 13, 1065-1072.	3.5	241
314	Cloning and analysis of a gene cluster from Streptomyces coelicolor that causes accelerated aerial mycelium formation in Streptomyces lividans. Journal of Bacteriology, 1994, 176, 3800-3811.	1.0	58
315	Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP.. EMBO Journal, 1994, 13, 6076-6086.	3.5	370
316	Genetic Bit Analysis: a solid phase method for typing single nucleotide polymorphisms. Nucleic Acids Research, 1994, 22, 4167-4175.	6.5	202
317	Construction and characterization of bacterial artificial chromosome library ofSorghum bicolor. Nucleic Acids Research, 1994, 22, 4922-4931.	6.5	389
318	Transfer of a constitutive viral pormoterâ€“cystic fibrosis transmembrance conductance regulator cDNA to human epithelial cells conveys resistance to down-regulation of cAMP-regulated Clâ¯secretion in the presence of inflammatory stimuli. Nucleic Acids Research, 1994, 22, 4470-4476.	6.5	3
319	Automated analysis of multiplex microsatellites.. Journal of Medical Genetics, 1994, 31, 937-943.	1.5	4
320	High-density multiplex detection of nucleic acid sequences: oligonucleotide ligation assay and sequence-coded separation. Nucleic Acids Research, 1994, 22, 4527-4534.	6.5	119
321	Identification of an ion channel-forming motif in the primary structure of CFTR, the cystic fibrosis chloride channel.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 1495-1499.	3.3	58
322	Mutation analysis in 600 French cystic fibrosis patients.. Journal of Medical Genetics, 1994, 31, 541-544.	1.5	29
323	Recent advances in cystic fibrosis.. Postgraduate Medical Journal, 1994, 70, 247-251.	0.9	2
324	A cluster of cystic fibrosis mutations in exon 17b of the CFTR gene: a site for rare mutations.. Journal of Medical Genetics, 1994, 31, 731-734.	1.5	7
325	Desensitisation of neutrophil responses by systemic interleukin 8 in cystic fibrosis.. Thorax, 1994, 49, 867-871.	2.7	36
326	Evaluation of laboratory methods for cystic fibrosis carrier screening: reliability, sensitivity, specificity, and costs.. Journal of Medical Genetics, 1994, 31, 545-550.	1.5	11

#	Article	IF	Citations
327	Cystic fibrosis-related diabetes is associated with HLADQB1 alleles encoding Asp-57â˜ molecules. Journal of Clinical Immunology, 1994, 14, 353-358.	2.0	17
328	Attitudes of high school students toward carrier screening and prenatal diagnosis of cystic fibrosis. Journal of Genetic Counseling, 1994, 3, 141-155.	0.9	14
329	New perspectives in understanding and management of the respiratory disease in cystic fibrosis. European Journal of Pediatrics, 1994, 153, 144-150.	1.3	10
330	Cystic fibrosis screening in neonates â€" measurement of immunoreactive trypsin and direct genotype analysis for Î"F508 mutation. European Journal of Pediatrics, 1994, 153, 569-573.	1.3	19
331	Unexpected inactivation of acceptor consensus splice sequence by a â˜3 C to T transition in intron 2 of the CFTR gene. Human Genetics, 1994, 94, 65-68.	1.8	15
332	Saccharomyces cerevisiae YDR1, which encodes a member of the ATP-binding cassette (ABC) superfamily, is required for multidrug resistance. Current Genetics, 1994, 26, 285-294.	0.8	151
333	Long-term survival of the exon 10 insertional cystic fibrosis mutant mouse is a consequence of low level residual wild-type Cftr gene expression. Mammalian Genome, 1994, 5, 465-472.	1.0	68
334	Cystic fibrosis. Lung, 1994, 172, 251-270.	1.4	32
335	Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition: evidence for involvement of the apolipoprotein A-II and cholesteryl ester transfer protein loci. Human Genetics, 1994, 93, 639-648.	1.8	69
336	Identification of three novel mutations (457 TAT?G, D192G, Q685X) in the Slovenian CF patients. Human Genetics, 1994, 93, 659-62.	1.8	11
337	Heterogeneity in the severity of cystic fibrosis and the role of CFTR gene mutations. Human Genetics, 1994, 93, 364-8.	1.8	77
338	Retrospective study of the cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Guthrie cards from a large cohort of neonatal screening for cystic fibrosis. Human Genetics, 1994, 93, 429-34.	1.8	23
339	Analysis of the CFTR gene confirms the high genetic heterogeneity of the Spanish population: 43 mutations account for only 78% of CF chromosomes. Human Genetics, 1994, 93, 447-51.	1.8	65
340	Novel cystic fibrosis mutation associated with mild disease in Cypriot patients. Human Genetics, 1994, 93, 529-32.	1.8	3
341	Identification of three novel mutations in the CFTR gene using temperature-optimized non-radioactive conditions for SSCP analysis. Human Genetics, 1994, 94, 154-8.	1.8	13
342	Skipping of multiple CFTR exons is not a result of single exon omissions. Human Genetics, 1994, 94, 311-3.	1.8	5
343	394delTT: a Nordic cystic fibrosis mutation. Human Genetics, 1994, 93, 157-61.	1.8	27
344	Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. Human Genetics, 1994, 94, 533-542.	1.8	100

#	Article	IF	Citations
345	Exon 9 of the CFTR gene: splice site haplotypes and cystic fibrosis mutations. Human Genetics, 1994, 93, 67-73.	1.8	44
346	Map-based cloning in crop plants: tomato as a model system II. Isolation and characterization of a set of overlapping yeast artificial chromosomes encompassing the jointless locus. Molecular Genetics and Genomics, 1994, 244, 613-621.	2.4	32
347	Map-based cloning in crop plants. Tomato as a model system: I. Genetic and physical mapping of jointless. Molecular Genetics and Genomics, 1994, 242, 681-688.	2.4	60
348	The Saccharomyces cerevisiae SGE1 gene product: a novel drug-resistance protein within the major facilitator superfamily. Molecular Genetics and Genomics, 1994, 244, 287-294.	2.4	47
349	DNA markers linked to Malus floribunda 821 scab resistance. Plant Molecular Biology, 1994, 26, 597-602.	2.0	65
350	Sequence relationships between integral inner membrane proteins of binding proteinâ€dependent transport systems: Evolution by recurrent gene duplications. Protein Science, 1994, 3, 325-344.	3.1	68
351	Microcompartmentation of energy metabolism at the outer mitochondrial membrane: Role in diabetes mellitus and other diseases. Journal of Bioenergetics and Biomembranes, 1994, 26, 317-325.	1.0	55
352	Follow-up of a report of a potential linkage for schizophrenia on chromosome 22q12-q13.1: Part 2. American Journal of Medical Genetics Part A, 1994, 54, 44-50.	2.4	145
353	Crohn's disease and cystic fibrosis. Digestive Diseases and Sciences, 1994, 39, 880-885.	1.1	89
354	Serum fatty acid profiles in cystic fibrosis patients and their parents. Lipids, 1994, 29, 569-575.	0.7	44
355	Differentiation of immortalized epithelial cells derived from cystic fibrosis airway submucosal glands. In Vitro Cellular and Developmental Biology - Animal, 1994, 30, 539-546.	0.7	6
356	Effect of ATP concentration on CFTR Cl- channels: a kinetic analysis of channel regulation. Biophysical Journal, 1994, 66, 1398-1403.	0.2	125
357	Intramolecular and intermolecular enzymatic modulation of ion channels in excised membrane patches. Biophysical Journal, 1994, 66, 1904-1914.	0.2	26
358	Dornase Alfa. Drugs, 1994, 48, 894-906.	4.9	30
359	Phosphorylation by protein kinase C and cyclic AMP-dependent protein kinase of synthetic peptides derived from the linker region of human P-glycoprotein. Biochemical Journal, 1994, 299, 309-315.	1.7	68
360	Asparagine-linked oligosaccharides are localized to single extracytosolic segments in multi-span membrane glycoproteins. Biochemical Journal, 1994, 302, 253-260.	1.7	117
361	Transcriptional analysis of the Pseudomonas aeruginosa genes algR, algB, and algD reveals a hierarchy of alginate gene expression which is modulated by algT. Journal of Bacteriology, 1994, 176, 6007-6014.	1.0	169
362	Rapid and accurate estimates of statistical significance for sequence data base searches.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 4625-4628.	3.3	154

#	Article	IF	Citations
363	Rapid endocytosis of the cystic fibrosis transmembrane conductance regulator chloride channel.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 5192-5196.	3.3	129
364	Two highly homologous members of the ClC chloride channel family in both rat and human kidney.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 6943-6947.	3.3	257
365	Characteristics of peptide and major histocompatibility complex class I/beta 2-microglobulin binding to the transporters associated with antigen processing (TAP1 and TAP2).. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 12716-12720.	3.3	149
366	Phosphatase inhibitors activate normal and defective CFTR chloride channels.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9160-9164.	3.3	156
367	Molecular cloning and functional expression of the bumetanide-sensitive Na-K-Cl cotransporter.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 2201-2205.	3.3	387
368	Regulation of the gating of cystic fibrosis transmembrane conductance regulator C1 channels by phosphorylation and ATP hydrolysis.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 4698-4702.	3.3	276
369	Impaired cell volume regulation in intestinal crypt epithelia of cystic fibrosis mice.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 9038-9041.	3.3	66
371	Vesicular targeting and the control of ion secretion in epithelial cells: implications for cystic fibrosis.. Journal of Physiology, 1995, 482, 27-30.	1.3	10
372	Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochemical Journal, 1995, 308, 381-390.	1.7	214
373	Nutritional management of the infant with cystic fibrosis.. Archives of Disease in Childhood, 1995, 72, 452-456.	1.0	22
374	Molecular analysis of the ovine cystic fibrosis transmembrane conductance regulator gene.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2293-2297.	3.3	40
375	Two cystic fibrosis transmembrane conductance regulator mutations have different effects on both pulmonary phenotype and regulation of outwardly rectified chloride currents.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 6832-6836.	3.3	77
376	Basal expression of the cystic fibrosis transmembrane conductance regulator gene is dependent on protein kinase A activity.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 7560-7564.	3.3	58
377	Molecular biology and its application in paediatric endocrinology. European Journal of Pediatrics, 1995, 154, S30-S39.	1.3	0
378	The resting membrane potential of cells are measures of electrical work, not of ionic currents. Integrative Psychological and Behavioral Science, 1995, 30, 283-307.	0.3	28
379	Purification and reconstitution of functional human P-glycoprotein. Journal of Bioenergetics and Biomembranes, 1995, 27, 23-29.	1.0	46
380	Drug-stimulated ATPase activity of the human P-glycoprotein. Journal of Bioenergetics and Biomembranes, 1995, 27, 37-41.	1.0	79
381	Effects of phosphorylation of P-glycoprotein on multidrug resistance. Journal of Bioenergetics and Biomembranes, 1995, 27, 53-61.	1.0	65

#	Article	IF	Citations
382	Transcript identification in the BRCA1 candidate region. Breast Cancer Research and Treatment, 1995, 33, 115-124.	1.1	2
383	A direct effect of forskolin on sodium channel bursting. Pflugers Archiv European Journal of Physiology, 1995, 429, 561-569.	1.3	18
384	Cystic fibrosis: Five years beyond the gene. Journal of Inherited Metabolic Disease, 1995, 18, 491-494.	1.7	0
385	Gene therapy for cystic fibrosis. Journal of Inherited Metabolic Disease, 1995, 18, 501-507.	1.7	2
386	Investigating hypothetical products from noncoding frames (HyPNoFs). Journal of Molecular Evolution, 1995, 40, 570-577.	0.8	2
387	Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses. Human Genetics, 1995, 96, 542-548.	1.8	41
388	Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from North-Eastern Italy: identification of 90% of the mutations. Human Genetics, 1995, 95, 397-402.	1.8	56
389	Fluorescent multiplex microsatellites used to identify haplotype associations with 15 CFTR mutations in 124 Northern Irish CF families. Human Genetics, 1995, 95, 462-4.	1.8	8
390	A new polymorphism in exon 7 of the cystic fibrosis transmembrane regulator (CFTR) gene. Human Genetics, 1995, 95, 465-466.	1.8	1
391	Extensive analysis of 40 infertile patients with congenital absence of the vas deferens: in 50% of cases only one CFTR allele could be detected. Human Genetics, 1995, 95, 205-11.	1.8	96
392	Search for mutations in pancreatic sufficient cystic fibrosis Italian patients: detection of 90% of molecular defects and identification of three novel mutations. Human Genetics, 1995, 96, 312-8.	1.8	23
393	Mutation analysis of ten exons of the CFTR gene in Greek cystic fibrosis patients: characterization of 74.5% of CF alleles including one novel mutation. Human Genetics, 1995, 96, 364-6.	1.8	21
394	Number and sex of offspring of Î”F508 carriers outside cystic fibrosis families. Human Genetics, 1995, 95, 575-576.	1.8	6
395	Characterization and mapping of three new mammalian ATP-binding transporter genes from an EST database. Mammalian Genome, 1995, 6, 114-117.	1.0	29
396	Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Current Genetics, 1995, 27, 320-329.	0.8	475
397	Identifying genes within microdissected genomic DNA: Isolation of brain expressed genes from a translocation region associated with inherited mental illness. Mammalian Genome, 1995, 6, 257-262.	1.0	5
398	Clinical characteristics of 16 cystic fibrosis patients with the missense mutation R334W, a pancreatic insufficiency mutation with variable age of onset and interfamilial clinical differences. Human Genetics, 1995, 95, 331-6.	1.8	36
399	The biology of the P-glycoproteins. Journal of Membrane Biology, 1995, 143, 89-102.	1.0	110

#	Article	IF	Citations
400	Molecular basis of epithelial Cl channels. Journal of Membrane Biology, 1995, 144, 189-97.	1.0	29
401	Monitoring the efficacy of hybrid selection during positional cloning: the search for BRCA1. Mammalian Genome, 1995, 6, 873-879.	1.0	7
402	Activation of the basolateral Cl? conductance by cAMP in rabbit renal proximal tubule S3 segments. Pflugers Archiv European Journal of Physiology, 1995, 430, 88-95.	1.3	14
403	Actin-dependent activation of ion conductances in bronchial epithelial cells. Pflugers Archiv European Journal of Physiology, 1995, 429, 682-690.	1.3	51
404	Epithelial cell specific properties and genetic complementation in a Î”F508 cystic fibrosis nasal polyp cell line. In Vitro Cellular and Developmental Biology - Animal, 1995, 31, 617-624.	0.7	11
405	Impact of the human genome project on medical practice. Annals of Surgical Oncology, 1995, 2, 14-25.	0.7	2
406	Magnesium Adenosine 5[prime]-Triphosphate-Energized Transport of Glutathione-S-Conjugates by Plant Vacuolar Membrane Vesicles. Plant Physiology, 1995, 107, 1257-1268.	2.3	92
407	Sinusitis in patients with cystic fibrosis. European Archives of Oto-Rhino-Laryngology, 1995, 252, 191-6.	0.8	21
408	Applications of the polymerase chain reaction (PCR) in diagnosis. Irish Journal of Medical Science, 1995, 164, 116-121.	0.8	0
409	Topology analysis of the colicin V export protein CvaA in Escherichia coli. Journal of Bacteriology, 1995, 177, 6153-6159.	1.0	23
410	Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency.. EMBO Journal, 1995, 14, 876-883.	3.5	87
411	A mouse model for the cystic fibrosis delta F508 mutation.. EMBO Journal, 1995, 14, 4403-4411.	3.5	213
412	A change in gating mode leading to increased intrinsic Cl- channel activity compensates for defective processing in a cystic fibrosis mutant corresponding to a mild form of the disease.. EMBO Journal, 1995, 14, 2417-2423.	3.5	38
413	An ABC transporter in the mitochondrial inner membrane is required for normal growth of yeast.. EMBO Journal, 1995, 14, 188-195.	3.5	182
414	Activation of CFTR chloride current by nitric oxide in human T lymphocytes.. EMBO Journal, 1995, 14, 2700-2707.	3.5	59
415	Regulation of CFTR Cl- channel gating by ADP and ATP analogues.. Journal of General Physiology, 1995, 105, 329-361.	0.9	60
416	Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3019-3023.	3.3	243
417	High incidence of delta I507 mutation of the CFTR gene in a limited area of the north west of France.. Journal of Medical Genetics, 1995, 32, 577-577.	1.5	2

#	Article	IF	Citations
418	The impact of newborn screening on cystic fibrosis testing in Victoria, Australia.. Journal of Medical Genetics, 1995, 32, 537-542.	1.5	29
419	Gene therapy for respiratory diseases: potential applications and difficulties.. Thorax, 1995, 50, 484-486.	2.7	6
420	Spinocerebellar ataxia 1 (SCA1) in the Japanese in Hokkaido may derive from a single common ancestry.. Journal of Medical Genetics, 1995, 32, 590-592.	1.5	23
421	Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years.. Thorax, 1995, 50, 1301-1304.	2.7	69
422	Overexpression of the cystic fibrosis transmembrane conductance regulator in NIH 3T3 cells lowers membrane potential and intracellular pH and confers a multidrug resistance phenotype. Biophysical Journal, 1995, 69, 883-895.	0.2	43
423	Structural and functional similarities between the nucleotide-binding domains of CFTR and GTP-binding proteins. Biophysical Journal, 1995, 69, 2443-2448.	0.2	50
424	Increased cation transport inmdr1-gene-expressing K562 cells. Cancer Chemotherapy and Pharmacology, 1995, 36, 87-90.	1.1	8
425	Na+ and Cl? conductances in airway epithelial cells: increased Na+ conductance in cystic fibrosis. Pflugers Archiv European Journal of Physiology, 1995, 431, 1-9.	1.3	76
426	Presymptomatic Testing for Genetic Diseases of Later Life. Drugs and Aging, 1995, 7, 117-130.	1.3	3
427	Drug Management of Noninfective Complications of Cystic Fibrosis. Drugs, 1995, 50, 626-635.	4.9	5
428	Quality of Life in Cystic Fibrosis. Pharmacoeconomics, 1995, 8, 23-33.	1.7	31
429	Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel. Human Genetics, 1995, 96, 193-197.	1.8	63
430	Rectification of cystic fibrosis transmembrane conductance regulator chloride channel mediated by extracellular divalent cations. Biophysical Journal, 1996, 71, 2458-2466.	0.2	4
431	Human epithelial cystic fibrosis transmembrane conductance regulator without exon 5 maintains partial chloride channel function in intracellular membranes. Biophysical Journal, 1996, 71, 3148-3156.	0.2	25
432	Slow conversions among subconductance states of cystic fibrosis transmembrane conductance regulator chloride channel. Biophysical Journal, 1996, 70, 743-753.	0.2	38
433	Identification of cystic fibrosis transmembrane conductance regulator channel-lining residues in and flanking the M6 membrane-spanning segment. Biophysical Journal, 1996, 70, 2688-2695.	0.2	102
434	Geographic distribution and origin of CFTR mutations in Germany. Human Genetics, 1996, 97, 727-731.	1.8	26
435	Regulation of epithelial ion channels by the cystic fibrosis transmembrane conductance regulator. Journal of Molecular Medicine, 1996, 74, 527-534.	1.7	46

#	Article	IF	Citations
436	Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting. Journal of Molecular Medicine, 1996, 74, 379-392.	1.7	67
437	Linkage disequilibrium and extended haplotypes in the HLA-A to D6S105 region: implications for mapping the hemochromatosis gene (HFE). Human Genetics, 1996, 97, 103-113.	1.8	34
438	Cystic fibrosis gene mutations detected in hereditary pancreatitis. Pflugers Archiv European Journal of Physiology, 1996, 431, R191-R192.	1.3	23
439	The amiloride inhibitable Na+ conductance of rat colonic crypt cells is suppressed by forskolin. Pflugers Archiv European Journal of Physiology, 1996, 431, 984-986.	1.3	41
440	Protein secretion in gram-negative bacteria: assembly of the three components of ABC protein-mediated exporters is ordered and promoted by substrate binding.. EMBO Journal, 1996, 15, 5804-5811.	3.5	132
441	The ATP binding cassette transporter ABC1, is required for the engulfment of corpses generated by apoptotic cell death.. EMBO Journal, 1996, 15, 226-235.	3.5	262
442	Cystic fibrosis transmembrane conductance regulator activation stimulates endosome fusion in vivo.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 12484-12489.	3.3	54
443	Cystic fibrosis gene encodes a cAMP-dependent chloride channel in heart.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 6343-6348.	3.3	61
444	A new method to measure alveolar-epithelium permeability in intact lung.. Journal of General Physiology, 1996, 108, 125-127.	0.9	0
445	Mutant cystic fibrosis transmembrane conductance regulator inhibits acidification and apoptosis in C127 cells: possible relevance to cystic fibrosis.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 3587-3591.	3.3	160
446	Studies of the membrane topology of the rat erythrocyte H+/lactate cotransporter (MCT1). Biochemical Journal, 1996, 320, 817-824.	1.7	120
447	The pfmdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 9942-9947.	3.3	44
448	Peptide nucleic acid pre-gel hybridization: An alternative to Southern hybridization. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 14670-14675.	3.3	77
449	Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis. Digestive Diseases and Sciences, 1996, 41, 540-542.	1.1	27
450	Cystic fibrosis-an Indian perspective on recent advances in diagnosis and management. Indian Journal of Pediatrics, 1996, 63, 189-198.	0.3	6
451	cAMP Stimulation of CFTR-expressing Xenopus oocytes activates a chromanol-inhibitable K+ conductance. Pflugers Archiv European Journal of Physiology, 1996, 432, 516-522.	1.3	43
452	Clusters of Clâ˜ channels in CFTR-expressing Sf9 cells switch spontaneously between slow and fast gating modes. Pflugers Archiv European Journal of Physiology, 1996, 432, 528-537.	1.3	17
453	The membrane transporters regulating epithelial NaCl secretion. Pflugers Archiv European Journal of Physiology, 1996, 432, 579-588.	1.3	45

#	Article	IF	Citations
454	Reduced allele dropout in single-cell analysis for preimplantation genetic diagnosis of cystic fibrosis. Journal of Assisted Reproduction and Genetics, 1996, 13, 104-106.	1.2	48
455	Allelic dropout caused by allele-specific amplification failure in single-cell PCR of the cystic fibrosis Î”F508 deletion. Journal of Assisted Reproduction and Genetics, 1996, 13, 112-114.	1.2	30
456	Altered drug translocation mediated by the MDR protein: Direct, indirect, or both?. Journal of Bioenergetics and Biomembranes, 1996, 28, 541-555.	1.0	45
457	Adenovirus infection in cystic fibrosis patients: Implications for the use of adenoviral vectors for gene transfer. Infection, 1996, 24, 5-8.	2.3	34
458	Priming of NADPH oxidase by tumor necrosis factor alpha in patients with inflammatory and autoimmune rheumatic diseases. Inflammation, 1996, 20, 427-438.	1.7	50
459	Molecular cloning of a mammalian ABC transporter homologous to Drosophila white gene. Mammalian Genome, 1996, 7, 673-676.	1.0	63
460	Genetics of subtilin and nisin biosyntheses. Antonie Van Leeuwenhoek, 1996, 69, 109-117.	0.7	57
461	A recombinant peptide model of the first nucleotideâ€binding fold of the cystic fibrosis transmembrane conductance regulator: Comparison of wildâ€type and Î”F508 mutant forms. Protein Science, 1996, 5, 89-97.	3.1	26
462	The proteins encoded by the rbs operon of escherichia coli: I. Overproduction, purification, characterization, and functional analysis of RbsA. Protein Science, 1996, 5, 1093-1099.	3.1	18
463	Identification of protein kinase A phosphorylation sites on NBD1 and R domains of CFTR using electrospray mass spectrometry with selective phosphate ion monitoring. Protein Science, 1996, 5, 1865-1873.	3.1	52
464	First report of three cystic fibrosis patients homozygous for the 1717-1G-->A mutation.. Journal of Medical Genetics, 1996, 33, 1052-1054.	1.5	3
465	CFTR: the nucleotide binding folds regulate the accessibility and stability of the activated state.. Journal of General Physiology, 1996, 107, 103-119.	0.9	56
466	Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.. Molecular Biology of the Cell, 1996, 7, 1485-1498.	0.9	75
467	A mild variant of cystic fibrosis.. Thorax, 1996, 51, S51-S54.	2.7	4
468	The genetics of complex ophthalmic disorders.. British Journal of Ophthalmology, 1996, 80, 763-768.	2.1	18
469	Thirteen cystic fibrosis patients, 12 compound heterozygous and one homozygous for the missense mutation G85E: a pancreatic sufficiency/insufficiency mutation with variable clinical presentation.. Journal of Medical Genetics, 1996, 33, 820-822.	1.5	12
470	Molecular epidemiology of cystic fibrosis mutations and haplotypes in southern Italy evaluated with an improved semiautomated robotic procedure.. Journal of Medical Genetics, 1996, 33, 475-479.	1.5	21
471	The PAL1 gene product is a peroxisomal ATP-binding cassette transporter in the yeast Saccharomyces cerevisiae.. Journal of Cell Biology, 1996, 132, 549-563.	2.3	74

#	Article	IF	Citations
472	A short CIC-2 mRNA transcript is produced by exon skipping. Nucleic Acids Research, 1996, 24, 3453-3457.	6.5	24
473	An ovine CFTR variant as a putative cystic fibrosis causing mutation.. Journal of Medical Genetics, 1996, 33, 623-624.	1.5	9
474	The elimination of primer-dimer accumulation in PCR. Nucleic Acids Research, 1997, 25, 3235-3241.	6.5	275
475	Permeability of Wild-Type and Mutant Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channels to Polyatomic Anions. Journal of General Physiology, 1997, 110, 355-364.	0.9	199
476	Genotype-phenotype relationship in 12 patients carrying cystic fibrosis mutation R334W.. Journal of Medical Genetics, 1997, 34, 89-91.	1.5	7
477	Delta F508 in cystic fibrosis: willing but not able. Archives of Disease in Childhood, 1997, 76, 278-282.	1.0	14
478	Novel and characteristic CFTR mutations in Saudi Arab children with severe cystic fibrosis.. Journal of Medical Genetics, 1997, 34, 996-999.	1.5	46
479	Molecular characterisation of cystic fibrosis patients in the state of Sao Paulo (Brazil). Journal of Medical Genetics, 1997, 34, 877-877.	1.5	10
480	An ancestral core haplotype defines the critical region harbouring the North Carolina macular dystrophy gene (MCDR1).. Journal of Medical Genetics, 1997, 34, 961-966.	1.5	24
481	Locating the Anion-selectivity Filter of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel. Journal of General Physiology, 1997, 109, 289-299.	0.9	98
482	The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP.. Journal of Medical Genetics, 1997, 34, 459-464.	1.5	36
483	Commentary Cystic Fibrosis Transmembrane Conductance Regulator. Journal of General Physiology, 1997, 110, 337-339.	0.9	4
484	Chloride secretion in the trachea of null cystic fibrosis mice: the effects of transfection with pTrial10â€CFTR2.. Journal of Physiology, 1997, 499, 677-687.	1.3	17
485	Fluorescence energy transfer detection as a homogeneous DNA diagnostic method. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 10756-10761.	3.3	133
486	Multi-Ion Mechanism for Ion Permeation and Block in the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel. Journal of General Physiology, 1997, 110, 365-377.	0.9	83
487	Interaction between ATP, oleandomycin and the OleB ATP-binding cassette transporter of Streptomyces antibioticus involved in oleandomycin secretion. Biochemical Journal, 1997, 321, 139-144.	1.7	25
488	Functional expression and apical localization of the cystic fibrosis transmembrane conductance regulator in MDCK I cells. Biochemical Journal, 1997, 322, 259-265.	1.7	65
489	Cross-species characterization of the promoter region of the cystic fibrosis transmembrane conductance regulator gene reveals multiple levels of regulation. Biochemical Journal, 1997, 327, 651-662.	1.7	43

#	Article	IF	Citations
490	Exercise Recommendations for Individuals with Cystic Fibrosis. Sports Medicine, 1997, 24, 17-37.	3.1	32
491	The Genetic Clock and the Age of the Founder Effect in Growing Populations: A Lesson from French Canadians and Ashkenazim. American Journal of Human Genetics, 1997, 61, 768-771.	2.6	68
492	What Is Significant in Whole-Genome Linkage Disequilibrium Studies?. American Journal of Human Genetics, 1997, 61, 810-812.	2.6	52
493	A mouse model for X-linked adrenoleukodystrophy. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9366-9371.	3.3	253
494	In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant ÂF508 in murine nasal epithelium. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 2604-2608.	3.3	92
495	Cystic Fibrosis of the Pancreas: Involvement of MUC6 Mucin in Obstruction of Pancreatic Ducts. Molecular Medicine, 1997, 3, 403-411.	1.9	39
496	Gene Therapy: The Case for Cystic Fibrosis. Journal of the Royal Society of Medicine, 1997, 90, 43-46.	1.1	0
497	P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 12908-12913.	3.3	174
498	The Candida albicans CDR3 gene codes for an opaque-phase ABC transporter. Journal of Bacteriology, 1997, 179, 7210-7218.	1.0	107
499	Mechanism of Glibenclamide Inhibition of Cystic Fibrosis Transmembrane Conductance Regulator Clâ˜Channels Expressed in a Murine Cell Line. Journal of Physiology, 1997, 503, 333-346.	1.3	187
500	Fluid transport across cultures of human tracheal glands is altered in cystic fibrosis. Journal of Physiology, 1997, 501, 637-647.	1.3	95
501	Complementation of null CF mice with a human CFTR YAC transgene. EMBO Journal, 1997, 16, 4238-4249.	3.5	76
502	Frontiers in research on cystic fibrosis: understanding its molecular and chemical basis and relationship to the pathogenesis of the disease. Journal of Bioenergetics and Biomembranes, 1997, 29, 417-427.	1.0	11
503	CFTR: domains, structure, and function. Journal of Bioenergetics and Biomembranes, 1997, 29, 443-451.	1.0	41
504	Coupling of ATP hydrolysis with channel gating by purified, reconstituted CFTR. Journal of Bioenergetics and Biomembranes, 1997, 29, 465-473.	1.0	25
505	Cystic fibrosis: a disease of altered protein folding. Journal of Bioenergetics and Biomembranes, 1997, 29, 483-490.	1.0	55
506	Modeling of nucleotide binding domains of ABC transporter proteins based on a F1-ATPase/recA topology: structural model of the nucleotide binding domains of the cystic fibrosis transmembrane conductance regulator (CFTR). Journal of Bioenergetics and Biomembranes, 1997, 29, 503-524.	1.0	67
507	Cystic fibrosis: channel, catalytic, and folding properties of the CFTR protein. Journal of Bioenergetics and Biomembranes, 1997, 29, 429-442.	1.0	43

#	Article	IF	Citations
508	Probing the structural and functional domains of the CFTR chloride channel. Journal of Bioenergetics and Biomembranes, 1997, 29, 453-463.	1.0	17
509	Purification, characterization, and expression of CFTR nucleotide-binding domains. Journal of Bioenergetics and Biomembranes, 1997, 29, 475-482.	1.0	1
510	Uridine nucleotide receptors and their ligands: structural, physiological, and pathophysiological aspects, with special emphasis on the nervous system. Neurochemical Research, 1997, 22, 1041-1050.	1.6	16
511	Strategies for correcting the delta F508 CFTR protein-folding defect. Journal of Bioenergetics and Biomembranes, 1997, 29, 491-502.	1.0	52
512	cDNA selection with YACs. Molecular Biotechnology, 1997, 8, 255-268.	1.3	1
513	Functional activity of the CFTR Clâ˜ channel in human myocardium. Heart and Vessels, 1997, 12, 255-261.	0.5	12
514	Protein secretion by gram-negative bacterial ABC exporters. Folia Microbiologica, 1997, 42, 179-183.	1.1	7
515	Amplification of Guthrie card DNA: Effect of guanidine thiocyanate on binding of natural whole blood PCR inhibitors. , 1997, 11, 87-93.		12
516	Aerosol delivery of lipid:DNA complexes to lungs of rhesus monkeys. Pharmaceutical Research, 1998, 15, 671-679.	1.7	49
517	P-glycoprotein structure and evolutionary homologies. , 1998, 27, 1-30.		27
518	CFTR Cl- channel and CFTR-associated ATP channel: distinct pores regulated by common gates. EMBO Journal, 1998, 17, 898-908.	3.5	121
519	Non-pore lining amino acid side chains influence anion selectivity of the human CFTR Clâ˜channel expressed in mammalian cell lines. Journal of Physiology, 1998, 512, 1-16.	1.3	69
520	Cystic fibrosis transmembrane conductance regulator mediates sulphonylurea block of the inwardly rectifying K⁺ channel Kir6.1. Journal of Physiology, 1998, 508, 23-30.	1.3	35
521	Importance of basolateral K+conductance in maintaining Clâ˜secretion in murine nasal and colonic epithelia. Journal of Physiology, 1998, 510, 237-247.	1.3	78
522	Comparison of the gating behaviour of human and murine cystic fibrosis transmembrane conductance regulator Clâ˜channels expressed in mammalian cells. Journal of Physiology, 1998, 508, 379-392.	1.3	50
523	Regulation of murine cystic fibrosis transmembrane conductance regulator Clâ˜channels expressed in Chinese hamster ovary cells. Journal of Physiology, 1998, 512, 751-764.	1.3	43
524	Clâ˜transport by cystic fibrosis transmembrane conductance regulator (CFTR) contributes to the inhibition of epithelial Na+channels (ENaCs) inXenopusoocytes co-expressing CFTR and ENaC. Journal of Physiology, 1998, 508, 825-836.	1.3	107
525	The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system. British Journal of Cancer, 1998, 77, 1267-1274.	2.9	35

#	Article	IF	Citations
526	Surfactant protein-A : New insights into an old protein-II. Indian Journal of Pediatrics, 1998, 65, 781-795.	0.3	1
527	Genomic DNA sequence of Rhesus (M. mulatta) cystic fibrosis (CFTR) gene. Mammalian Genome, 1998, 9, 301-305.	1.0	17
528	Evidence for Genetic Heterogeneity in X-Linked Congenital Stationary Night Blindness. American Journal of Human Genetics, 1998, 62, 865-875.	2.6	53
529	Prenatal Screening for Cystic Fibrosis Carriers: An Economic Evaluation. American Journal of Human Genetics, 1998, 63, 1160-1174.	2.6	64
530	Selective Up-Regulation of Chemokine IL-8 Expression in Cystic Fibrosis Bronchial Gland Cells in Vivo and in Vitro. American Journal of Pathology, 1998, 153, 921-930.	1.9	158
531	Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Anion Binding as a Probe of the Pore. Biophysical Journal, 1998, 74, 1320-1332.	0.2	70
532	Aggresomes: A Cellular Response to Misfolded Proteins. Journal of Cell Biology, 1998, 143, 1883-1898.	2.3	1,977
533	A novel process for mutation detection using uracil DNA-glycosylase. Nucleic Acids Research, 1998, 26, 810-815.	6.5	33
534	MALDI-TOF mass spectrometric typing of single nucleotide polymorphisms with mass-tagged ddNTPs. Nucleic Acids Research, 1998, 26, 2827-2828.	6.5	70
535	Costs, effects, and savings of screening for cystic fibrosis gene carriers. Journal of Epidemiology and Community Health, 1998, 52, 459-467.	2.0	35
536	Perspective: The List of Potential Volume-sensitive Chloride Currents Continues to Swell (and Shrink). Journal of General Physiology, 1998, 111, 623-624.	0.9	58
537	A Homogeneous, Ligase-Mediated DNA Diagnosticâ€‰Test. Genome Research, 1998, 8, 549-556.	2.4	137
538	Linkage disequilibrium between the M470V variant and the IVS8 polyT alleles of the CFTR gene in CBAVD.. Journal of Medical Genetics, 1998, 35, 594-596.	1.5	48
539	Adenosine Triphosphateâ€“dependent Asymmetry of Anion Permeation in the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel. Journal of General Physiology, 1998, 111, 601-614.	0.9	138
540	Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10158-10163.	3.3	62
541	Actions of Genistein on Cystic Fibrosis Transmembrane Conductance Regulator Channel Gating. Journal of General Physiology, 1998, 111, 477-490.	0.9	156
542	Structural analysis of cloned plasma membrane proteins by freeze-fracture electron microscopy. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11235-11240.	3.3	172
543	Syntaxin 1A inhibits CFTR chloride channels by means of domain-specific protein-protein interactions. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10972-10977.	3.3	143

#	Article	IF	Citations
544	Mapping a disease locus by allelic association. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 1741-1745.	3.3	169
545	The antigen-binding characteristics of mAbs derived from in vivo priming of avian B cells. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 1166-1171.	3.3	21
546	Induction of stress-activated protein kinases/c-Jun N-terminal kinases by the p55 tumour necrosis factor receptor does not require sphingomyelinases. Biochemical Journal, 1998, 333, 343-350.	1.7	22
547	Cell-cycle-dependent changes in ceramide levels preceding retinoblastoma protein dephosphorylation in G2/M. Biochemical Journal, 1998, 334, 457-461.	1.7	66
548	Pathology of pancreatic and intestinal disorders in cystic fibrosis. Journal of the Royal Society of Medicine, 1998, 91, 40-49.	1.1	49
549	Role of ABC Transporters in Aureobasidin A Resistance. Antimicrobial Agents and Chemotherapy, 1998, 42, 755-761.	1.4	39
550	Chloride channel and chloride conductance regulator domains of CFTR, the cystic fibrosis transmembrane conductance regulator. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 2674-2679.	3.3	82
551	Cftr Channel Gating. Journal of General Physiology, 1999, 114, 49-54.	0.9	8
552	In Vivo Analysis of DNase I Hypersensitive Sites in the Human CFTR Gene. Molecular Medicine, 1999, 5, 211-223.	1.9	22
553	Pharmacogenomics of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and the Cystic Fibrosis Drug CPX Using Genome Microarray Analysis. Molecular Medicine, 1999, 5, 753-767.	1.9	61
554	Fas and Fas ligand expression in cystic fibrosis airway epithelium. Thorax, 1999, 54, 1093-1098.	2.7	30
555	Inflammation and CFTR: Might Neutrophils be the Key in Cystic Fibrosis?. Mediators of Inflammation, 1999, 8, 7-11.	1.4	35
556	Dynamic Association of Proteasomal Machinery with the Centrosome. Journal of Cell Biology, 1999, 145, 481-490.	2.3	479
557	Dual Effects of Adp and Adenylylimidodiphosphate on Cftr Channel Kinetics Show Binding to Two Different Nucleotide Binding Sites. Journal of General Physiology, 1999, 114, 55-70.	0.9	54
558	Human ATP-binding cassette transporter 1 (ABC1): Genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 12685-12690.	3.3	254
559	Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis. Archives of Disease in Childhood: Fetal and Neonatal Edition, 1999, 80, F118-F122.	1.4	33
560	Gating of Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channels by Adenosine Triphosphate Hydrolysis. Journal of General Physiology, 1999, 113, 541-554.	0.9	109
561	CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5734-5739.	3.3	77

#	Article	IF	Citations
562	Prospects for gene therapy in cystic fibrosis. Archives of Disease in Childhood, 1999, 80, 286-289.	1.0	20
563	Effects of Worldwide Population Subdivision on ALDH2 Linkage Disequilibrium. Genome Research, 1999, 9, 844-852.	2.4	41
564	A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr-/- mice. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 13995-14000.	3.3	279
565	Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clinical and Experimental Immunology, 1999, 117, 561-567.	1.1	53
566	Purinoceptor-coupled Clâ˜channels in mouse heart: a novel, alternative pathway for CFTR regulation. Journal of Physiology, 1999, 521, 43-56.	1.3	40
567	Structural and ionic determinants of 5-nitro-2-(3-phenylpropylamino)-benzoic acid block of the CFTR chloride channel. British Journal of Pharmacology, 1999, 127, 369-376.	2.7	40
568	Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulator Clâ˜ channels by non-sulphonylurea hypoglycaemic agents. British Journal of Pharmacology, 1999, 128, 108-118.	2.7	27
569	Attitudes Toward Cystic Fibrosis Carrier and Prenatal Testing and Utilization of Carrier Testing Among Relatives of Individuals with Cystic Fibrosis. Journal of Genetic Counseling, 1999, 8, 17-36.	0.9	34
570	Update and Review: Cystic Fibrosis. Journal of Genetic Counseling, 1999, 8, 137-162.	0.9	5
571	A simple in vivo assay for increased protein solubility. Protein Science, 1999, 8, 1908-1911.	3.1	153
572	Diagnosis of cystic fibrosis : Indian perspective. Indian Journal of Pediatrics, 1999, 66, 923-928.	0.3	4
573	Mutation detection by stacking hybridization on genosensor arrays. Molecular Biotechnology, 1999, 11, 13-25.	1.3	30
574	Cystic fibrosis in the pancreas: Recent advances provide new insights. Current Gastroenterology Reports, 1999, 1, 161-165.	1.1	5
575	Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. Journal of Clinical Investigation, 1999, 104, 431-437.	3.9	381
576	Assessment of Linkage Disequilibrium by the Decay of Haplotype Sharing, with Application to Fine-Scale Genetic Mapping. American Journal of Human Genetics, 1999, 65, 858-875.	2.6	224
577	The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO Journal, 1999, 18, 1492-1505.	3.5	298
578	Genistein Inhibits Constitutive and Inducible NFÎºB Activation and Decreases IL-8 Production by Human Cystic Fibrosis Bronchial Gland Cells. American Journal of Pathology, 1999, 155, 473-481.	1.9	91
579	Inhibition of ATPase, GTPase and adenylate kinase activities of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator by genistein. Biochemical Journal, 1999, 340, 227-235.	1.7	51

#	Article	IF	Citations
580	Analysis of DNase-I-hypersensitive sites at the 3â€² end of the cystic fibrosis transmembrane conductance regulator gene (CFTR). Biochemical Journal, 1999, 341, 601-611.	1.7	43
581	Potent stimulation and inhibition of the CFTR Clâ^' current by phloxine B. British Journal of Pharmacology, 2000, 131, 433-440.	2.7	16
582	Deletion of phenylalanine 508 causes attenuated phosphorylationâ€dependent activation of CFTR chloride channels. Journal of Physiology, 2000, 524, 637-648.	1.3	93
583	Two mechanisms of genistein inhibition of cystic fibrosis transmembrane conductance regulator Cl â^' channels expressed in murine cell line. Journal of Physiology, 2000, 524, 317-330.	1.3	69
584	Terminal glycosylation of cystic fibrosis airway epithelial cells. Glycoconjugate Journal, 2000, 17, 385-391.	1.4	24
585	A novel CFTR disease-associated mutation causes addition of an extra N-linked oligosaccharide. Glycoconjugate Journal, 2000, 17, 807-813.	1.4	10
586	Terminal glycosylation and disease: influence on cancer and cystic fibrosis. , 2000, 17, 617-626.		34
587	ABC-me: a novel mitochondrial transporter induced by GATA-1 during erythroid differentiation. EMBO Journal, 2000, 19, 2492-2502.	3.5	138
588	Pitfalls in the immunohistochemical localization of the cystic fibrosis transmembrane conductance regulator in paraffin embedded sweat glands. The Histochemical Journal, 2000, 32, 617-624.	0.6	0
589	Advances in nutritional management of chronic pancreatitis. Current Gastroenterology Reports, 2000, 2, 323-326.	1.1	8
590	Why should a clinician care about the molecular biology of transport?. Current Gastroenterology Reports, 2000, 2, 378-386.	1.1	3
591	Genetic causes of male infertility: Current concepts. Current Urology Reports, 2000, 1, 273-281.	1.0	4
592	Genetic archaeology and the origins of the Irish population. Irish Journal of Medical Science, 2000, 169, 258-261.	0.8	2
593	Comparative genomic sequence analysis of the human and mouse cystic fibrosis transmembrane conductance regulator genes. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1172-1177.	3.3	64
594	High-Resolution Transcript Map of the Region Spanning D12S1629 and D12S312 at Chromosome 12q13: Triple A Syndrome-Linked Region. Genome Research, 2000, 10, 1561-1567.	2.4	9
595	A new approach for the identification and cloning of genes: the pBACwich system using Cre/lox site-specific recombination. Nucleic Acids Research, 2000, 28, 19e-19.	6.5	35
596	Predicting the range of linkage disequilibrium. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 2-3.	3.3	67
597	Pseudoxanthoma elasticum: Mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 6001-6006.	3.3	381

#	Article	IF	Citations
598	A functional R domain from cystic fibrosis transmembrane conductance regulator is predominantly unstructured in solution. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 5657-5662.	3.3	106
599	Overexpression of Acid Ceramidase Protects from Tumor Necrosis Factorâ€“Induced Cell Death. Journal of Experimental Medicine, 2000, 192, 601-612.	4.2	164
600	Genomic Sequence Analysis of Fugu rubripes CFTR and Flanking Genes in a 60 kb Region Conserving Synteny with 800 kb of Human Chromosome 7. Genome Research, 2000, 10, 1194-1203.	2.4	26
601	Identification of a Novel Member of the Chloride Intracellular Channel Gene Family (CLIC5) That Associates with the Actin Cytoskeleton of Placental Microvilli. Molecular Biology of the Cell, 2000, 11, 1509-1521.	0.9	147
602	Complete genomic sequence of the human ABCA1 gene: Analysis of the human and mouse ATP-binding cassette A promoter. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 7987-7992.	3.3	196
603	Severed Channels Probe Regulation of Gating of Cystic Fibrosis Transmembrane Conductance Regulator by Its Cytoplasmic Domains. Journal of General Physiology, 2000, 116, 477-500.	0.9	117
604	Functional Loss of ABCA1 in Mice Causes Severe Placental Malformation, Aberrant Lipid Distribution, and Kidney Glomerulonephritis As Well As High-Density Lipoprotein Cholesterol Deficiency. American Journal of Pathology, 2000, 157, 1017-1029.	1.9	226
605	Interaction Between Permeation and Gating in a Putative Pore Domain Mutant in the Cystic Fibrosis Transmembrane Conductance Regulator. Biophysical Journal, 2000, 79, 298-313.	0.2	41
606	Conformation, Independent of Charge, in the R Domain Affects Cystic Fibrosis Transmembrane Conductance Regulator Channel Openings. Biophysical Journal, 2000, 78, 1293-1305.	0.2	16
607	Haplotype Fine Mapping by Evolutionary Trees. American Journal of Human Genetics, 2000, 66, 659-673.	2.6	58
608	Fine Localization of a Major Disease-Susceptibility Locus for Diffuse Panbronchiolitis. American Journal of Human Genetics, 2000, 66, 501-507.	2.6	72
609	Effects of Cystic Fibrosis and Congenital Bilateral Absence of the Vas Deferensâ€“Associated Mutations on Cystic Fibrosis Transmembrane Conductance Regulatorâ€“Mediated Regulation of Separate Channels. American Journal of Human Genetics, 2000, 66, 1485-1495.	2.6	9
610	Bayesian Fine-Scale Mapping of Disease Loci, by Hidden Markov Models. American Journal of Human Genetics, 2000, 67, 155-169.	2.6	95
611	Taking stock of gene therapy for cystic fibrosis. Respiratory Research, 2000, 1, 78-81.	1.4	7
612	Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Research, 2000, 28, 3752-3761.	6.5	293
613	Simple and Complex ABCR: Genetic Predisposition to Retinal Disease. American Journal of Human Genetics, 2000, 67, 793-799.	2.6	122
614	Nonâ€specific activation of the epithelial sodium channel by the CFTR chloride channel. EMBO Reports, 2001, 2, 249-254.	2.0	59
615	New and Emerging Therapies for Pulmonary Complications of Cystic Fibrosis. Drugs, 2001, 61, 1379-1385.	4.9	12

#	Article	IF	Citations
616	Glycosylation and the cystic fibrosis transmembrane conductance regulator. Respiratory Research, 2001, 2, 276.	1.4	12
617	Worldwide Genetic Analysis of the CFTR Region. American Journal of Human Genetics, 2001, 68, 103-117.	2.6	55
618	On Discovery, Genomes, The Society, and Society*. American Journal of Human Genetics, 2001, 68, 819-825.	2.6	3
619	Pharmacogenetic Tactics and Strategies. Paediatric Drugs, 2001, 3, 863-881.	1.3	5
620	Bayesian Analysis of Haplotypes for Linkage Disequilibrium Mapping. Genome Research, 2001, 11, 1716-1724.	2.4	139
621	Multiple endocytic signals in the C-terminal tail of the cystic fibrosis transmembrane conductance regulator. Biochemical Journal, 2001, 354, 561.	1.7	31
622	Susceptibility genes in asthma and allergy. Current Allergy and Asthma Reports, 2001, 1, 174-179.	2.4	22
623	Ileal mucosal bile acid absorption is increased in Cftr knockout mice. BMC Gastroenterology, 2001, 1, 10.	0.8	9
624	Terminal glycosylation in cystic fibrosis (CF): a review emphasizing the airway epithelial cell. Glycoconjugate Journal, 2001, 18, 649-659.	1.4	48
625	Cell line dependent involvement of ceramide in ultraviolet light-induced apoptosis. , 2001, 219, 21-27.		31
626	Complete characterization of the human ABC gene family. Journal of Bioenergetics and Biomembranes, 2001, 33, 475-479.	1.0	249
627	Cystic fibrosis: a brief look at some highlights of a decade of research focused on elucidating and correcting the molecular basis of the disease. Journal of Bioenergetics and Biomembranes, 2001, 33, 513-521.	1.0	20
628	Overview: ABC transporters and human disease. Journal of Bioenergetics and Biomembranes, 2001, 33, 453-458.	1.0	304
629	Aberrant CFTR-dependent HCO-3 transport in mutations associated with cystic fibrosis. Nature, 2001, 410, 94-97.	13.7	362
630	Voltageâ€dependent flickery block of an open cystic fibrosis transmembrane conductance regulator (CFTR) channel pore. Journal of Physiology, 2001, 532, 435-448.	1.3	50
631	A cluster of negative charges at the amino terminal tail of CFTR regulates ATPâ€dependent channel gating. Journal of Physiology, 2001, 536, 459-470.	1.3	44
632	Linkage Disequilibrium Between Microsatellite Markers Extends Beyond 1 cM on Chromosome 20 in Finns. Genome Research, 2001, 11, 1221-1226.	2.4	60
633	Cooh-Terminal Truncations Promote Proteasome-Dependent Degradation of Mature Cystic Fibrosis Transmembrane Conductance Regulator from Post-Golgi Compartments. Journal of Cell Biology, 2001, 153, 957-970.	2.3	78

#	Article	IF	Citations
634	Respiratory diseases in pregnancy bullet 4: Women with cystic fibrosis and their potential for reproduction. Thorax, 2001, 56, 649-655.	2.7	75
635	Duplex Scorpion primers in SNP analysis and FRET applications. Nucleic Acids Research, 2001, 29, 96e-96.	6.5	123
636	Is Cystic Fibrosis Lung Disease Caused by Abnormal Ion Composition or Abnormal Volume?. Journal of General Physiology, 2001, 118, 219-222.	0.9	12
637	Regulation of cystic fibrosis transmembrane conductance regulator single-channel gating by bivalent PDZ-domain-mediated interaction. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1300-1305.	3.3	204
638	Domain Interactions in the Yeast ATP Binding Cassette Transporter Ycf1p: Intragenic Suppressor Analysis of Mutations in the Nucleotide Binding Domains. Journal of Bacteriology, 2001, 183, 4761-4770.	1.0	23
639	Cftr. Journal of General Physiology, 2001, 118, 407-432.	0.9	97
640	Airway Surface Liquid. Journal of General Physiology, 2001, 117, 419-422.	0.9	9
641	Defective regulatory volume decrease in human cystic fibrosis tracheal cells because of altered regulation of intermediate conductance Ca2+-dependent potassium channels. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5329-5334.	3.3	66
642	Hsp70 Molecular Chaperone Facilitates Endoplasmic Reticulum-associated Protein Degradation of Cystic Fibrosis Transmembrane Conductance Regulator in Yeast. Molecular Biology of the Cell, 2001, 12, 1303-1314.	0.9	260
643	CFTR with a partially deleted R domain corrects the cystic fibrosis chloride transport defect in human airway epithelia in vitro and in mouse nasal mucosa in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3093-3098.	3.3	51
644	Clara cell impact in air-side activation of CFTR in small pulmonary airways. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6796-6801.	3.3	54
645	Vanadate-catalyzed photocleavage of the signature motif of an ATP-binding cassette (ABC) transporter. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9685-9690.	3.3	129
646	CFTR chloride channels are regulated by a SNAP-23/syntaxin 1A complex. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12477-12482.	3.3	70
647	HapScope: a software system for automated and visual analysis of functionally annotated haplotypes. Nucleic Acids Research, 2002, 30, 5213-5221.	6.5	34
648	Probing an Open CFTR Pore with Organic Anion Blockers. Journal of General Physiology, 2002, 120, 647-662.	0.9	62
649	Genetic screening using the colour change of a PNA-DNA hybrid-binding cyanine dye. Nucleic Acids Research, 2002, 30, 3e-3.	6.5	27
650	Intestinal mucins from cystic fibrosis mice show increased fucosylation due to an induced FucÎ±1-2 glycosyltransferase. Biochemical Journal, 2002, 367, 609-616.	1.7	50
651	Functional analysis of the C-terminal boundary of the second nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator and structural implications. Biochemical Journal, 2002, 366, 541-548.	1.7	28

#	Article	IF	Citations
652	Lung Infections Associated with Cystic Fibrosis. Clinical Microbiology Reviews, 2002, 15, 194-222.	5.7	1,412
653	Guanylin and Functional Coupling Proteins in the Human Salivary Glands and Gland Tumors. American Journal of Pathology, 2002, 161, 655-664.	1.9	35
654	Can a Place of Origin of the Main Cystic Fibrosis Mutations Be Identified?. American Journal of Human Genetics, 2002, 70, 257-264.	2.6	37
655	Bayesian Haplotype Inference for Multiple Linked Single-Nucleotide Polymorphisms. American Journal of Human Genetics, 2002, 70, 157-169.	2.6	591
656	Fine-Scale Mapping of Disease Loci via Shattered Coalescent Modeling of Genealogies. American Journal of Human Genetics, 2002, 70, 686-707.	2.6	123
657	Partition-Ligationâ€“Expectation-Maximization Algorithm for Haplotype Inference with Single-Nucleotide Polymorphisms. American Journal of Human Genetics, 2002, 71, 1242-1247.	2.6	458
658	ATP Binding to the Motor Domain from an ABC Transporter Drives Formation of a Nucleotide Sandwich Dimer. Molecular Cell, 2002, 10, 139-149.	4.5	738
659	In vitrocorrection of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique. BMC Medical Genetics, 2002, 3, 8.	2.1	39
660	Survey of CF mutations in the clinical laboratory. BMC Clinical Pathology, 2002, 2, 4.	1.8	5
661	The PEST sequence does not contribute to the stability of the cystic fibrosis transmembrane conductance regulator. , 2002, 3, 29.		5
662	Mutation of Walkerâ€A lysine 464 in cystic fibrosis transmembrane conductance regulator reveals functional interaction between its nucleotideâ€binding domains. Journal of Physiology, 2002, 539, 333-346.	1.3	66
663	Characterization of basolateral K + channels underlying anion secretion in the human airway cell line Caluâ€3. Journal of Physiology, 2002, 538, 747-757.	1.3	84
664	On the transport of lipoplexes through cystic fibrosis sputum. Pharmaceutical Research, 2002, 19, 451-456.	1.7	32
665	Cystic fibrosis transmembrane conductance regulators (CFTR) in biliary epithelium of patients with hepatolithiasis. Digestive Diseases and Sciences, 2002, 47, 1758-1765.	1.1	6
666	Transport ATPases in biological systems and relationship to human disease: a brief overview. Journal of Bioenergetics and Biomembranes, 2002, 34, 327-332.	1.0	14
667	Detection of Mutations in RET Proto-Oncogene Codon 634 Through Double Tandem Hybridization. Molecular Biotechnology, 2003, 25, 113-130.	1.3	6
668	CFTR directly mediates nucleotide-regulated glutathione flux. EMBO Journal, 2003, 22, 1981-1989.	3.5	193
669	Oligomerization of type III secretion proteins PopB and PopD precedes pore formation in Pseudomonas. EMBO Journal, 2003, 22, 4957-4967.	3.5	137

#	Article	IF	Citations
670	GFP-tagged CFTR transgene is functional in the G551D cystic fibrosis mouse colon. Journal of Membrane Biology, 2003, 192, 159-167.	1.0	10
671	Negative Regulation of CFTR Activity by Extracellular ATP Involves P2Y2 Receptors in CFTR-expressing CHO Cells. Journal of Membrane Biology, 2003, 194, 21-32.	1.0	10
672	Comparative Pharmacology of the Activity of Wild-type and G551D Mutated CFTR Chloride Channel: Effect of the Benzimidazolone Derivative NS004. Journal of Membrane Biology, 2003, 194, 109-117.	1.0	18
673	Definition of the domain boundaries is critical to the expression of the nucleotide-binding domains of P-glycoprotein. European Biophysics Journal, 2003, 32, 644-654.	1.2	12
674	Screening for cystic fibrosis: the practice and the debate. European Journal of Pediatrics, 2003, 162, S42-S45.	1.3	9
675	Impact of public health strategies on the birth prevalence of cystic fibrosis in Brittany, France. Human Genetics, 2003, 113, 280-285.	1.8	27
676	Online tool for the discrimination of equi-distributions. BMC Bioinformatics, 2003, 4, 58.	1.2	1
677	Study of human SP-A, SP-B and SP-D loci: allele frequencies, linkage disequilibrium and heterozygosity in different races and ethnic groups. BMC Genetics, 2003, 4, 13.	2.7	47
678	Disruptive effects of Anion Secretion Inhibitors on Airway Mucus Morphology in Isolated Perfused Pig Lung. Journal of Physiology, 2003, 549, 845-853.	1.3	26
679	Interleukin-10 Inhibits Elevated Chemokine Interleukin-8 and Regulated on Activation Normal T Cell Expressed and Secreted Production in Cystic Fibrosis Bronchial Epithelial Cells by Targeting the IκB Kinase Î±/Î² Complex. American Journal of Pathology, 2003, 162, 293-302.	1.9	29
680	Proposal of a CT scoring system of the paranasal sinuses in diagnosing cystic fibrosis. European Radiology, 2003, 13, 1451-1460.	2.3	27
681	Unraveling Monogenic Channelopathies and Their Implications for Complex Polygenic Disease. American Journal of Human Genetics, 2003, 72, 785-803.	2.6	64
682	â€œAre We There Yet?â€• Deciding When One Has Demonstrated Specific Genetic Causation in Complex Diseases and Quantitative Traits. American Journal of Human Genetics, 2003, 73, 711-719.	2.6	181
683	A Comparison of Bayesian Methods for Haplotype Reconstruction from Population Genotype Data. American Journal of Human Genetics, 2003, 73, 1162-1169.	2.6	3,291
684	Fine-Scale Mapping of Disease Genes with Multiple Mutations via Spatial Clustering Techniques. American Journal of Human Genetics, 2003, 73, 1368-1384.	2.6	91
685	Quality of Life in Children and Adolescents with Cystic Fibrosis. Paediatric Drugs, 2003, 5, 41-56.	1.3	31
686	On the Mechanism of MgATP-dependent Gating of CFTR Clâ^' Channels. Journal of General Physiology, 2003, 121, 17-36.	0.9	182
687	Impact of respiratory viral infections on cystic fibrosis. Postgraduate Medical Journal, 2003, 79, 201-203.	0.9	32

#	Article	IF	Citations
688	Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut, 2003, 52, 1159-1164.	6.1	143
689	Voltage-dependent Gating of the Cystic Fibrosis Transmembrane Conductance Regulator Clâ^' Channel. Journal of General Physiology, 2003, 122, 605-620.	0.9	53
690	Effects of Nitric Oxide on Pseudomonas aeruginosa Infection of Epithelial Cells from a Human Respiratory Cell Line Derived from a Patient with Cystic Fibrosis. Infection and Immunity, 2003, 71, 2341-2349.	1.0	74
691	Chronic pancreatitis and cystic fibrosis. Gut, 2003, 52, 31ii-41.	6.1	48
692	Prolonged Nonhydrolytic Interaction of Nucleotide with CFTR's NH2-terminal Nucleotide Binding Domain and its Role in Channel Gating. Journal of General Physiology, 2003, 122, 333-348.	0.9	139
693	Haplotype Information and Linkage Disequilibrium Mapping for Single Nucleotide Polymorphisms. Genome Research, 2003, 13, 2112-2117.	2.4	34
694	Effects of C-terminal deletions on cystic fibrosis transmembrane conductance regulator function in cystic fibrosis airway epithelia. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1937-1942.	3.3	59
695	Advanced glossary on genetic epidemiology. Journal of Epidemiology and Community Health, 2003, 57, 562-564.	2.0	6
696	Integration of association statistics over genomic regions using Bayesian adaptive regression splines. Human Genomics, 2003, 1, 20-9.	1.4	36
697	Cystic fibrosis transmembrane conductance regulator: the NBF1+R (nucleotide-binding fold 1 and) Tj ETQq1 1 0.784314 rgBT /Overlo inhibited by both Cd2+ and the transition-state analogue orthovanadate. Biochemical Journal, 2003, 371, 451-462.	1.7	8
698	Dimeric cystic fibrosis transmembrane conductance regulator exists in the plasma membrane. Biochemical Journal, 2003, 374, 793-797.	1.7	41
699	Stable dimeric assembly of the second membrane-spanning domain of CFTR (cystic fibrosis) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 2003, 375, 633-641.	1.7	19
700	A foldable CFTRÎ”F508 biogenic intermediate accumulates upon inhibition of the Hsc70â€“CHIP E3 ubiquitin ligase. Journal of Cell Biology, 2004, 167, 1075-1085.	2.3	161
701	Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7693-7698.	3.3	87
702	Bacterial Overgrowth in the Cystic Fibrosis Transmembrane Conductance Regulator Null Mouse Small Intestine. Infection and Immunity, 2004, 72, 6040-6049.	1.0	160
703	Î”F508 CFTR Pool in the Endoplasmic Reticulum Is Increased by Calnexin Overexpression. Molecular Biology of the Cell, 2004, 15, 563-574.	0.9	87
704	Epithelial Cell Polarity Alters Rho-GTPase Responses toPseudomonas aeruginosa. Molecular Biology of the Cell, 2004, 15, 411-419.	0.9	42
705	Cystic Fibrosis Transmembrane Conductance Regulator Degradation Depends on the Lectins Htm1p/EDEM and the Cdc48 Protein Complex in Yeast. Molecular Biology of the Cell, 2004, 15, 4125-4135.	0.9	90

#	Article	IF	Citations
706	Interleukin 8 Secretion from Monocytes of Subjects Heterozygous for the Î”F508 Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutation Is Altered. Vaccine Journal, 2004, 11, 819-824.	2.6	77
707	Vitamin C controls the cystic fibrosis transmembrane conductance regulator chloride channel. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3691-3696.	3.3	83
708	Jaagsiekte Sheep Retrovirus Envelope Efficiently Pseudotypes Human Immunodeficiency Virus Type 1-Based Lentiviral Vectors. Journal of Virology, 2004, 78, 2642-2647.	1.5	22
709	Ceramide, a target for antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15452-15457.	3.3	94
710	Reversal of cystic fibrosis phenotype in a cultured Â508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8150-8155.	3.3	35
711	AlgX Is a Periplasmic Protein Required for Alginate Biosynthesis in Pseudomonas aeruginosa. Journal of Bacteriology, 2004, 186, 7369-7377.	1.0	67
712	Impact of population structure, effective bottleneck time, and allele frequency on linkage disequilibrium maps. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 18075-18080.	3.3	44
713	Stimulatory and inhibitory protein kinase C consensus sequences regulate the cystic fibrosis transmembrane conductance regulator. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 390-395.	3.3	74
714	Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO Journal, 2004, 23, 282-293.	3.5	376
715	Protein kinaseâ€independent activation of CFTR by phosphatidylinositol phosphates. EMBO Reports, 2004, 5, 85-90.	2.0	26
716	Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation. EMBO Reports, 2004, 5, 1071-1077.	2.0	65
717	Gene therapy for cystic fibrosis: an example for lung gene therapy. Gene Therapy, 2004, 11, S43-S50.	2.3	49
718	General anesthetic octanol and related compounds activate wild-type and delF508 cystic fibrosis chloride channels. British Journal of Pharmacology, 2004, 141, 905-914.	2.7	10
719	Faster activation of polymorphonuclear neutrophils in resistant mice during early innate response to Pseudomonas aeruginosa lung infection. Clinical and Experimental Immunology, 2004, 137, 478-485.	1.1	27
720	Liquid secretion properties of airway submucosal glands. Journal of Physiology, 2004, 556, 1-10.	1.3	84
721	Haplotype frequency estimation error analysis in the presence of missing genotype data. BMC Bioinformatics, 2004, 5, 188.	1.2	8
722	GeneLink: a database to facilitate genetic studies of complex traits. BMC Genomics, 2004, 5, 81.	1.2	7
723	Activation of VPAC1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion. British Journal of Pharmacology, 2004, 141, 698-708.	2.7	46

#	Article	IF	Citations
724	CFTR and Chaperones: Processing and Degradation. Journal of Molecular Neuroscience, 2004, 23, 041-048.	1.1	121
725	CFTR Transgene Expression in Primary Î”F508 Epithelial Cell Cultures From Human Nasal Polyps Following Gene Transfer With Cationic Phosphonolipids. Molecular Biotechnology, 2004, 26, 193-206.	1.3	14
726	Ion channels and membrane rafts in apoptosis. Pflugers Archiv European Journal of Physiology, 2004, 448, 304-312.	1.3	63
727	Direct effects of 9-anthracene compounds on cystic fibrosis transmembrane conductance regulator gating. Pflugers Archiv European Journal of Physiology, 2004, 449, 88-95.	1.3	15
728	Three ATP-binding cassette transporter genes, Abca14 , Abca15 , and Abca16 , form a cluster on mouse Chromosome 7F3. Mammalian Genome, 2004, 15, 335-343.	1.0	17
729	Steady-State Interactions of Glibenclamide with CFTR: Evidence for Multiple Sites in the Pore. Journal of Membrane Biology, 2004, 199, 15-28.	1.0	24
730	Time-dependent Interactions of Glibenclamide with CFTR: Kinetically Complex Block of Macroscopic Currents. Journal of Membrane Biology, 2004, 201, 139-155.	1.0	16
731	Biogenesis of CFTR and other Polytopic Membrane Proteins: New Rolesfor the Ribosome-Translocon Complex. Journal of Membrane Biology, 2004, 202, 115-126.	1.0	46
732	Hepatobiliary complications of cystic fibrosis. Current Gastroenterology Reports, 2004, 6, 231-239.	1.1	43
733	The "Goldilocks effect" in cystic fibrosis: identification of a lung phenotype in the cftr knockout and heterozygous mouse. BMC Genetics, 2004, 5, 21.	2.7	48
734	Molecular analysis using DHPLC of cystic fibrosis: increase of the mutation detection rate among the affected population in Central Italy. BMC Medical Genetics, 2004, 5, 8.	2.1	19
735	Characterization of the Adenosinetriphosphatase and Transport Activities of Purified Cystic Fibrosis Transmembrane Conductance Regulator. Biochemistry, 2004, 43, 1045-1053.	1.2	16
737	Pharmacokinetics of Ibuprofen in Children with Cystic Fibrosis. Clinical Pharmacokinetics, 2004, 43, 145-156.	1.6	7
738	Microsphere Bead Arrays and Sequence Validation of 5/7/9T Genotypes for Multiplex Screening of Cystic Fibrosis Polymorphisms. Journal of Molecular Diagnostics, 2004, 6, 348-355.	1.2	16
739	Characteristic Multiorgan Pathology of Cystic Fibrosis in a Long-Living Cystic Fibrosis Transmembrane Regulator Knockout Murine Model. American Journal of Pathology, 2004, 164, 1481-1493.	1.9	152
740	Gene therapy in clinical medicine. Postgraduate Medical Journal, 2004, 80, 560-570.	0.9	52
741	Positional Cloning by Linkage Disequilibrium. American Journal of Human Genetics, 2004, 74, 846-855.	2.6	53
742	Linkage Disequilibrium Mapping via Cladistic Analysis of Single-Nucleotide Polymorphism Haplotypes. American Journal of Human Genetics, 2004, 75, 35-43.	2.6	173

#	Article	IF	Citations
743	Novel molecular approaches to cystic fibrosis gene therapy. Biochemical Journal, 2005, 387, 1-15.	1.7	73
744	Diagnosis of chronic rhinosinusitis in patients with cystic fibrosis: correlation between anamnesis, nasal endoscopy and computed tomography. Brazilian Journal of Otorhinolaryngology, 2005, 71, 705-710.	0.4	23
745	Control of the CFTR channel's gates. Biochemical Society Transactions, 2005, 33, 1003.	1.6	31
746	Mucin glycosylation changes in cystic fibrosis lung disease are not manifest in submucosal gland secretions. Biochemical Journal, 2005, 387, 911-919.	1.7	48
747	Sphingomyelins suppress the targeted disruption of lysosomes/endosomes by the photosensitizer NPe6 during photodynamic therapy. Biochemical Journal, 2005, 392, 325-334.	1.7	46
748	Side chain and backbone contributions of Phe508 to CFTR folding. Nature Structural and Molecular Biology, 2005, 12, 10-16.	3.6	173
749	Deficiency of the mannan-binding lectin pathway of complement and poor outcome in cystic fibrosis: bacterial colonization may be decisive for a relationship. Clinical and Experimental Immunology, 2005, 139, 306-313.	1.1	70
750	CFTR fails to inhibit the epithelial sodium channel ENaC expressed inXenopus laevisoocytes. Journal of Physiology, 2005, 564, 671-682.	1.3	45
751	Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Clâ"transport of mouse aortic smooth muscle cells. Journal of Physiology, 2005, 568, 483-495.	1.3	69
752	A haplotype map of the human genome. Nature, 2005, 437, 1299-1320.	13.7	5,440
753	Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment. Pediatric Radiology, 2005, 35, 739-757.	1.1	33
754	Fifty-year perspective of â€œcystic fibrosis of the pancreasâ€• Pediatric Radiology, 2005, 35, 735-738.	1.1	2
756	Linkage disequilibrium in European elite maize germplasm investigated with SSRs. Theoretical and Applied Genetics, 2005, 111, 723-730.	1.8	167
757	Analysis of most common CFTR mutations in patients affected by nasal polyps. European Archives of Oto-Rhino-Laryngology, 2005, 262, 982-986.	0.8	9
758	Retinol binding protein status in relation to ocular surface changes in patients with cystic fibrosis treated with daily vitamin A supplements. European Journal of Pediatrics, 2005, 164, 202-206.	1.3	9
759	A neutral variant involved in a complex CFTR allele contributes to a severe cystic fibrosis phenotype. Human Genetics, 2005, 116, 454-460.	1.8	26
760	The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Human Genetics, 2005, 118, 372-381.	1.8	112
761	The epidemiology and impact of pancreatic diseases in the United States. Current Gastroenterology Reports, 2005, 7, 90-95.	1.1	74

#	Article	IF	Citations
762	Rescue of Folding Defects in ABC Transporters Using Pharmacological Chaperones. Journal of Bioenergetics and Biomembranes, 2005, 37, 501-507.	1.0	51
763	Cystic Fibrosis Prenatal Screening in Genetic Counseling Practice: Recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 2005, 14, 1-15.	0.9	25
764	Mutation Analysis of SPINK1 and CFTR Gene in Korean Patients with Alcoholic Chronic Pancreatitis. Digestive Diseases and Sciences, 2005, 50, 1852-1856.	1.1	23
765	Targeted activation of transcription in vivo through hairpin-triplex forming oligonucleotide in Saccharomyces cerevisiae. Molecular and Cellular Biochemistry, 2005, 278, 147-155.	1.4	15
766	Characterization of Polarized Expression of Point- or Deletion-Mutated Human BCRP/ABCG2 in LLC-PK1 Cells. Pharmaceutical Research, 2005, 22, 458-464.	1.7	46
767	Pathophysiologic consequences following inhibition of a CFTR-dependent developmental cascade in the lung. , 2005, 5, 2.		29
768	Potential genetic modifiers of the cystic fibrosis intestinal inflammatory phenotype on mouse chromosomes 1, 9, and 10. , 2005, 6, 29.		17
769	Early Immune Response to the Components of the Type III System of Pseudomonas aeruginosa in Children with Cystic Fibrosis. Journal of Clinical Microbiology, 2005, 43, 3956-3962.	1.8	59
770	Coalescent-Based Association Mapping and Fine Mapping of Complex Trait Loci. Genetics, 2005, 169, 1071-1092.	1.2	111
771	Human pancreatic exocrine response to nutrients in health and disease. Gut, 2005, 54, 1-28.	6.1	272
772	Polymorphisms in Cinnamoyl CoA Reductase (CCR) Are Associated With Variation in Microfibril Angle in Eucalyptus spp.. Genetics, 2005, 171, 1257-1265.	1.2	214
773	CFTR Gating I. Journal of General Physiology, 2005, 125, 361-375.	0.9	58
774	Reversible Silencing of CFTR Chloride Channels by Glutathionylation. Journal of General Physiology, 2005, 125, 127-141.	0.9	79
775	Pseudomonas aeruginosa Acquires Biofilm-Like Properties within Airway Epithelial Cells. Infection and Immunity, 2005, 73, 8298-8305.	1.0	110
776	A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2952-2957.	3.3	86
777	Binding of Pseudomonas aeruginosa AlgZ to Sites Upstream of the algZ Promoter Leads to Repression of Transcription. Journal of Bacteriology, 2005, 187, 4430-4443.	1.0	26
778	Preferential Phosphorylation of R-domain Serine 768 Dampens Activation of CFTR Channels by PKA. Journal of General Physiology, 2005, 125, 171-186.	0.9	66
779	ADP inhibits function of the ABC transporter cystic fibrosis transmembrane conductance regulator via its adenylate kinase activity. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2216-2220.	3.3	28

#	Article	IF	Citations
780	Functional Roles of Nonconserved Structural Segments in CFTR's NH2-terminal Nucleotide Binding Domain. Journal of General Physiology, 2005, 125, 43-55.	0.9	55
781	Pathogenâ€“Host Interactions inPseudomonas aeruginosaPneumonia. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1209-1223.	2.5	701
782	Normal gating of CFTR requires ATP binding to both nucleotide-binding domains and hydrolysis at the second nucleotide-binding domain. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 455-460.	3.3	85
783	Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. Journal of Experimental Medicine, 2005, 202, 249-259.	4.2	142
784	Breakpoints for Predicting Pseudomonas aeruginosa Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips. Journal of Clinical Microbiology, 2005, 43, 4480-4485.	1.8	50
785	Complete Gene Scanning by Temperature Gradient Capillary Electrophoresis Using the Cystic Fibrosis Transmembrane Conductance Regulator Gene as a Model. Journal of Molecular Diagnostics, 2005, 7, 111-120.	1.2	16
786	Diagnostic Testing by CFTR Gene Mutation Analysis in a Large Group of Hispanics. Journal of Molecular Diagnostics, 2005, 7, 289-299.	1.2	40
787	Bayesian Association-Based Fine Mapping in Small Chromosomal Segments. Genetics, 2005, 169, 427-439.	1.2	32
788	ATP-binding cassette (ABC) transporters in normal and pathological lung. Respiratory Research, 2005, 6, 59.	1.4	167
789	Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review. Health and Quality of Life Outcomes, 2005, 3, 19.	1.0	44
790	Asymmetric Addition of Ceramides but not Dihydroceramides Promotes Transbilayer (Flip-Flop) Lipid Motion in Membranes. Biophysical Journal, 2005, 88, 348-359.	0.2	100
791	The Block of CFTR by Scorpion Venom is State-Dependent. Biophysical Journal, 2005, 89, 3960-3975.	0.2	17
792	Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax, 2005, 60, 558-563.	2.7	81
793	A New Insertion/Deletion of the Cystic Fibrosis Transmembrane Conductance Regulator Gene Accounts for 3.4% of Cystic Fibrosis Mutations in Sardinia: Implications for Population Screening. Journal of Molecular Diagnostics, 2006, 8, 499-503.	1.2	15
794	No Longer Just Looking under the Lamppost**Previously presented at the annual meeting of The American Society of Human Genetics, in Salt Lake City, on October 28, 2005.. American Journal of Human Genetics, 2006, 79, 421-426.	2.6	16
795	Regulation of Chemokine Expression by NaCl Occurs Independently of Cystic Fibrosis Transmembrane Conductance Regulator in Macrophages. American Journal of Pathology, 2006, 169, 12-20.	1.9	14
796	Detection of an Apparent Homozygous 3120G>A Cystic Fibrosis Mutation on a Routine Carrier Screen. Journal of Molecular Diagnostics, 2006, 8, 137-140.	1.2	8
797	Obesity and Its Therapy: From Genes to Community Action. Pediatric Clinics of North America, 2006, 53, 777-794.	0.9	11

#	Article	IF	Citations
798	Detergent-Resistant, Ceramide-Enriched Domains in Sphingomyelin/Ceramide Bilayers. Biophysical Journal, 2006, 90, 903-914.	0.2	141
799	Membrane Lateral Diffusion and Capture of CFTR within Transient Confinement Zones. Biophysical Journal, 2006, 91, 1046-1058.	0.2	81
800	Evidence that CFTR is expressed in rat tracheal smooth muscle cells and contributes to bronchodilation. Respiratory Research, 2006, 7, 113.	1.4	54
801	Activation of chloride transport in CF airway epithelial cell lines and primary CF nasal epithelial cells by S-nitrosoglutathione. Respiratory Research, 2006, 7, 124.	1.4	33
802	Azithromycin reduces spontaneous and induced inflammation in Î”F508 cystic fibrosis mice. Respiratory Research, 2006, 7, 134.	1.4	88
803	Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator. Respiratory Research, 2006, 7, 51.	1.4	22
804	CFTR Expression in Human Neutrophils and the Phagolysosomal Chlorination Defect in Cystic Fibrosisâ€. Biochemistry, 2006, 45, 10260-10269.	1.2	241
805	A Haplotype Framework for Cystic Fibrosis Mutations in Iran. Journal of Molecular Diagnostics, 2006, 8, 119-127.	1.2	29
806	The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants. Biochemical Journal, 2006, 395, 537-542.	1.7	45
807	Spontaneous rescue from cystic fibrosis in a mouse model. BMC Genetics, 2006, 7, 18.	2.7	23
808	Cryptosporidium parvum infects human cholangiocytes via sphingolipid-enriched membrane microdomains. Cellular Microbiology, 2006, 8, 1932-1945.	1.1	42
809	p97 functions as an auxiliary factor to facilitate TM domain extraction during CFTR ER-associated degradation. EMBO Journal, 2006, 25, 4557-4566.	3.5	60
810	Serum Factors from Pseudoxanthoma Elasticum Patients Alter Elastic Fiber Formation In Vitro. Journal of Investigative Dermatology, 2006, 126, 1497-1505.	0.3	73
811	CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clinical and Experimental Immunology, 2006, 145, 235-242.	1.1	44
812	Using a cysteine-less mutant to provide insight into the structure and mechanism of CFTR. Journal of Physiology, 2006, 572, 312-312.	1.3	9
813	Radiological imaging of inflammatory lesions in the nasal cavity and paranasal sinuses. European Radiology, 2006, 16, 872-888.	2.3	116
814	The nature of amino acid 482 of human ABCG2 affectsÂsubstrate transport and ATP hydrolysis but not substrate binding. Protein Science, 2006, 15, 1597-1607.	3.1	67
815	Nocturnal Hydrationâ€"An Effective Modality to Reduce Recurrent Abdominal Pain and Recurrent Pancreatitis in Patients with Adult-Onset Cystic Fibrosis. Digestive Diseases and Sciences, 2006, 51, 1744-1748.	1.1	5

#	Article	IF	Citations
816	Light and alcohol evoked electro-oculograms in cystic fibrosis. Documenta Ophthalmologica, 2006, 113, 133-143.	1.0	12
817	Fifty years of genetic epidemiology, with special reference to Japan. Journal of Human Genetics, 2006, 51, 269-277.	1.1	5
818	Differential expression of calcium-activated chloride channels (CLCA) gene family members in the small intestine of cystic fibrosis mouse models. Histochemistry and Cell Biology, 2006, 126, 239-250.	0.8	19
819	Detecting genome wide haplotype sharing using SNP or microsatellite haplotype data. Human Genetics, 2006, 119, 38-50.	1.8	10
820	Characterisation of chloride currents across the proximal colon in Cftr TgH(neoim)1Hgu congenic mice. Journal of Comparative Physiology B: Biochemical, Systemic, and Environmental Physiology, 2006, 177, 61-73.	0.7	12
821	Abdominal manifestations of cystic fibrosis in children. Pediatric Radiology, 2006, 36, 233-240.	1.1	96
822	Diversity of Clâ˜' Channels. Cellular and Molecular Life Sciences, 2006, 63, 12-24.	2.4	98
824	The motor domains of ABC-transporters. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 372, 385-399.	1.4	127
825	Liver involvement in cystic fibrosis. Current Treatment Options in Gastroenterology, 2006, 9, 484-496.	0.3	14
826	Whole genome association mapping by incompatibilities and local perfect phylogenies. BMC Bioinformatics, 2006, 7, 454.	1.2	41
827	Application of DETECTER, an evolutionary genomic tool to analyze genetic variation, to the cystic fibrosis gene family. BMC Genomics, 2006, 7, 44.	1.2	8
828	Abnormalities in the Pulmonary Innate Immune System in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 364-374.	1.4	36
829	Restoration of Mucociliary Transport in the Fluid-DepletedTrachea by Surface-Active Instillates. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 500-504.	1.4	27
830	SERCA Pump Inhibitors Do Not Correct Biosynthetic Arrest of Î"F508 CFTR in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 355-363.	1.4	52
831	Apoptosis of Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 399-409.	1.4	84
832	Positive Charges at the Intracellular Mouth of the Pore Regulate Anion Conduction in the CFTR Chloride Channel. Journal of General Physiology, 2006, 128, 535-545.	0.9	73
833	Newborn screening for cystic fibrosis: do we need a second IRT?. Archives of Disease in Childhood, 2006, 91, 209-210.	1.0	13
834	Association Mapping of Complex Trait Loci With Context-Dependent Effects and Unknown Context Variable. Genetics, 2006, 174, 1597-1611.	1.2	14

#	Article	IF	Citations
835	Phospholipase A 2 Functions in Pseudomonas aeruginosa - Induced Apoptosis. Infection and Immunity, 2006, 74, 850-860.	1.0	30
836	The cystic fibrosis transmembrane conductance regulator (Cftr) modulates the timing of puberty in mice. Journal of Medical Genetics, 2006, 43, e29-e29.	1.5	23
837	Acid Sphingomyelinase Deficiency Increases Susceptibility to Fatal Alphavirus Encephalomyelitis. Journal of Virology, 2006, 80, 10989-10999.	1.5	35
838	COX-2: a link between airway inflammation and disordered chloride secretion in cystic fibrosis?. Thorax, 2006, 61, 552-553.	2.7	7
839	The Two ATP Binding Sites of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Play Distinct Roles in Gating Kinetics and Energetics. Journal of General Physiology, 2006, 128, 413-422.	0.9	71
840	Thermodynamics of CFTR Channel Gating: A Spreading Conformational Change Initiates an Irreversible Gating Cycle. Journal of General Physiology, 2006, 128, 523-533.	0.9	54
841	Role of Sphingolipids in Microbial Pathogenesis. Infection and Immunity, 2006, 74, 28-39.	1.0	188
842	The Pseudomonas aeruginosa Secreted Protein PA2934 Decreases Apical Membrane Expression of the Cystic Fibrosis Transmembrane Conductance Regulator. Infection and Immunity, 2007, 75, 3902-3912.	1.0	107
843	Resistance to Pseudomonas aeruginosa Chronic Lung Infection Requires Cystic Fibrosis Transmembrane Conductance Regulator-Modulated Interleukin-1 (IL-1) Release and Signaling through the IL-1 Receptor. Infection and Immunity, 2007, 75, 1598-1608.	1.0	66
844	The Formation of the cAMP/Protein Kinase A-dependent Annexin 2â€“S100A10 Complex with Cystic Fibrosis Conductance Regulator Protein (CFTR) Regulates CFTR Channel Function. Molecular Biology of the Cell, 2007, 18, 3388-3397.	0.9	50
845	G551D and G1349D, Two CF-associated Mutations in the Signature Sequences of CFTR, Exhibit Distinct Gating Defects. Journal of General Physiology, 2007, 129, 285-298.	0.9	131
846	Haplotype Thinking in Lung Disease. Proceedings of the American Thoracic Society, 2007, 4, 4-8.	3.5	11
847	Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis. Proceedings of the American Thoracic Society, 2007, 4, 370-377.	3.5	57
848	Inhibition of CFTR Cl- channel function caused by enzymatic hydrolysis of sphingomyelin. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6448-6453.	3.3	33
849	Heritability of Lung Disease Severity in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1036-1043.	2.5	171
850	Strategies for Identifying Modifier Genes in Cystic Fibrosis. Proceedings of the American Thoracic Society, 2007, 4, 52-57.	3.5	41
851	VCP/p97 AAA-ATPase Does Not Interact with the Endogenous Wild-Type Cystic Fibrosis Transmembrane Conductance Regulator. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 706-714.	1.4	13
852	Prediction of Cellular Immune Responses against CFTR in Patients with Cystic Fibrosis after Gene Therapy. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 529-533.	1.4	18

#	Article	IF	Citations
853	Inhibiting Endoplasmic Reticulum (ER)-associated Degradation of Misfolded Yor1p Does Not Permit ER Export Despite the Presence of a Diacidic Sorting Signal. Molecular Biology of the Cell, 2007, 18, 3398-3413.	0.9	51
854	Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens. Philosophical Transactions of the Royal Society B: Biological Sciences, 2007, 362, 1213-1222.	1.8	149
855	Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening. Archives of Disease in Childhood, 2007, 92, 842-846.	1.0	30
856	Genetics of Gestational Diabetes Mellitus and Type 2 Diabetes. Diabetes Care, 2007, 30, S134-S140.	4.3	51
857	Acute renal failure in people with cystic fibrosis. Thorax, 2007, 62, 472-473.	2.7	5
858	Constitutive Acid Sphingomyelinase Enhances Early and Late Macrophage Killing of Salmonella enterica Serovar Typhimurium. Infection and Immunity, 2007, 75, 5346-5352.	1.0	41
859	Sphingomyelinase Restricts the Lateral Diffusion of CD4 and Inhibits Human Immunodeficiency Virus Fusion. Journal of Virology, 2007, 81, 5294-5304.	1.5	55
860	Processing and function of CFTR-Î”F508 are species-dependent. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15370-15375.	3.3	105
861	The Walker B motif of the second nucleotide-binding domain (NBD2) of CFTR plays a key role in ATPase activity by the NBD1â€“NBD2 heterodimer. Biochemical Journal, 2007, 401, 581-586.	1.7	41
862	Pseudomonas aeruginosa and sPLA2 IB stimulate ABCA1-mediated phospholipid efflux via ERK-activation of PPARÎ±â€“RXR. Biochemical Journal, 2007, 403, 409-420.	1.7	33
863	Activation mechanisms for the cystic fibrosis transmembrane conductance regulator protein involve direct binding of cAMP. Biochemical Journal, 2007, 405, 181-189.	1.7	6
864	Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochemical Journal, 2007, 406, 257-263.	1.7	55
865	Liquid movement across the surface epithelium of large airways. Respiratory Physiology and Neurobiology, 2007, 159, 256-270.	0.7	81
866	Fluid secretion by submucosal glands of the tracheobronchial airways. Respiratory Physiology and Neurobiology, 2007, 159, 271-277.	0.7	69
867	Hydrogen-bond formation of the residue in H-loop of the nucleotide binding domain 2 with the ATP in this site and/or other residues of multidrug resistance protein MRP1 plays a crucial role during ATP-dependent solute transport. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 324-335.	1.4	11
868	Effect of ceramide N-acyl chain and polar headgroup structure on the properties of ordered lipid domains (lipid rafts). Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 2205-2212.	1.4	85
869	The phenyltetraene lysophospholipid analog PTE-ET-18-OMe as a fluorescent anisotropy probe of liquid ordered membrane domains (lipid rafts) and ceramide-rich membrane domains. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 2213-2221.	1.4	4
870	Rad50 Adenylate Kinase Activity Regulates DNA Tethering by Mre11/Rad50 Complexes. Molecular Cell, 2007, 25, 647-661.	4.5	94

#	Article	IF	Citations
871	Antioxidants in cystic fibrosisâ˜†Conclusions from the CF Antioxidant Workshop, Bethesda, Maryland, November 11-12, 2003. Free Radical Biology and Medicine, 2007, 42, 15-31.	1.3	105
872	Genome Scanning by Composite Likelihood. American Journal of Human Genetics, 2007, 80, 19-28.	2.6	17
873	Infections in Chronic Lung Diseases. Infectious Disease Clinics of North America, 2007, 21, 673-695.	1.9	8
874	Host Resistance to Lung Infection Mediated by Major Vault Protein in Epithelial Cells. Science, 2007, 317, 130-132.	6.0	116
875	A Comparative Study of Five Technologically Diverse CFTR Testing Platforms. Journal of Molecular Diagnostics, 2007, 9, 401-407.	1.2	23
876	Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut, 2007, 56, 1153-1163.	6.1	140
877	Cystic Fibrosis Transmembrane Regulator Protein Mutations. Paediatric Drugs, 2007, 9, 1-10.	1.3	34
878	Design, Development, Validation, and Use of Synthetic Nucleic Acid Controls for Diagnostic Purposes and Application to Cystic Fibrosis Testing. Journal of Molecular Diagnostics, 2007, 9, 315-319.	1.2	11
879	AnÃ¡lisis farmacoeconÃ³mico de la pentoxifilina en Ãºlceras venosas. Angiologia, 2007, 59, 45-54.	0.0	65
880	Simulation of the Coupling between Nucleotide Binding and Transmembrane Domains in the ATP Binding Cassette Transporter BtuCD. Biophysical Journal, 2007, 92, 2727-2734.	0.2	53
881	Evaluating candidate agents of selective pressure for cystic fibrosis. Journal of the Royal Society Interface, 2007, 4, 91-98.	1.5	53
882	Recent insights into the cellular mechanisms of acute pancreatitis. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 19-24.	1.8	31
883	Genetic mapping of a new heart rate QTL on chromosome 8 of spontaneously hypertensive rats. BMC Medical Genetics, 2007, 8, 17.	2.1	30
884	Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 256-262.	1.0	61
885	CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. Nature Structural and Molecular Biology, 2007, 14, 738-745.	3.6	267
886	Burkholderia cenocepacia ET12 strain activates TNFR1 signalling in cystic fibrosis airway epithelial cells. Cellular Microbiology, 2007, 10, 070816152918003-???.	1.1	22
887	Recent advances in the immunobiology of ceramide. Experimental and Molecular Pathology, 2007, 82, 298-309.	0.9	35
888	Characterization of a 7,8-Benzoflavone Double Effect on CFTR Cl- Channel Activity. Journal of Membrane Biology, 2007, 220, 1-9.	1.0	5

#	Article	IF	Citations
889	Variation in the ligand binding domains of the CD94/NKG2 family of receptors in the squirrel monkey. Immunogenetics, 2007, 59, 799-811.	1.2	2
890	Bayesian association mapping of multiple quantitative trait loci and its application to the analysis of genetic variation among Oryza sativa L. germplasms. Theoretical and Applied Genetics, 2007, 114, 1437-1449.	1.8	47
891	Potential causes of linkage disequilibrium in a European maize breeding program investigated with computer simulations. Theoretical and Applied Genetics, 2007, 115, 529-536.	1.8	20
892	Hepatolithiasis and Cholangiocarcinoma in Cystic Fibrosis: A Case Series and Review of the Literature. Digestive Diseases and Sciences, 2007, 52, 2638-2642.	1.1	21
893	Inhibition of anion channels derived from mitochondrial membranes of the rat heart by stilbene disulfonateâ€"DIDS. Journal of Bioenergetics and Biomembranes, 2007, 39, 301-311.	1.0	16
894	Identification of ClC-2 and CIC-K2 Chloride Channels in Cultured Rat Type IV Spiral Ligament Fibrocytes. JARO - Journal of the Association for Research in Otolaryngology, 2007, 8, 205-219.	0.9	16
895	CFTR (ABCC7) is a hydrolyzable-ligand-gated channel. Pflugers Archiv European Journal of Physiology, 2007, 453, 693-702.	1.3	74
896	Unexpected diagnosis of cystic fibrosis at liver biopsy: a report of four pediatric cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 57-64.	1.4	9
897	Genetic aspects of tropical calcific pancreatitis. Reviews in Endocrine and Metabolic Disorders, 2008, 9, 213-226.	2.6	22
898	Expression of cystic fibrosis transmembrane conductance regulator in rat ovary. Journal of Huazhong University of Science and Technology [Medical Sciences], 2008, 28, 584-587.	1.0	3
899	Role of Ca2+-activated ion transport in the treatment of cystic fibrosis. Wiener Medizinische Wochenschrift, 2008, 158, 562-564.	0.5	4
900	Evidence for phosphorylation of serine 753 in CFTR using a novel metalâ€ion affinity resin and matrixâ€assisted laser desorption mass spectrometry. Protein Science, 1997, 6, 2436-2445.	3.1	228
901	Update on gene modifiers in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2008, 14, 559-566.	1.2	115
902	Genetic Mapping in Human Disease. Science, 2008, 322, 881-888.	6.0	1,289
903	Spiperone, identified through compound screening, activates calcium-dependent chloride secretion in the airway. American Journal of Physiology - Cell Physiology, 2009, 296, C131-C141.	2.1	13
904	ATP hydrolysis-driven gating in cystic fibrosis transmembrane conductance regulator. Philosophical Transactions of the Royal Society B: Biological Sciences, 2009, 364, 247-255.	1.8	49
905	CFTR and defective endocytosis: new insights in the renal phenotype of cystic fibrosis. Pflugers Archiv European Journal of Physiology, 2009, 457, 1227-1236.	1.3	35
906	Allelic Association: Linkage Disequilibrium Structure and Gene Mapping. Molecular Biotechnology, 2009, 41, 83-89.	1.3	19

#	Article	IF	Citations
907	CFTR structure and function: is there a role in the kidney?. Biophysical Reviews, 2009, 1, 3-12.	1.5	18
908	Salmeterol Restores Secretory Functions in Cystic Fibrosis Airway Submucosal Gland Serous Cells. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 388-397.	1.4	30
909	Nasal endoscopic evaluation of children and adolescents with cystic fibrosis. Brazilian Journal of Otorhinolaryngology, 2009, 75, 806-813.	0.4	7
910	Role of multislice computed tomography in the diagnosis of gene-mutation-associated pancreatitis (GMAP). Radiologia Medica, 2010, 115, 875-888.	4.7	6
911	Rehabilitation Programs for Cystic Fibrosis - View from a CF Center. Open Respiratory Medicine Journal, 2010, 4, 1-8.	1.3	12
912	Lentiviral Vectors and Cystic Fibrosis Gene Therapy. Viruses, 2010, 2, 395-412.	1.5	22
913	Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis. Genetics in Medicine, 2010, 12, S194-S211.	1.1	36
914	Cholesterol and Ion Channels. Sub-Cellular Biochemistry, 2010, 51, 509-549.	1.0	179
915	Whole-Genome Sequencing in a Patient with Charcotâ€“Marieâ€“Tooth Neuropathy. New England Journal of Medicine, 2010, 362, 1181-1191.	13.9	698
916	In Vitro Recovery of ATP-Sensitive Potassium Channels in Â-Cells From Patients With Congenital Hyperinsulinism of Infancy. Diabetes, 2011, 60, 1223-1228.	0.3	17
917	Genetic modifiers of nutritional status in cystic fibrosis. American Journal of Clinical Nutrition, 2012, 96, 1299-1308.	2.2	34
918	Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clinical Investigation, 2012, 2, 163-175.	0.0	31
919	Manipulation of Cell Physiology Enables Gene Silencing in Well-differentiated Airway Epithelia. Molecular Therapy - Nucleic Acids, 2012, 1, e41.	2.3	24
920	Use of Kinase Inhibitors to Correct Î”F508-CFTR Function. Molecular and Cellular Proteomics, 2012, 11, 745-757.	2.5	31
921	Seizure control in a patient with Dravet syndrome and cystic fibrosis. Epilepsy & Behavior Case Reports, 2013, 1, 42-44.	1.5	3
922	Incorporate gene signature profiling into routine molecular testing. Applied & Translational Genomics, 2013, 2, 28-33.	2.1	3
923	Membrane Signaling Induced by High Doses of Ionizing Radiation in the Endothelial Compartment. Relevance in Radiation Toxicity. International Journal of Molecular Sciences, 2013, 14, 22678-22696.	1.8	62
924	Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. European Respiratory Review, 2013, 22, 58-65.	3.0	88

#	Article	IF	Citations
925	Evidence for the Formation of Symmetric and Asymmetric DLPC-DAPC Lipid Bilayer Domains. Cellular Physiology and Biochemistry, 2013, 32, 46-52.	1.1	2,686
926	Efficient Gene Delivery to Pig Airway Epithelia and Submucosal Glands Using Helper-Dependent Adenoviral Vectors. Molecular Therapy - Nucleic Acids, 2013, 2, e127.	2.3	37
927	Ceramide in cystic fibrosis. Clinical Lipidology, 2013, 8, 681-692.	0.4	4
928	A comprehensive review of genetics and genetic testing in azoospermia. Clinics, 2013, 68, 39-60.	0.6	148
929	GBA2-Encoded Î²-Glucosidase Activity Is Involved in the Inflammatory Response to Pseudomonas aeruginosa. PLoS ONE, 2014, 9, e104763.	1.1	19
930	Genetic Testing in the Diagnosis of Primary Ciliary Dyskinesia: State-of-the-Art and Future Perspectives. Journal of Clinical Medicine, 2014, 3, 491-503.	1.0	21
931	Regulation of the Inflammasome by Ceramide in Cystic Fibrosis Lungs. Cellular Physiology and Biochemistry, 2014, 34, 45-55.	1.1	49
932	Invariant Natural Killer T (iNKT) Cells Prevent Autoimmunity, but Induce Pulmonary Inflammation in Cystic Fibrosis. Cellular Physiology and Biochemistry, 2014, 34, 56-70.	1.1	24
933	Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons. Frontiers in Physiology, 2014, 5, 331.	1.3	103
934	Ivacaftor: A Novel Mutation Modulating Drug. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, SE01-5.	0.8	10
935	Differential Activation of Acid Sphingomyelinase and Ceramide Release Determines Invasiveness of Neisseria meningitidis into Brain Endothelial Cells. PLoS Pathogens, 2014, 10, e1004160.	2.1	67
936	First report of c. 1499G>C mutation in a 6-month-child with cystic fibrosis. Indian Journal of Human Genetics, 2014, 20, 199.	0.7	1
937	Spondylocheirodysplastic Ehlers-Danlos syndrome (SCD-EDS) and the mutant zinc transporter ZIP13. Rare Diseases (Austin, Tex), 2014, 2, e974982.	1.8	24
938	Harnessing the power of yeast to elucidate the role of sphingolipids in metabolic and signaling processes pertinent to psychiatric disorders. Clinical Lipidology, 2014, 9, 533-551.	0.4	1
939	CFTR and lung homeostasis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 307, L917-L923.	1.3	73
940	Current concepts of immune dysregulation in cystic fibrosis. International Journal of Biochemistry and Cell Biology, 2014, 52, 108-112.	1.2	47
941	Proteome of the porosome complex in human airway epithelia: Interaction with the cystic fibrosis transmembrane conductance regulator (CFTR). Journal of Proteomics, 2014, 96, 82-91.	1.2	18
942	Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy, 2014, 10, 2053-2074.	4.3	135

#	Article	IF	Citations
943	Eradication ofPseudomonas aeruginosain adults with cystic fibrosis. BMJ Open Respiratory Research, 2014, 1, e000021.	1.2	22
944	Bisphosphonates for osteoporosis in people with cystic fibrosis. The Cochrane Library, 2014, , CD002010.	1.5	36
945	Lung gene therapyâ€"How to capture illumination from the light already present in the tunnel. Genes and Diseases, 2014, 1, 40-52.	1.5	17
946	Purifying the Impure: Sequencing Metagenomes and Metatranscriptomes from Complex Animal-associated Samples. Journal of Visualized Experiments, 2014, , .	0.2	21
947	Role of epithelial sodium channels in the regulation of lung fluid homeostasis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L1229-L1238.	1.3	108
948	Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors. Pediatric Pulmonology, 2015, 50, S3-S13.	1.0	56
949	Inflammation and its genesis in cystic fibrosis. Pediatric Pulmonology, 2015, 50, S39-56.	1.0	148
950	Increased efficacy of <scp>VX</scp>â€809 in different cellular systems results from an early stabilization effect of F508delâ€<scp>CFTR</scp>. Pharmacology Research and Perspectives, 2015, 3, e00152.	1.1	39
951	Validation of a semiconductor next-generation sequencing assay for the clinical genetic screening ofCFTR. Molecular Genetics & Genomic Medicine, 2015, 3, 396-403.	0.6	18
952	Potential application of mi<scp>RNA</scp>s as diagnostic and therapeutic tools in chronic pancreatitis. Journal of Cellular and Molecular Medicine, 2015, 19, 2049-2057.	1.6	15
953	ABC transporter research: going strong 40 years on. Biochemical Society Transactions, 2015, 43, 1033-1040.	1.6	231
954	A new twist to the emerging functions of ceramides in cancer: novel role for platelet acid sphingomyelinase in cancer metastasis. EMBO Molecular Medicine, 2015, 7, 692-694.	3.3	10
955	Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery. Scientific Reports, 2015, 5, 9038.	1.6	55
956	Hijacking and Use of Host Lipids by Intracellular Pathogens. Microbiology Spectrum, 2015, 3, .	1.2	46
957	Within-host microevolution of Pseudomonas aeruginosa in Italian cystic fibrosis patients. BMC Microbiology, 2015, 15, 218.	1.3	62
958	Chloride transporters and receptorâ€mediated endocytosis in the renal proximal tubule. Journal of Physiology, 2015, 593, 4151-4164.	1.3	39
959	Global genetic carrier testing: a vision for the future. Genome Medicine, 2015, 7, 79.	3.6	4
960	Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. The Cochrane Library, 2021, 2021, CD001399.	1.5	27

#	Article	IF	Citations
961	Localization of cystic fibrosis transmembrane conductance regulator signaling complexes in human salivary gland striated duct cells. European Journal of Oral Sciences, 2015, 123, 140-148.	0.7	13
962	Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry. ChemBioChem, 2015, 16, 2017-2022.	1.3	24
963	Cystic fibrosis â€“ a multiorgan protein misfolding disease. Future Science OA, 2015, 1, FSO57.	0.9	24
964	Sonographic evidence of abnormal tracheal cartilage ring structure in cystic fibrosis. Laryngoscope, 2015, 125, 2398-2404.	1.1	16
965	Impact of the F508del mutation on ovine CFTR, a Cl^{â^'} channel with enhanced conductance and ATPâ€dependent gating. Journal of Physiology, 2015, 593, 2427-2446.	1.3	19
966	Potential of metabolomics to reveal Burkholderia cepacia complex pathogenesis and antibiotic resistance. Frontiers in Microbiology, 2015, 6, 668.	1.5	20
967	Chromatin Dynamics in the Regulation of CFTR Expression. Genes, 2015, 6, 543-558.	1.0	24
968	Cholic Acid Induces a Cftr Dependent Biliary Secretion and Liver Growth Response in Mice. PLoS ONE, 2015, 10, e0117599.	1.1	16
969	A Rapid Molecular Approach for Chromosomal Phasing. PLoS ONE, 2015, 10, e0118270.	1.1	58
970	Ultrasound Echo-Intensity Predicts Severe Pancreatic Affection in Cystic Fibrosis Patients. PLoS ONE, 2015, 10, e0121121.	1.1	5
971	Rescue of NBD2 Mutants N1303K and S1235R of CFTR by Small-Molecule Correctors and Transcomplementation. PLoS ONE, 2015, 10, e0119796.	1.1	40
972	Modulation of Chloride Channel Functions by the Plant Lignan Compounds Kobusin and Eudesmin. Frontiers in Plant Science, 2015, 6, 1041.	1.7	7
973	Role of Sphingolipids in the Pathobiology of Lung Inflammation. Mediators of Inflammation, 2015, 2015, 1-19.	1.4	99
974	Physiological Impact of Abnormal Lipoxin A4Production on Cystic Fibrosis Airway Epithelium and Therapeutic Potential. BioMed Research International, 2015, 2015, 1-10.	0.9	22
975	Nasal Potential Difference in Cystic Fibrosis considering SevereCFTRMutations. Disease Markers, 2015, 2015, 1-11.	0.6	7
976	A new Era of Personalized Medicine for Cystic Fibrosis â€“ at Last!. Canadian Respiratory Journal, 2015, 22, 257-260.	0.8	6
977	Cystic Fibrosis: Breakthrough Drugs at Break-the-Bank Prices. Global Advances in Health and Medicine, 2015, 4, 8-9.	0.7	11
978	Recurrent episodes of unexplained hypoelectrolytaemia of a rare cause in a young Saudi girl: TableÂ1. BMJ Case Reports, 2015, 2015, bcr2014208925.	0.2	0

#	Article	IF	Citations
979	PharmGKB summary. Pharmacogenetics and Genomics, 2015, 25, 149-156.	0.7	5
980	Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein. Journal of Visualized Experiments, 2015, , .	0.2	5
981	Demographic, clinical, and laboratory parameters of cystic fibrosis during the last two decades: a comparative analysis. BMC Pulmonary Medicine, 2015, 15, 3.	0.8	14
982	Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array Enhancers. Human Gene Therapy, 2015, 26, 334-346.	1.4	49
983	Salt, chloride, bleach, and innate host defense. Journal of Leukocyte Biology, 2015, 98, 163-172.	1.5	35
984	Targeted Next-Generation Sequencing Effectively Analyzed the Cystic Fibrosis Transmembrane Conductance Regulator Gene in Pancreatitis. Digestive Diseases and Sciences, 2015, 60, 1297-1307.	1.1	19
985	Raft-Like Membrane Domains in Pathogenic Microorganisms. Current Topics in Membranes, 2015, 75, 233-268.	0.5	46
986	In VivoEfficacy of Antimicrobials against Biofilm-Producing Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2015, 59, 4974-4981.	1.4	30
987	Nano-risk Science: application of toxicogenomics in an adverse outcome pathway framework for risk assessment of multi-walled carbon nanotubes. Particle and Fibre Toxicology, 2015, 13, 15.	2.8	108
988	Pediatric Cystic Fibrosis Sputum Can Be Chemically Dynamic, Anoxic, and Extremely Reduced Due to Hydrogen Sulfide Formation. MBio, 2015, 6, e00767.	1.8	137
989	Curcumin, bisdemethoxycurcumin and dimethoxycurcumin complexed with cyclodextrins have structure specific effect on the paracellular integrity of lung epithelia in vitro. Biochemistry and Biophysics Reports, 2015, 4, 405-410.	0.7	11
990	Diagnostic Accuracy of a Short Endoscopic Secretin Test in Patients With Cystic Fibrosis. Pancreas, 2015, 44, 1266-1272.	0.5	18
991	IgY antibodies in human nutrition for disease prevention. Nutrition Journal, 2015, 14, 109.	1.5	48
992	The Evolution of Cystic Fibrosis Care. Chest, 2015, 148, 533-542.	0.4	43
993	Developing pressures: fluid forces driving morphogenesis. Current Opinion in Genetics and Development, 2015, 32, 24-30.	1.5	60
994	Successful implantation and live birth of a healthy boy after triple biopsy and double vitrification of oocyte-embryo-blastocyst. SpringerPlus, 2015, 4, 22.	1.2	14
995	Synonymous Codon Usage Affects the Expression of Wild Type and F508del CFTR. Journal of Molecular Biology, 2015, 427, 1464-1479.	2.0	30
996	Cigarette smoke exposure reveals a novel role for the MEK/ERK1/2 MAPK pathway in regulation of CFTR. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 1224-1232.	1.1	40

#	Article	IF	Citations
997	A Stable Human-Cell System Overexpressing Cystic Fibrosis Transmembrane Conductance Regulator Recombinant Protein at the Cell Surface. Molecular Biotechnology, 2015, 57, 391-405.	1.3	22
998	Modulation of CFTR gating by permeant ions. Journal of General Physiology, 2015, 145, 47-60.	0.9	44
999	Autophagy in lung disease pathogenesis and therapeutics. Redox Biology, 2015, 4, 215-225.	3.9	110
1000	Efficient generation of functional CFTR-expressing airway epithelial cells from human pluripotent stem cells. Nature Protocols, 2015, 10, 363-381.	5.5	67
1001	Whole-Genome Sequence of Chryseobacterium oranimense, a Colistin-Resistant Bacterium Isolated from a Cystic Fibrosis Patient in France. Antimicrobial Agents and Chemotherapy, 2015, 59, 1696-1706.	1.4	29
1002	Loss of cftr function leads to pancreatic destruction in larval zebrafish. Developmental Biology, 2015, 399, 237-248.	0.9	44
1003	Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. American Journal of Physiology - Renal Physiology, 2015, 308, G459-G471.	1.6	41
1004	Intracellular Delivery of Peptidyl Ligands by Reversible Cyclization: Discovery of a PDZ Domain Inhibitor that Rescues CFTR Activity. Angewandte Chemie - International Edition, 2015, 54, 5874-5878.	7.2	68
1005	Cystic fibrosis. Nature Reviews Disease Primers, 2015, 1, 15010.	18.1	403
1006	Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respiratory Medicine,the, 2015, 3, 524-533.	5.2	197
1007	Spontaneous Pancreatitis Caused by Tissue-Specific Gene Ablation of Hhex in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 550-569.	2.3	11
1008	The Fifth Transmembrane Segment of Cystic Fibrosis Transmembrane Conductance Regulator Contributes to Its Anion Permeation Pathway. Biochemistry, 2015, 54, 3839-3850.	1.2	18
1009	Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme Delivery. Molecular Pharmaceutics, 2015, 12, 1366-1376.	2.3	13
1010	miR-16 rescues F508del-CFTR function in native cystic fibrosis epithelial cells. Gene Therapy, 2015, 22, 908-916.	2.3	20
1011	Co-option of Membrane Wounding Enables Virus Penetration into Cells. Cell Host and Microbe, 2015, 18, 75-85.	5.1	114
1012	Changing the Paradigm â€“ Treating the Basic Defect in Cystic Fibrosis. Indian Journal of Pediatrics, 2015, 82, 727-736.	0.3	8
1013	Cholesterol Modulates CFTR Confinement in the Plasma Membrane of Primary Epithelial Cells. Biophysical Journal, 2015, 109, 85-94.	0.2	58
1014	A tug-of-war between the host and the pathogen generates strategic hotspots for the development of novel therapeutic interventions against infectious diseases. Virulence, 2015, 6, 566-580.	1.8	22

#	Article	IF	Citations
1015	Ferret and Pig Models of Cystic Fibrosis: Prospects and Promise for Gene Therapy. Human Gene Therapy Clinical Development, 2015, 26, 38-49.	3.2	57
1016	New and Emerging Treatments for Cystic Fibrosis. Drugs, 2015, 75, 1165-1175.	4.9	14
1017	Regulation of the cystic fibrosis transmembrane conductance regulator anion channel by tyrosine phosphorylation. FASEB Journal, 2015, 29, 3945-3953.	0.2	21
1018	Prevalence estimation for monogenic autosomal recessive diseases using population-based genetic data. Human Genetics, 2015, 134, 659-669.	1.8	27
1019	Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium. Nature Communications, 2015, 6, 6952.	5.8	114
1020	Localizing a gate in CFTR. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2461-2466.	3.3	39
1021	Generating human intestinal tissues from pluripotent stem cells to study development and disease. EMBO Journal, 2015, 34, 1149-1163.	3.5	86
1022	Sphingolipids as cell fate regulators in lung development and disease. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 740-757.	2.2	43
1023	Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis. Journal of Pediatrics, 2015, 166, 1152-1157.e6.	0.9	45
1024	Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. Journal of Cystic Fibrosis, 2015, 14, 419-430.	0.3	371
1025	Disruption of sphingolipid metabolism augments ceramide-induced autophagy in preeclampsia. Autophagy, 2015, 11, 653-669.	4.3	119
1026	Fecal Human Î²-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?. Digestive Diseases and Sciences, 2015, 60, 2946-2952.	1.1	23
1027	ABCC9/SUR2 in the brain: Implications for hippocampal sclerosis of aging and a potential therapeutic target. Ageing Research Reviews, 2015, 24, 111-125.	5.0	60
1028	<scp>NVP</scp>â€<scp>QBE</scp>170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia. British Journal of Pharmacology, 2015, 172, 2814-2826.	2.7	17
1029	Inhibition of acidic sphingomyelinase reduces established hepatic fibrosis in mice. Hepatology Research, 2015, 45, 305-314.	1.8	21
1030	Pseudomonas aeruginosaPyocyanin Induces Neutrophil DeathviaMitochondrial Reactive Oxygen Species and Mitochondrial Acid Sphingomyelinase. Antioxidants and Redox Signaling, 2015, 22, 1097-1110.	2.5	122
1031	Advancing Pediatric Psychiatry Research: Linking Neurobiological Processes to Novel Treatment and Diagnosis Through the Research Domain Criteria (RDoC) Project. Therapeutic Innovation and Regulatory Science, 2015, 49, 643-646.	0.8	5
1032	Above the fray: Surface remodeling by secreted lysosomal enzymes leads to endocytosis-mediated plasma membrane repair. Seminars in Cell and Developmental Biology, 2015, 45, 10-17.	2.3	41

#	Article	IF	Citations
1033	Role of acid sphingomyelinase bioactivity in human CD4+ T-cell activation and immune responses. Cell Death and Disease, 2015, 6, e1828-e1828.	2.7	37
1034	The activin A antagonist follistatin inhibits cystic fibrosisâ€like lung inflammation and pathology. Immunology and Cell Biology, 2015, 93, 567-574.	1.0	28
1035	Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. Gastroenterology, 2015, 149, 1131-1133.	0.6	9
1036	Metabolomic Profiling of Plasma from Patients with Tuberculosis by Use of Untargeted Mass Spectrometry Reveals Novel Biomarkers for Diagnosis. Journal of Clinical Microbiology, 2015, 53, 3750-3759.	1.8	44
1037	Targeted Correction and Restored Function of the CFTR Gene in Cystic Fibrosis Induced Pluripotent Stem Cells. Stem Cell Reports, 2015, 4, 569-577.	2.3	168
1038	MRP1 knockdown down-regulates the deposition of collagen and leads to a reduced hypertrophic scar fibrosis. Journal of Molecular Histology, 2015, 46, 357-364.	1.0	2
1039	Genome-wide analysis of the ATP-binding cassette (ABC) transporter gene family in sea lamprey and Japanese lamprey. BMC Genomics, 2015, 16, 436.	1.2	22
1040	Cilia Dysfunction in Lung Disease. Annual Review of Physiology, 2015, 77, 379-406.	5.6	306
1041	Match-making for posaconazole through systems thinking. Trends in Parasitology, 2015, 31, 46-51.	1.5	9
1042	Role of Cigarette Smokeâ€"Induced Aggresome Formation in Chronic Obstructive Pulmonary Diseaseâ€"Emphysema Pathogenesis. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 159-173.	1.4	101
1043	Rational coupled dynamics network manipulation rescues disease-relevant mutant cystic fibrosis transmembrane conductance regulator. Chemical Science, 2015, 6, 1237-1246.	3.7	49
1044	Cystic fibrosis genetics: from molecular understanding to clinical application. Nature Reviews Genetics, 2015, 16, 45-56.	7.7	730
1045	CF Patientâ€™s Pneumothoraxes Unique Genes. Global Pediatric Health, 2016, 3, 2333794X1665482.	0.3	0
1046	Neutral sphingomyelinase-2, acid sphingomyelinase, and ceramide levels in COPD patients compared to controls. International Journal of COPD, 2016, Volume 11, 2139-2147.	0.9	14
1047	Analysis of the CFTR gene in Venezuelan cystic fibrosis patients, identification of six novel cystic fibrosis-causing genetic variants. The Application of Clinical Genetics, 2016, 9, 33.	1.4	4
1048	Effects of Reusing Gel Electrophoresis and Electrotransfer Buffers on Western Blotting. Journal of Biomolecular Techniques, 2016, 27, 113-118.	0.8	2
1049	Natural Compounds as Therapeutic Agents in the Treatment Cystic Fibrosis. Journal of Genetic Syndromes & Gene Therapy, 2016, 07, .	0.2	26
1050	Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences. BioMed Research International, 2016, 2016, 1-14.	0.9	99

#	Article	IF	Citations
1051	Epithelial Anion Transport as Modulator of Chemokine Signaling. Mediators of Inflammation, 2016, 2016, 1-20.	1.4	10
1052	Up-Regulation of Claudin-6 in the Distal Lung Impacts Secondhand Smoke-Induced Inflammation. International Journal of Environmental Research and Public Health, 2016, 13, 1018.	1.2	5
1053	The TAK1â†'IKKÎ²â†'TPL2â†'MKK1/MKK2 Signaling Cascade Regulates IL-33 Expression in Cystic Fibrosis Airway Epithelial Cells Following Infection by Pseudomonas aeruginosa. Frontiers in Cell and Developmental Biology, 2015, 3, 87.	1.8	16
1054	Role of Cytokine-Induced Glycosylation Changes in Regulating Cell Interactions and Cell Signaling in Inflammatory Diseases and Cancer. Cells, 2016, 5, 43.	1.8	60
1055	Targeted Integration of a Super-Exon into the CFTR Locus Leads to Functional Correction of a Cystic Fibrosis Cell Line Model. PLoS ONE, 2016, 11, e0161072.	1.1	41
1056	Role of Acid Sphingomyelinase in the Regulation of Social Behavior and Memory. PLoS ONE, 2016, 11, e0162498.	1.1	19
1057	Endoplasmic Reticulum-Targeted Subunit Toxins Provide a New Approach to Rescue Misfolded Mutant Proteins and Revert Cell Models of Genetic Diseases. PLoS ONE, 2016, 11, e0166948.	1.1	10
1058	CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. Frontiers in Pharmacology, 2016, 7, 275.	1.6	115
1059	Role of Quercetin in Modulating Chloride Transport in the Intestine. Frontiers in Physiology, 2016, 7, 549.	1.3	13
1060	Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives. Clinical Pharmacology: Advances and Applications, 2016, Volume 8, 127-140.	0.8	35
1061	Emerging role of cystic fibrosis transmembrane conductance regulator - an epithelial chloride channel in gastrointestinal cancers. World Journal of Gastrointestinal Oncology, 2016, 8, 282.	0.8	22
1062	Colonization of CF patientsâ€™ upper airways with S. aureus contributes more decisively to upper airway inflammation than P. aeruginosa. Medical Microbiology and Immunology, 2016, 205, 485-500.	2.6	11
1063	The effect of synthetic ceramide analogues on gastritis and esophagitis in rats. Archives of Pharmacal Research, 2016, 39, 1313-1323.	2.7	1
1064	On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator. Journal of Physiology, 2016, 594, 3227-3244.	1.3	35
1065	Correctors Rescue CFTR Mutations in Nucleotideâ€Binding Domain 1 (NBD1) by Modulating Proteostasis. ChemBioChem, 2016, 17, 493-505.	1.3	26
1066	Rescue of protein expression defects may not be enough to abolish the proâ€arrhythmic phenotype of long QT type 2 mutations. Journal of Physiology, 2016, 594, 4031-4049.	1.3	28
1067	Cystic fibrosis. Current Opinion in Pediatrics, 2016, 28, 312-317.	1.0	44
1068	Leukocyte Adhesion Deficiency IV. Monocyte Integrin Activation Deficiency in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1075-1077.	2.5	19

#	Article	IF	Citations
1069	Genetics in Keratoconus: where are we?. Eye and Vision (London, England), 2016, 3, 16.	1.4	78
1070	FAM111B Mutation Is Associated With Inherited Exocrine Pancreatic Dysfunction. Pancreas, 2016, 45, 858-862.	0.5	34
1071	Pathophysiologic evaluation of the transgenic CFTR â€œgut-correctedâ€•porcine model of cystic fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L779-L787.	1.3	11
1072	A sequence upstream of canonical PDZ-binding motif within CFTR COOH-terminus enhances NHERF1 interaction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L1170-L1182.	1.3	13
1073	CFTR Controls the Activity of NF-Î¹B by Enhancing the Degradation of TRADD. Cellular Physiology and Biochemistry, 2016, 40, 1063-1078.	1.1	28
1074	Newborn Screening Quality Assurance Program for CFTR Mutation Detection and Gene Sequencing to Identify Cystic Fibrosis. FIRE Forum for International Research in Education, 2016, 4, 232640981666135.	0.7	7
1075	Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections. Scientific Reports, 2016, 6, 21465.	1.6	70
1076	Positioning of extracellular loop 1 affects pore gating of the cystic fibrosis transmembrane conductance regulator. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L403-L414.	1.3	18
1077	Accelerating Scientific Advancement for Pediatric Rare Lung Disease Research. Report from a National Institutes of Healthâ€“NHLBI Workshop, September 3 and 4, 2015. Annals of the American Thoracic Society, 2016, 13, 385-393.	1.5	9
1078	The distinct fate of smooth and roughMycobacterium abscessusvariants inside macrophages. Open Biology, 2016, 6, 160185.	1.5	132
1079	Differential DNA methylation in peripheral blood mononuclear cells in adolescents exposed to significant early but not later childhood adversity. Development and Psychopathology, 2016, 28, 1385-1399.	1.4	61
1080	Frontline Science: Sphingosine rescues burn-injured mice from pulmonary Pseudomonas aeruginosa infection. Journal of Leukocyte Biology, 2016, 100, 1233-1237.	1.5	33
1081	Deep resequencing of CFTR in 762 F508del homozygotes reveals clusters of non-coding variants associated with cystic fibrosis disease traits. Human Genome Variation, 2016, 3, 16038.	0.4	34
1082	New and emerging targeted therapies for cystic fibrosis. BMJ, The, 2016, 352, i859.	3.0	112
1083	c.3623Gâ€‰>â€‰A mutation encodes a CFTR protein with impaired channel function. Respiratory Research, 2016, 17, 8.	1.4	7
1084	Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L928-L939.	1.3	58
1085	Clinical significance, antimicrobial susceptibility and molecular identification of Nocardia species isolated from children with cystic fibrosis. Brazilian Journal of Microbiology, 2016, 47, 531-535.	0.8	11
1086	Development and characterization of synthetic antibodies binding to the cystic fibrosis conductance regulator. MAbs, 2016, 8, 1167-1176.	2.6	3

#	Article	IF	Citations
1087	Newborn Cystic Fibrosis Pigs Have a Blunted Early Response to an Inflammatory Stimulus. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 845-854.	2.5	32
1088	Ion channels in regulated cell death. Cellular and Molecular Life Sciences, 2016, 73, 2387-2403.	2.4	78
1089	Islet-intrinsic effects of CFTR mutation. Diabetologia, 2016, 59, 1350-1355.	2.9	41
1090	Dental treatment for people with cystic fibrosis. European Archives of Paediatric Dentistry: Official Journal of the European Academy of Paediatric Dentistry, 2016, 17, 195-203.	0.7	9
1091	Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1459-1471.	1.8	38
1092	Spatial positioning of CFTRâ€™s pore-lining residues affirms an asymmetrical contribution of transmembrane segments to the anion permeation pathway. Journal of General Physiology, 2016, 147, 407-422.	0.9	13
1093	Global impact of bronchiectasis and cystic fibrosis. Breathe, 2016, 12, 222-235.	0.6	51
1094	Differential regulation of autophagy and mitophagy in pulmonary diseases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L433-L452.	1.3	97
1095	Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L550-L559.	1.3	42
1096	Long Non-coding RNA BGas Regulates the Cystic Fibrosis Transmembrane Conductance Regulator. Molecular Therapy, 2016, 24, 1351-1357.	3.7	28
1097	Characterization of Staphylococcus aureus isolates from pediatric patients with cystic fibrosis. World Journal of Microbiology and Biotechnology, 2016, 32, 162.	1.7	11
1098	Unravelling the role of sphingolipids in cystic fibrosis lung disease. Chemistry and Physics of Lipids, 2016, 200, 94-103.	1.5	26
1099	Esculentin-1a-Derived Peptides Promote Clearance of Pseudomonas aeruginosa Internalized in Bronchial Cells of Cystic Fibrosis Patients and Lung Cell Migration: Biochemical Properties and a Plausible Mode of Action. Antimicrobial Agents and Chemotherapy, 2016, 60, 7252-7262.	1.4	47
1100	Whole-gene CFTR sequencing combined with digital RT-PCR improves genetic diagnosis of cystic fibrosis. Journal of Human Genetics, 2016, 61, 977-984.	1.1	12
1101	Pancreatic pathophysiology in cystic fibrosis. Journal of Pathology, 2016, 238, 311-320.	2.1	96
1102	Translating cancer genomes and transcriptomes for precision oncology. Ca-A Cancer Journal for Clinicians, 2016, 66, 75-88.	157.7	133
1103	Autophagy in Pulmonary Diseases. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1196-1207.	2.5	62
1104	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncology, The, 2016, 17, 1363-1373.	5.1	133

#	Article	IF	Citations
1105	Back to the Future: Mutant Hunts Are Still the Way To Go. Genetics, 2016, 203, 1007-1010.	1.2	7
1106	The evolution of big ideas. EMBO Reports, 2016, 17, 1261-1263.	2.0	0
1107	The history of progressive myoclonus epilepsies. Epileptic Disorders, 2016, 18, 3-10.	0.7	22
1108	The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. Hepatology, 2016, 64, 2118-2134.	3.6	55
1109	Intratracheal myriocin enhances allergenâ€induced Th2 inflammation and airway hyperâ€responsiveness. Immunity, Inflammation and Disease, 2016, 4, 248-262.	1.3	13
1110	The role of stretch-activated ion channels in acute respiratory distress syndrome: finally a new target?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L639-L652.	1.3	26
1111	Targeting sphingosine-1-phosphate signaling in lung diseases. , 2016, 168, 143-157.		54
1112	New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator. Pediatric Clinics of North America, 2016, 63, 751-764.	0.9	26
1113	Genome editing revolutionize the creation of genetically modified pigs for modeling human diseases. Human Genetics, 2016, 135, 1093-1105.	1.8	41
1114	Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate. Molecular Pharmacology, 2016, 90, 275-285.	1.0	31
1115	Long-Term Pulmonal Therapy of Cystic Fibrosis-Patients with Amitriptyline. Cellular Physiology and Biochemistry, 2016, 39, 565-572.	1.1	29
1116	Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis. Scientific Reports, 2016, 6, 24857.	1.6	85
1117	Analysis of gene repair tracts from Cas9/gRNA double-stranded breaks in the human CFTR gene. Scientific Reports, 2016, 6, 32230.	1.6	26
1118	Innate immunity and the new forward genetics. Best Practice and Research in Clinical Haematology, 2016, 29, 379-387.	0.7	6
1119	Minicircle DNA Provides Enhanced and Prolonged Transgene Expression Following Airway Gene Transfer. Scientific Reports, 2016, 6, 23125.	1.6	50
1120	Lack of Sphingosine Causes Susceptibility to Pulmonary Staphylococcus Aureus Infections in Cystic Fibrosis. Cellular Physiology and Biochemistry, 2016, 38, 2094-2102.	1.1	59
1121	Disease-specific clinical trials networks: the example of cystic fibrosis. European Journal of Pediatrics, 2016, 175, 817-824.	1.3	15
1122	Refining the continuum of <scp>CFTR</scp>â€associated disorders in the era of newborn screening. Clinical Genetics, 2016, 89, 539-549.	1.0	34

#	Article	IF	Citations
1124	De Novo sphingolipid synthesis is essential for Salmonella-induced autophagy and human beta-defensin 2 expression in intestinal epithelial cells. Gut Pathogens, 2016, 8, 5.	1.6	15
1125	Clâ˜ channels in apoptosis. European Biophysics Journal, 2016, 45, 599-610.	1.2	41
1126	Impact of gene editing on the study of cystic fibrosis. Human Genetics, 2016, 135, 983-992.	1.8	15
1127	Lessons learned from the cystic fibrosis pig. Theriogenology, 2016, 86, 427-432.	0.9	18
1128	Kleefstra syndrome in Hungarian patients: additional symptoms besides the classic phenotype. Molecular Cytogenetics, 2016, 9, 22.	0.4	14
1129	Metallacarboranes as tunable redox potential electrochemical indicators for screening of gene mutation. Chemical Science, 2016, 7, 5786-5797.	3.7	35
1130	RPTOR, a novel target of miR-155, elicits a fibrotic phenotype of cystic fibrosis lung epithelium by upregulating CTGF. RNA Biology, 2016, 13, 837-847.	1.5	21
1131	Chelation of Membrane-Bound Cations by Extracellular DNA Activates the Type VI Secretion System in Pseudomonas aeruginosa. Infection and Immunity, 2016, 84, 2355-2361.	1.0	29
1132	Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study. Genetics in Medicine, 2016, 18, 231-238.	1.1	76
1133	Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants. Neurology: Genetics, 2016, 2, e44.	0.9	31
1134	Cystic fibrosis from the gastroenterologist's perspective. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 175-185.	8.2	112
1135	From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Molecular Biology of the Cell, 2016, 27, 424-433.	0.9	446
1136	Pre- and post-test genetic counseling for chromosomal and Mendelian disorders. Seminars in Perinatology, 2016, 40, 44-55.	1.1	34
1137	Analysis of long-range interactions in primary human cells identifies cooperativeCFTRregulatory elements. Nucleic Acids Research, 2016, 44, 2564-2576.	6.5	19
1138	Using the BacMam Baculovirus System to Study Expression and Function of Recombinant Efflux Drug Transporters in Polarized Epithelial Cell Monolayers. Drug Metabolism and Disposition, 2016, 44, 180-188.	1.7	5
1139	Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study. Infection, 2016, 44, 513-520.	2.3	87
1140	Characterization and small-molecule stabilization of the multisite tandem binding between 14-3-3 and the R domain of CFTR. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1152-61.	3.3	121
1141	Microbial sphingomyelinase induces RhoA-mediated reorganization of the apical brush border membrane and is protective against invasion. Molecular Biology of the Cell, 2016, 27, 1120-1130.	0.9	5

#	Article	IF	Citations
1142	Function and regulation of TRPM7, as well as intracellular magnesium content, are altered in cells expressing Î”F508-CFTR and G551D-CFTR. Cellular and Molecular Life Sciences, 2016, 73, 3351-3373.	2.4	8
1143	Development of rAAV2-CFTR: History of the First rAAV Vector Product to be Used in Humans. Human Gene Therapy Methods, 2016, 27, 49-58.	2.1	19
1144	Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome. ISME Journal, 2016, 10, 1483-1498.	4.4	88
1145	Divergent signaling via SUMO modification: potential for CFTR modulation. American Journal of Physiology - Cell Physiology, 2016, 310, C175-C180.	2.1	17
1146	Ceramide inhibits PKCÎ¸ by regulating its phosphorylation and translocation to lipid rafts in Jurkat cells. Immunologic Research, 2016, 64, 869-886.	1.3	3
1147	Rare neurological channelopathies â€" networks to study patients, pathogenesis and treatment. Nature Reviews Neurology, 2016, 12, 195-203.	4.9	8
1148	Inhibition of ceramide de novo synthesis by myriocin produces the double effect of reducing pathological inflammation and exerting antifungal activity against A. fumigatus airways infection. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1089-1097.	1.1	33
1149	Cystic fibrosis on the African continent. Genetics in Medicine, 2016, 18, 653-662.	1.1	31
1150	CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene, 2016, 35, 4191-4199.	2.6	129
1151	A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders. Molecular Pharmaceutics, 2016, 13, 357-368.	2.3	36
1152	Recent progress on lipid lateral heterogeneity in plasma membranes: From rafts to submicrometric domains. Progress in Lipid Research, 2016, 62, 1-24.	5.3	134
1153	TALENs Facilitate Single-step Seamless SDF Correction of F508del CFTR in Airway Epithelial Submucosal Gland Cell-derived CF-iPSCs. Molecular Therapy - Nucleic Acids, 2016, 5, e273.	2.3	38
1154	Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell. European Journal of Pediatrics, 2016, 175, 1-8.	1.3	38
1155	Vaccine strategies against cystic fibrosis pathogens. Human Vaccines and Immunotherapeutics, 2016, 12, 751-756.	1.4	4
1156	Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies. Osteoporosis International, 2016, 27, 1401-1412.	1.3	33
1157	Airway Exposure to E-Cigarette Vapors Impairs Autophagy and Induces Aggresome Formation. Antioxidants and Redox Signaling, 2016, 24, 186-204.	2.5	60
1158	PRIMUS: improving pedigree reconstruction using mitochondrial and Y haplotypes. Bioinformatics, 2016, 32, 596-598.	1.8	11
1159	De novo ceramide synthesis is involved in acute inflammation during labor. Biological Chemistry, 2016, 397, 147-155.	1.2	9

#	Article	IF	Citations
1160	A synonymous codon change alters the drug sensitivity of Î”F508 cystic fibrosis transmembrane conductance regulator. FASEB Journal, 2016, 30, 201-213.	0.2	13
1161	Screening for cystic fibrosis in New York State: considerations for algorithm improvements. European Journal of Pediatrics, 2016, 175, 181-193.	1.3	23
1162	Cystic fibrosis carrier screening effects on birth prevalence and newborn screening. Genetics in Medicine, 2016, 18, 145-151.	1.1	31
1163	The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology, 2017, 120, 11-19.	2.0	239
1164	Improved fluorescence assays to measure the defects associated with F508delâ€CFTR allow identification of new active compounds. British Journal of Pharmacology, 2017, 174, 525-539.	2.7	17
1165	Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor. Pediatrics, 2017, 139, .	1.0	44
1166	Role of CFTR mutation analysis in the diagnostic algorithm for cystic fibrosis. World Journal of Pediatrics, 2017, 13, 129-135.	0.8	10
1167	Cellular Uptake of Clostridium botulinum C2 Toxin Requires Acid Sphingomyelinase Activity. Infection and Immunity, 2017, 85, .	1.0	13
1168	Unraveling the role of membrane microdomains during microbial infections. Cell Biology and Toxicology, 2017, 33, 429-455.	2.4	38
1169	Quantitative Proteomic Analysis of Human Airway Cilia Identifies Previously Uncharacterized Proteins of High Abundance. Journal of Proteome Research, 2017, 16, 1579-1592.	1.8	63
1170	Altering intracellular pH reveals the kinetic basis of intraburst gating in the CFTR Cl^{â^'} channel. Journal of Physiology, 2017, 595, 1059-1076.	1.3	11
1171	Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation. Cellular Signalling, 2017, 34, 86-91.	1.7	16
1172	2016 Presidential Address: Letâ€™s Make Human Genetics Great (Again): The Importance of Beauty in Science 1. American Journal of Human Genetics, 2017, 100, 379-384.	2.6	0
1173	Electrostatic tuning of the pre- and post-hydrolytic open states in CFTR. Journal of General Physiology, 2017, 149, 355-372.	0.9	13
1174	Cystic fibrosis in Afro-Brazilians: XK haplotypes analysis supports the European origin of p.F508del mutation. Genetica, 2017, 145, 19-25.	0.5	0
1175	Partial Restoration of CFTR Function in cftr-Null Mice following Targeted Cell Replacement Therapy. Molecular Therapy, 2017, 25, 654-665.	3.7	18
1176	Inhibitors of ceramide de novo biosynthesis rescue damages induced by cigarette smoke in airways epithelia. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 753-759.	1.4	17
1177	Acid sphingomyelinase/ceramide regulates carotid intima-media thickness in simulated weightless rats. Pflugers Archiv European Journal of Physiology, 2017, 469, 751-765.	1.3	12

#	Article	IF	Citations
1178	Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence. Therapeutic Advances in Respiratory Disease, 2017, 11, 193-209.	1.0	31
1179	AJRCCM: 100-Y<scp>ear</scp> A<scp>nniversary</scp>.Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1092-1099.	2.5	25
1180	Academic, Foundation, and Industry Collaboration in Finding New Therapies. New England Journal of Medicine, 2017, 376, 1762-1769.	13.9	57
1181	Sleep Phase Delay in Cystic Fibrosis. Chest, 2017, 152, 386-393.	0.4	21
1182	Combination of Correctors Rescues CFTR Transmembrane-Domain Mutants by Mitigating their Interactions with Proteostasis. Cellular Physiology and Biochemistry, 2017, 41, 2194-2210.	1.1	41
1183	Best practices in the treatment of early cystic fibrosis lung disease. Therapeutic Advances in Respiratory Disease, 2017, 11, 97-104.	1.0	10
1184	Research and progress on ClC-2. Molecular Medicine Reports, 2017, 16, 11-22.	1.1	40
1185	A novel homozygous complex deletion in CFTR caused cystic fibrosis in a Chinese patient. Molecular Genetics and Genomics, 2017, 292, 1083-1089.	1.0	10
1186	CRISPR/Cas9-Mediated Three Nucleotide Insertion Corrects a Deletion Mutation in MRP1/ABCC1 and Restores Its Proper Folding and Function. Molecular Therapy - Nucleic Acids, 2017, 7, 429-438.	2.3	4
1187	A Fast and Accurate Algorithm to Test for Binary Phenotypes and Its Application to PheWAS. American Journal of Human Genetics, 2017, 101, 37-49.	2.6	116
1188	Genome-Wide Survey of Pseudomonas aeruginosa PA14 Reveals a Role for the Glyoxylate Pathway and Extracellular Proteases in the Utilization of Mucin. Infection and Immunity, 2017, 85, .	1.0	22
1189	Association between spirometry controlled chest CT scores using computer-animated biofeedback and clinical markers of lung disease in children with cystic fibrosis. European Clinical Respiratory Journal, 2017, 4, 1318027.	0.7	12
1190	Regulatory dynamics of 11p13 suggest a role for EHF in modifying CF lung disease severity. Nucleic Acids Research, 2017, 45, 8773-8784.	6.5	18
1191	Î²1-Integrin Accumulates in Cystic Fibrosis Luminal Airway Epithelial Membranes and Decreases Sphingosine, Promoting Bacterial Infections. Cell Host and Microbe, 2017, 21, 707-718.e8.	5.1	86
1192	Sinus hypoplasia in the cystic fibrosis rat resolves in the absence of chronic infection. International Forum of Allergy and Rhinology, 2017, 7, 904-909.	1.5	10
1193	Phenotypic diversity and genotypic flexibility of Burkholderia cenocepacia during long-term chronic infection of cystic fibrosis lungs. Genome Research, 2017, 27, 650-662.	2.4	64
1194	Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells. Scientific Reports, 2017, 7, 44867.	1.6	22
1195	Microbiome effects on immunity, health and disease in the lung. Clinical and Translational Immunology, 2017, 6, e133.	1.7	225

#	Article	IF	Citations
1196	Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract. Gene Therapy, 2017, 24, 290-297.	2.3	27
1197	Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis. Scientific Reports, 2017, 7, 700.	1.6	51
1198	Role of second-hand smoke (SHS)-induced proteostasis/autophagy impairment in pediatric lung diseases. Molecular and Cellular Pediatrics, 2017, 4, 3.	1.0	2
1199	The Identification of Alpha-Synuclein asÂtheÂFirst Parkinson Disease Gene. Journal of Parkinson's Disease, 2017, 7, S43-S49.	1.5	56
1200	Staphylococcus aureus Survives in Cystic Fibrosis Macrophages, Forming a Reservoir for Chronic Pneumonia. Infection and Immunity, 2017, 85, .	1.0	33
1201	Augmentation of S-Nitrosoglutathione Controls Cigarette Smoke-Induced Inflammatoryâ€“Oxidative Stress and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis by Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function. Antioxidants and Redox Signaling, 2017, 27, 433-451.	2.5	48
1202	Respiratory Viral Infections in Chronic Lung Diseases. Clinics in Chest Medicine, 2017, 38, 87-96.	0.8	40
1203	Molecular Genetics of Neurodegenerative Dementias. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023705.	2.3	51
1204	CFTR structure: lassoing cystic fibrosis. Nature Structural and Molecular Biology, 2017, 24, 13-14.	3.6	6
1205	Matrine in association with FD-2 stimulates F508del-cystic fibrosis transmembrane conductance regulator activity in the presence of corrector VX809. Molecular Medicine Reports, 2017, 16, 8849-8853.	1.1	4
1206	A common mechanism for CFTR potentiators. Journal of General Physiology, 2017, 149, 1105-1118.	0.9	50
1207	Thiol-benzo-triazolo-quinazolinone Inhibits Alg44 Binding to c-di-GMP and Reduces Alginate Production by Pseudomonas aeruginosa. ACS Chemical Biology, 2017, 12, 3076-3085.	1.6	27
1208	New perspectives in nanotherapeutics for chronic respiratory diseases. Biophysical Reviews, 2017, 9, 793-803.	1.5	54
1209	MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology. Nature Communications, 2017, 8, 710.	5.8	56
1210	Ion channels of the lung and their role in disease pathogenesis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L859-L872.	1.3	68
1211	microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense. Scientific Reports, 2017, 7, 13519.	1.6	24
1212	Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease. EBioMedicine, 2017, 23, 173-184.	2.7	28
1213	Single nucleotide editing without DNA cleavage using CRISPR/Cas9â€deaminase in the sea urchin embryo. Developmental Dynamics, 2017, 246, 1036-1046.	0.8	25

#	Article	IF	Citations
1214	Chansporter complexes in cell signaling. FEBS Letters, 2017, 591, 2556-2576.	1.3	18
1215	Glucosylceramide Critically Contributes to the Host Defense of Cystic Fibrosis Lungs. Cellular Physiology and Biochemistry, 2017, 41, 1208-1218.	1.1	10
1216	Targeting the Potassium Channel Kv1.3 Kills Glioblastoma Cells. NeuroSignals, 2017, 25, 26-38.	0.5	40
1217	Methods to Study Lipid Alterations in Neutrophils and the Subsequent Formation of Neutrophil Extracellular Traps. Journal of Visualized Experiments, 2017, , .	0.2	5
1218	Acid sphingomyelinase mediates human CD4+ T-cell signaling: potential roles in T-cell responses and diseases. Cell Death and Disease, 2017, 8, e2963-e2963.	2.7	40
1219	Establishment and long-term culture of human cystic fibrosis endothelial cells. Laboratory Investigation, 2017, 97, 1375-1384.	1.7	8
1220	Metabolomic similarities between bronchoalveolar lavage fluid and plasma in humans and mice. Scientific Reports, 2017, 7, 5108.	1.6	19
1221	Characterization of primary rat nasal epithelial cultures in CFTR knockout rats as a model for CF sinus disease. Laryngoscope, 2017, 127, E384-E391.	1.1	12
1222	Cystic Fibrosis Transmembrane Conductance Regulator Reduces Microtubule-Dependent Campylobacter jejuni Invasion. Infection and Immunity, 2017, 85, .	1.0	2
1223	A primer to clinical genome sequencing. Current Opinion in Pediatrics, 2017, 29, 513-519.	1.0	22
1224	Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1). Scientific Reports, 2017, 7, 17481.	1.6	15
1225	A Review of Recent Advances in Translational Bioinformatics: Bridges from Biology to Medicine. Yearbook of Medical Informatics, 2017, 26, 178-187.	0.8	20
1226	CFTR potentiators: from bench to bedside. Current Opinion in Pharmacology, 2017, 34, 98-104.	1.7	33
1227	Networks Underpinning Symbiosis Revealed Through Cross-Species eQTL Mapping. Genetics, 2017, 206, 2175-2184.	1.2	15
1228	Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside. Journal of Molecular Medicine, 2017, 95, 1053-1064.	1.7	34
1229	Defective CFTR leads to aberrant Î²-catenin activation and kidney fibrosis. Scientific Reports, 2017, 7, 5233.	1.6	24
1230	Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg?. Cellular Signalling, 2017, 38, 134-145.	1.7	33
1231	Human Genome Sequencing at the Population Scale: A Primer on High-Throughput DNA Sequencing and Analysis. American Journal of Epidemiology, 2017, 186, 1000-1009.	1.6	63

#	Article	IF	Citations
1232	Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery. Orphanet Journal of Rare Diseases, 2017, 12, 61.	1.2	34
1233	Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments. Expert Opinion on Biological Therapy, 2017, 17, 1265-1273.	1.4	40
1234	Master Autophagy Regulator Transcription Factor EB Regulates Cigarette Smoke-Induced Autophagy Impairment and Chronic Obstructive Pulmonary Diseaseâ€“Emphysema Pathogenesis. Antioxidants and Redox Signaling, 2017, 27, 150-167.	2.5	54
1235	The roles of RNA processing in translating genotype to phenotype. Nature Reviews Molecular Cell Biology, 2017, 18, 102-114.	16.1	176
1236	New insights into interactions between the nucleotideâ€binding domain of CFTR and keratin 8. Protein Science, 2017, 26, 343-354.	3.1	10
1237	Cystic Fibrosis is Associated with Adverse Neonatal Outcomes in Washington State, 1996-2013. Journal of Pediatrics, 2017, 180, 206-211.e1.	0.9	7
1238	Cystic fibrosis: a clinical view. Cellular and Molecular Life Sciences, 2017, 74, 129-140.	2.4	168
1239	Molecular modelling and molecular dynamics of CFTR. Cellular and Molecular Life Sciences, 2017, 74, 3-22.	2.4	35
1240	The biophysics, biochemistry and physiology of CFTR. Cellular and Molecular Life Sciences, 2017, 74, 1-2.	2.4	31
1241	From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking. Cellular and Molecular Life Sciences, 2017, 74, 39-55.	2.4	89
1242	Architecture and functional properties of the CFTR channel pore. Cellular and Molecular Life Sciences, 2017, 74, 67-83.	2.4	44
1243	The gating of the CFTR channel. Cellular and Molecular Life Sciences, 2017, 74, 85-92.	2.4	45
1244	Cystic Fibrosis and the Nervous System. Chest, 2017, 151, 1147-1155.	0.4	32
1245	Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?. Clinical Pharmacology and Therapeutics, 2017, 101, 130-141.	2.3	33
1246	Impairing the function of MLCK, myosin Va or myosin Vb disrupts Rhinovirus B14 replication. Scientific Reports, 2017, 7, 17153.	1.6	8
1247	What can the CF registry tell us about rare CFTR-mutations? A Belgian study. Orphanet Journal of Rare Diseases, 2017, 12, 142.	1.2	11
1248	The Mechanistic Links between Insulin and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Clâ¯ Channel. International Journal of Molecular Sciences, 2017, 18, 1767.	1.8	7
1249	ClC Channels and Transporters: Structure, Physiological Functions, and Implications in Human Chloride Channelopathies. Frontiers in Pharmacology, 2017, 8, 151.	1.6	83

#	Article	IF	Citations
1250	Development of Automated Patch Clamp Technique to Investigate CFTR Chloride Channel Function. Frontiers in Pharmacology, 2017, 8, 195.	1.6	17
1251	Comparative Effects of Chloride Channel Inhibitors on LRRC8/VRAC-Mediated Chloride Conductance. Frontiers in Pharmacology, 2017, 8, 328.	1.6	50
1252	Current and future therapies for inherited cholestatic liver diseases. World Journal of Gastroenterology, 2017, 23, 763.	1.4	61
1253	Reduced Abundance and Subverted Functions of Proteins in Prion-Like Diseases: Gained Functions Fascinate but Lost Functions Affect Aetiology. International Journal of Molecular Sciences, 2017, 18, 2223.	1.8	9
1254	Sinus Bacteriology in Patients with Cystic Fibrosis or Primary Ciliary Dyskinesia: A Systematic Review. American Journal of Rhinology and Allergy, 2017, 31, 293-298.	1.0	22
1255	Emerging pharmaceutical therapies for COPD. International Journal of COPD, 2017, Volume 12, 2141-2156.	0.9	44
1256	The Role of Sphingolipids on Innate Immunity to Intestinal Salmonella Infection. International Journal of Molecular Sciences, 2017, 18, 1720.	1.8	14
1257	Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic Fibrosis. International Journal of Molecular Sciences, 2017, 18, 1752.	1.8	8
1258	CFTR-NHERF2-LPA2 Complex in the Airway and Gut Epithelia. International Journal of Molecular Sciences, 2017, 18, 1896.	1.8	10
1259	Interactions between Neutrophils and Pseudomonas aeruginosa in Cystic Fibrosis. Pathogens, 2017, 6, 10.	1.2	74
1260	Subtle mutation, far-reaching effects. Journal of General Physiology, 2017, 149, 969-973.	0.9	2
1261	Recent advances in understanding Pseudomonas aeruginosa as a pathogen. F1000Research, 2017, 6, 1261.	0.8	147
1262	Sphingolipid Organization in the Plasma Membrane and the Mechanisms That Influence It. Frontiers in Cell and Developmental Biology, 2016, 4, 154.	1.8	76
1263	Determinants of Serum Glycerophospholipid Fatty Acids in Cystic Fibrosis. International Journal of Molecular Sciences, 2017, 18, 185.	1.8	9
1264	Sphingolipids Are Dual Specific Drug Targets for the Management of Pulmonary Infections: Perspective. Frontiers in Immunology, 2017, 8, 378.	2.2	59
1265	The Activity of the Neutral Sphingomyelinase Is Important in T Cell Recruitment and Directional Migration. Frontiers in Immunology, 2017, 8, 1007.	2.2	35
1266	Insights into Cystic Fibrosis Polymicrobial Consortia: The Role of Species Interactions in Biofilm Development, Phenotype, and Response to In-Use Antibiotics. Frontiers in Microbiology, 2016, 7, 2146.	1.5	58
1267	Persistent Bacterial Bronchitis: Time to Venture beyond the Umbrella. Frontiers in Pediatrics, 2017, 5, 264.	0.9	18

#	Article	IF	Citations
1268	Evidence for the Involvement of Lipid Rafts and Plasma Membrane Sphingolipid Hydrolases in Pseudomonas aeruginosa Infection of Cystic Fibrosis Bronchial Epithelial Cells. Mediators of Inflammation, 2017, 2017, 1-16.	1.4	16
1269	Biophysical Approaches Facilitate Computational Drug Discovery for ATP-Binding Cassette Proteins. International Journal of Medicinal Chemistry, 2017, 2017, 1-9.	2.2	4
1270	Cigarette Smoke Exposure Inhibits Bacterial Killing via TFEB-Mediated Autophagy Impairment and Resulting Phagocytosis Defect. Mediators of Inflammation, 2017, 2017, 1-14.	1.4	19
1271	Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics, 2017, 7, 1543-1588.	4.6	502
1272	In silico search for modifier genes associated with pancreatic and liver disease in Cystic Fibrosis. PLoS ONE, 2017, 12, e0173822.	1.1	14
1273	Dendrimer-based selective autophagy-induction rescues Î”F508-CFTR and inhibits Pseudomonas aeruginosa infection in cystic fibrosis. PLoS ONE, 2017, 12, e0184793.	1.1	22
1274	Buserelin alleviates chloride transport defect in human cystic fibrosis nasal epithelial cells. PLoS ONE, 2017, 12, e0187774.	1.1	1
1275	Nationwide trends of hospitalizations for cystic fibrosis in the United States from 2003 to 2013. Intractable and Rare Diseases Research, 2017, 6, 191-198.	0.3	24
1276	SLC6A14 Is a Genetic Modifier of Cystic Fibrosis That Regulates Pseudomonas aeruginosa Attachment to Human Bronchial Epithelial Cells. MBio, 2017, 8, .	1.8	45
1277	SpartaABC: a web server to simulate sequences with indel parameters inferred using an approximate Bayesian computation algorithm. Nucleic Acids Research, 2017, 45, W453-W457.	6.5	5
1278	Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense. Current Molecular Pharmacology, 2017, 10, 27-45.	0.7	10
1279	Animal models of hospital-acquired pneumonia: current practices and future perspectives. Annals of Translational Medicine, 2017, 5, 132-132.	0.7	29
1280	A role for the cystic fibrosis transmembrane conductance regulator in the nitric oxide-dependent release of Cl^{â^'} from acidic organelles in amacrine cells. Journal of Neurophysiology, 2017, 118, 2842-2852.	0.9	7
1281	A Different Microbiome Gene Repertoire in the Airways of Cystic Fibrosis Patients with Severe Lung Disease. International Journal of Molecular Sciences, 2017, 18, 1654.	1.8	39
1282	The CFTR-Associated Ligand Arrests the Trafficking of the Mutant Î”F508 CFTR Channel in the ER Contributing to Cystic Fibrosis. Cellular Physiology and Biochemistry, 2018, 45, 639-655.	1.1	9
1283	Phagocytosis depends on TRPV2-mediated calcium influx and requires TRPV2 in lipids rafts: alteration in macrophages from patients with cystic fibrosis. Scientific Reports, 2018, 8, 4310.	1.6	58
1284	Precision medicine. Brazilian Journal of Otorhinolaryngology, 2018, 84, 263-264.	0.4	0
1285	Deciding on cystic fibrosis carrier screening: three citizensâ€™ juries and an online survey. European Journal of Public Health, 2018, 28, 973-977.	0.1	6

#	Article	IF	Citations
1286	Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum. Pediatric Pulmonology, 2018, 53, 872-880.	1.0	7
1287	Membrane microdomains regulate NLRP10- and NLRP12-dependent signalling in A549 cells challenged with cigarette smoke extract. Archives of Toxicology, 2018, 92, 1767-1783.	1.9	12
1288	Pulmonary infection of cystic fibrosis mice with Staphylococcus aureus requires expression of Î±-toxin. Biological Chemistry, 2018, 399, 1203-1213.	1.2	16
1289	Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study. Journal of Visualized Experiments, 2018, , .	0.2	23
1290	NM23 proteins: innocent bystanders or local energy boosters for CFTR?. Laboratory Investigation, 2018, 98, 272-282.	1.7	3
1291	Cystic fibrosis transmembrane conductance regulatorâ€"emerging regulator of cancer. Cellular and Molecular Life Sciences, 2018, 75, 1737-1756.	2.4	20
1292	Structural stability of purified human CFTR is systematically improved by mutations in nucleotide binding domain 1. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1193-1204.	1.4	17
1293	Critical effects of long non-coding RNA on fibrosis diseases. Experimental and Molecular Medicine, 2018, 50, e428-e428.	3.2	33
1294	Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	12
1295	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews, 2018, 118, 1599-1663.	23.0	64
1296	The role of sphingolipids in psychoactive drug use and addiction. Journal of Neural Transmission, 2018, 125, 651-672.	1.4	20
1297	Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients. BMC Pulmonary Medicine, 2018, 18, 35.	0.8	25
1298	Sphingolipids as targets for inhalation treatment of cystic fibrosis. Advanced Drug Delivery Reviews, 2018, 133, 66-75.	6.6	25
1299	Evaluation of autophagy inducers in epithelial cells carrying the Î”F508 mutation of the cystic fibrosis transmembrane conductance regulator CFTR. Cell Death and Disease, 2018, 9, 191.	2.7	19
1300	Molecular dynamics simulation study on the structural instability of the most common cystic fibrosis-associated mutant Î”F508-CFTR. Biophysics and Physicobiology, 2018, 15, 33-44.	0.5	10
1301	Structural mechanisms of CFTR function and dysfunction. Journal of General Physiology, 2018, 150, 539-570.	0.9	90
1302	Discovery of N-hydroxy-3-alkoxybenzamides as direct acid sphingomyelinase inhibitors using a ligand-based pharmacophore model. European Journal of Medicinal Chemistry, 2018, 151, 389-400.	2.6	13
1303	Clinical characterization and diagnosis of cystic fibrosis through exome sequencing in Chinese infants with Bartter-syndrome-like hypokalemia alkalosis. Frontiers of Medicine, 2018, 12, 550-558.	1.5	11

#	Article	IF	Citations
1304	Meconium Ileus. Clinics in Colon and Rectal Surgery, 2018, 31, 121-126.	0.5	15
1305	Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study. Clinical Infectious Diseases, 2018, 67, 1089-1095.	2.9	47
1306	Cigarette smoke-induced autophagy impairment accelerates lung aging, COPD-emphysema exacerbations and pathogenesis. American Journal of Physiology - Cell Physiology, 2018, 314, C73-C87.	2.1	199
1307	Neutrophil elastase increases airway ceramide levels via upregulation of serine palmitoyltransferase. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L206-L214.	1.3	13
1308	Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin. Journal of Antibiotics, 2018, 71, 205-214.	1.0	9
1309	Recent progress in translational cystic fibrosis research using precision medicine strategies. Journal of Cystic Fibrosis, 2018, 17, S52-S60.	0.3	37
1310	Cigarette smoke activates CFTR through ROS-stimulated cAMP signaling in human bronchial epithelial cells. American Journal of Physiology - Cell Physiology, 2018, 314, C118-C134.	2.1	18
1311	Src kinase inhibition reduces inflammatory and cytoskeletal changes in Î”F508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. Hepatology, 2018, 67, 972-988.	3.6	42
1312	Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 214-224.	2.5	152
1313	Abundant off-target edits from site-directed RNA editing can be reduced by nuclear localization of the editing enzyme. RNA Biology, 2018, 15, 104-114.	1.5	71
1314	Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling. Andrology, 2018, 6, 127-135.	1.9	94
1315	Staphylococcus aureus Alpha-Toxin Disrupts Endothelial-Cell Tight Junctions via Acid Sphingomyelinase and Ceramide. Infection and Immunity, 2018, 86, .	1.0	37
1316	Changes in the lung bacteriome in relation to antipseudomonal therapy in children with cystic fibrosis. Folia Microbiologica, 2018, 63, 237-248.	1.1	5
1317	Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and humans by targeting a lung epithelial cystic fibrosis transmembrane regulatorâ€“IL-6â€“antimicrobialâ€“repair pathway. Thorax, 2018, 73, 49-61.	2.7	74
1318	CHAC1 Is Differentially Expressed in Normal and Cystic Fibrosis Bronchial Epithelial Cells and Regulates the Inflammatory Response Induced by Pseudomonas aeruginosa. Frontiers in Immunology, 2018, 9, 2823.	2.2	25
1319	Molecular basis of cystic fibrosis: from bench to bedside. Annals of Translational Medicine, 2018, 6, 334-334.	0.7	36
1320	Functional characterization reveals that zebrafish CFTR prefers to occupy closed channel conformations. PLoS ONE, 2018, 13, e0209862.	1.1	15
1321	Nebulised hypertonic saline for cystic fibrosis. The Cochrane Library, 2018, 2018, CD001506.	1.5	99

#	Article	IF	Citations
1322	Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes, 2018, 9, 538.	1.0	87
1323	Quantitative comparison of ABC membrane protein type I exporter structures in a standardized way. Computational and Structural Biotechnology Journal, 2018, 16, 396-403.	1.9	4
1324	Molecular structure of the ATP-bound, phosphorylated human CFTR. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12757-12762.	3.3	190
1325	Mucociliary Transport in Healthy and Cystic Fibrosis Pig Airways. Annals of the American Thoracic Society, 2018, 15, S171-S176.	1.5	19
1326	Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. Scientific Reports, 2018, 8, 16776.	1.6	59
1327	Host membrane glycosphingolipids and lipid microdomains facilitateHistoplasma capsulatuminternalisation by macrophages. Cellular Microbiology, 2019, 21, e12976.	1.1	17
1328	Cystic Fibrosis of the Pancreas: The Role of CFTR Channel in the Regulation of Intracellular Ca2+ Signaling and Mitochondrial Function in the Exocrine Pancreas. Frontiers in Physiology, 2018, 9, 1585.	1.3	36
1329	A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. International Journal of Respiratory and Pulmonary Medicine, 2018, 5, .	0.1	10
1330	Viral-Bacterial Co-infections in the Cystic Fibrosis Respiratory Tract. Frontiers in Immunology, 2018, 9, 3067.	2.2	90
1331	Clinical and genetic characteristics of cystic fibrosis in CHINESE patients: a systemic review of reported cases. Orphanet Journal of Rare Diseases, 2018, 13, 224.	1.2	32
1332	Personalized Medicine and Molecular Interaction Networks in Amyotrophic Lateral Sclerosis (ALS): Current Knowledge. Journal of Personalized Medicine, 2018, 8, 44.	1.1	13
1333	Acid Sphingomyelinase Promotes Cellular Internalization of Clostridium perfringens Iota-Toxin. Toxins, 2018, 10, 209.	1.5	5
1334	Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation. PLoS ONE, 2018, 13, e0209026.	1.1	8
1335	Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation. Scientific Reports, 2018, 8, 17834.	1.6	99
1336	Bicarbonate Inhibits Bacterial Growth and Biofilm Formation of Prevalent Cystic Fibrosis Pathogens. Frontiers in Microbiology, 2018, 9, 2245.	1.5	42
1337	Consuming Genistein Improves Survival Rates in the Absence of Laxative in Î”F508-CF Female Mice. Nutrients, 2018, 10, 1418.	1.7	8
1338	Identification of genes and pathways in esophageal adenocarcinoma using bioinformatics analysis. Biomedical Reports, 2018, 9, 305-312.	0.9	8
1339	Objective and Subjective Sleep Efficiency in Adult Patients with Cystic Fibrosis and Impact on Quality of Life. Lung, 2018, 196, 761-767.	1.4	8

#	Article	IF	Citations
1340	Stressâ€induced host membrane remodeling protects from infection by nonâ€motile bacterial pathogens. EMBO Journal, 2018, 37, .	3.5	17
1341	In vivo competition and horizontal gene transfer among distinct Staphylococcus aureus lineages as major drivers for adaptational changes during long-term persistence in humans. BMC Microbiology, 2018, 18, 152.	1.3	24
1342	Emerging microRNA Therapeutic Approaches for Cystic Fibrosis. Frontiers in Pharmacology, 2018, 9, 1113.	1.6	29
1343	VX-659â€"Tezacaftorâ€"Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. New England Journal of Medicine, 2018, 379, 1599-1611.	13.9	280
1344	Derivatization of common antidepressant drugs increases inhibition of acid sphingomyelinase and reduces induction of phospholipidosis. Journal of Neural Transmission, 2018, 125, 1837-1845.	1.4	11
1345	An Increase in Chromogranin A-Positive, Hormone-Negative Endocrine Cells in Pancreas in Cystic Fibrosis. Journal of the Endocrine Society, 2018, 2, 1058-1066.	0.1	8
1346	Plasma Membrane Lipid Domains as Platforms for Vesicle Biogenesis and Shedding?. Biomolecules, 2018, 8, 94.	1.8	112
1347	Cystic fibrosis transmembrane conductance regulator (CFTR): Making an ion channel out of an active transporter structure. Channels, 2018, 12, 284-290.	1.5	27
1348	CFTR prevents neuronal apoptosis following cerebral ischemia reperfusion via regulating mitochondrial oxidative stress. Journal of Molecular Medicine, 2018, 96, 611-620.	1.7	29
1349	Rapid detection of four non-fermenting Gram-negative bacteria directly from cystic fibrosis patient's respiratory samples on the BD MAXâ„¢ system. Practical Laboratory Medicine, 2018, 12, e00102.	0.6	4
1350	Airway Epithelium Dysfunction in Cystic Fibrosis and COPD. Mediators of Inflammation, 2018, 2018, 1-20.	1.4	70
1351	Cigarette Smoke-Induced Acquired Dysfunction of Cystic Fibrosis Transmembrane Conductance Regulator in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-13.	1.9	19
1352	The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology. Mediators of Inflammation, 2018, 2018, 1-22.	1.4	30
1353	The Many Facets of Sphingolipids in the Specific Phases of Acute Inflammatory Response. Mediators of Inflammation, 2018, 2018, 1-12.	1.4	25
1354	Spleen Tyrosine Kinase as a Target Therapy for <i>Pseudomonas aeruginosa</i> Infection. Journal of Innate Immunity, 2018, 10, 255-263.	1.8	13
1355	A novel triple combination of pharmacological chaperones improves F508del-CFTR correction. Scientific Reports, 2018, 8, 11404.	1.6	27
1356	Skin Biomarkers for Cystic Fibrosis: A Potential Non-Invasive Approach for Patient Screening. Frontiers in Pediatrics, 2017, 5, 290.	0.9	12
1357	Recent Progress in CFTR Interactome Mapping and Its Importance for Cystic Fibrosis. Frontiers in Pharmacology, 2017, 8, 997.	1.6	28

#	Article	IF	Citations
1358	Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique. Frontiers in Pharmacology, 2018, 9, 396.	1.6	39
1359	Opposite Expression of Hepatic and Pulmonary Corticosteroid-Binding Globulin in Cystic Fibrosis Patients. Frontiers in Pharmacology, 2018, 9, 545.	1.6	2
1360	Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice. Journal of Visualized Experiments, 2018, , .	0.2	2
1361	Sonographic pancreas echogenicity in cystic fibrosis compared to exocrine pancreatic function and pancreas fat content at Dixon-MRI. PLoS ONE, 2018, 13, e0201019.	1.1	9
1362	Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases. Physiological Reviews, 2018, 98, 697-725.	13.1	74
1363	Antidepressants act by inducing autophagy controlled by sphingomyelinâ€“ceramide. Molecular Psychiatry, 2018, 23, 2324-2346.	4.1	166
1364	Genome sequencing in the clinic: the past, present, and future of genomic medicine. Physiological Genomics, 2018, 50, 563-579.	1.0	59
1365	Cystic Fibrosis-Related Diabetes. Frontiers in Endocrinology, 2018, 9, 20.	1.5	74
1366	Nitric Oxide Generated by Tumor-Associated Macrophages Is Responsible for Cancer Resistance to Cisplatin and Correlated With Syntaxin 4 and Acid Sphingomyelinase Inhibition. Frontiers in Immunology, 2018, 9, 1186.	2.2	76
1367	Molecular Signatures of High-Grade Cervical Lesions. Frontiers in Oncology, 2018, 8, 99.	1.3	12
1368	SLC6A14, an amino acid transporter, modifies the primary CF defect in fluid secretion. ELife, 2018, 7, .	2.8	25
1369	Sphingolipids in Ventilator Induced Lung Injury: Role of Sphingosine-1-Phosphate Lyase. International Journal of Molecular Sciences, 2018, 19, 114.	1.8	26
1370	The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients. Marine Drugs, 2018, 16, 184.	2.2	15
1371	Chitosan in Non-Viral Gene Delivery: Role of Structure, Characterization Methods, and Insights in Cancer and Rare Diseases Therapies. Polymers, 2018, 10, 444.	2.0	83
1372	Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses. Respiratory Research, 2018, 19, 2.	1.4	29
1373	Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung. Thorax, 2018, 73, 847-856.	2.7	50
1374	Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators. Frontiers in Pharmacology, 2018, 9, 719.	1.6	28
1375	SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis. Frontiers in Pharmacology, 2018, 9, 828.	1.6	29

#	Article	IF	Citations
1376	Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L529-L543.	1.3	34
1377	Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis. Respiratory Research, 2018, 19, 149.	1.4	39
1378	Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis. European Journal of Human Genetics, 2018, 26, 1832-1839.	1.4	45
1379	Long-term culture and cloning of primary human bronchial basal cells that maintain multipotent differentiation capacity and CFTR channel function. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L313-L327.	1.3	48
1380	RsmV, a Small Noncoding Regulatory RNA in Pseudomonas aeruginosa That Sequesters RsmA and RsmF from Target mRNAs. Journal of Bacteriology, 2018, 200, .	1.0	46
1381	Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells?. Alcoholism: Clinical and Experimental Research, 2018, 42, 1572-1590.	1.4	11
1382	Human Genetics of Obesity and Type 2 Diabetes Mellitus. Circulation Genomic and Precision Medicine, 2018, 11, e002090.	1.6	58
1383	The role of acid sphingomyelinase and modulation of sphingolipid metabolism in bacterial infection. Biological Chemistry, 2018, 399, 1135-1146.	1.2	18
1384	Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respiratory Medicine,the, 2018, 6, 545-553.	5.2	205
1385	Physiological and pharmacological characterization of the N1303K mutant CFTR. Journal of Cystic Fibrosis, 2018, 17, 573-581.	0.3	26
1386	Ion Channel Modulators in Cystic Fibrosis. Chest, 2018, 154, 383-393.	0.4	128
1387	Ligand binding to a remote site thermodynamically corrects the F508del mutation in the human cystic fibrosis transmembrane conductance regulator. Journal of Biological Chemistry, 2018, 293, 17685-17704.	1.6	9
1388	Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. Molecular Therapy, 2018, 26, 2034-2046.	3.7	184
1389	Kcnn4 is a modifier gene of intestinal cystic fibrosis preventing lethality in the Cftr-F508del mouse. Scientific Reports, 2018, 8, 9320.	1.6	14
1390	Animal models for cystic fibrosis liver disease (CFLD). Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 965-969.	1.8	9
1391	Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology, 2019, 69, 1648-1656.	3.6	93
1392	Characterization of Î”(G970-T1122)-CFTR, the most frequent CFTR mutant identified in Japanese cystic fibrosis patients. Journal of Physiological Sciences, 2019, 69, 103-112.	0.9	5
1393	Impact of NR1I2, adenosine triphosphateâ€“binding cassette transporters genetic polymorphisms on the pharmacokinetics of ginsenoside compound K in healthy Chinese volunteers. Journal of Ginseng Research, 2019, 43, 460-474.	3.0	7

#	Article	IF	Citations
1394	Reducing the frequency of respiratory tract infections in severe neurological disorders by inhaled antibiotics: a retrospective data analysis. ERJ Open Research, 2019, 5, 00149-2018.	1.1	9
1395	Cystic fibrosis transmembrane conductance regulator modulates enteric cholinergic activities and is abnormally expressed in the enteric ganglia of patients with slow transit constipation. Journal of Gastroenterology, 2019, 54, 994-1006.	2.3	15
1396	Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications. Pharmaceutics, 2019, 11, 379.	2.0	34
1397	Hsp70 and DNAJA2 limit CFTR levels through degradation. PLoS ONE, 2019, 14, e0220984.	1.1	19
1398	Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis. Frontiers in Pharmacology, 2019, 10, 849.	1.6	29
1399	Cholesterol Interaction Directly Enhances Intrinsic Activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). Cells, 2019, 8, 804.	1.8	23
1400	Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator. Molecular Therapy, 2019, 27, 1737-1748.	3.7	25
1401	The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology, 2019, 19, 98.	0.8	72
1402	Advances in gene therapy for cystic fibrosis lung disease. Human Molecular Genetics, 2019, 28, R88-R94.	1.4	72
1403	Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy . Drug Design, Development and Therapy, 2019, Volume 13, 2405-2412.	2.0	35
1404	Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis. PLoS ONE, 2019, 14, e0219182.	1.1	21
1405	Diverse Facets of Sphingolipid Involvement in Bacterial Infections. Frontiers in Cell and Developmental Biology, 2019, 7, 203.	1.8	37
1406	An Intriguing Involvement of Mitochondria in Cystic Fibrosis. Journal of Clinical Medicine, 2019, 8, 1890.	1.0	21
1407	Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis. ACS Medicinal Chemistry Letters, 2019, 10, 1543-1548.	1.3	32
1408	Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors. International Journal of Molecular Sciences, 2019, 20, 5463.	1.8	15
1409	Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. The Cochrane Library, 2019, 2019, CD009841.	1.5	15
1410	VikNGS: a C++ variant integration kit for next generation sequencing association analysis. Bioinformatics, 2020, 36, 1283-1285.	1.8	10
1411	Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosisâ€causing mutation. FASEB BioAdvances, 2019, 1, 661-670.	1.3	17

#	Article	IF	Citations
1413	RNA Sequencing: A Potentiator of Discovery-based Research. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 558-559.	1.4	1
1414	Plasma membrane damage repair is mediated by an acid sphingomyelinase in Entamoeba histolytica. PLoS Pathogens, 2019, 15, e1008016.	2.1	5
1415	A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders. United European Gastroenterology Journal, 2019, 7, 881-888.	1.6	27
1416	Reduced expression of the Ion channel CFTR contributes to airspace enlargement as a consequence of aging and in response to cigarette smoke in mice. Respiratory Research, 2019, 20, 200.	1.4	8
1417	Determining the pathogenicity of CFTR missense variants: Multiple comparisons of in silico predictors and variant annotation databases. Genetics and Molecular Biology, 2019, 42, 560-570.	0.6	6
1418	Sphingomyelin Breakdown in T Cells: Role of Membrane Compartmentalization in T Cell Signaling and Interference by a Pathogen. Frontiers in Cell and Developmental Biology, 2019, 7, 152.	1.8	14
1419	Isolation and identification of PandoraeaÂspp. From bronchoalveolar lavage of cystic fibrosis patients in Iran. Italian Journal of Pediatrics, 2019, 45, 118.	1.0	7
1420	How to Avoid a No-Deal ER Exit. Cells, 2019, 8, 1051.	1.8	5
1421	The Evolving Field of Genetic Epidemiology: From Familial Aggregation to Genomic Sequencing. American Journal of Epidemiology, 2019, 188, 2069-2077.	1.6	6
1422	Monitoring the Sphingolipid de novo Synthesis by Stable-Isotope Labeling and Liquid Chromatography-Mass Spectrometry. Frontiers in Cell and Developmental Biology, 2019, 7, 210.	1.8	44
1423	Association genetics of bunch weight and its component traits in East African highland banana (Musa) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.8	17
1425	Deconstructing the sources of genotype-phenotype associations in humans. Science, 2019, 365, 1396-1400.	6.0	170
1426	Changes in Membrane Ceramide Pools in Rat Soleus Muscle in Response to Short-Term Disuse. International Journal of Molecular Sciences, 2019, 20, 4860.	1.8	18
1427	Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis . Therapeutics and Clinical Risk Management, 2019, Volume 15, 1029-1040.	0.9	1
1428	Targeting airway inflammation in cystic fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 1041-1055.	1.0	16
1429	Loci Encoding Compounds Potentially Active against Drug-Resistant Pathogens amidst a Decreasing Pool of Novel Antibiotics. Applied and Environmental Microbiology, 2019, 85, .	1.4	4
1430	The impact of cigarette smoke exposure, COPD, or asthma status on ABC transporter gene expression in human airway epithelial cells. Scientific Reports, 2019, 9, 153.	1.6	33
1431	Chaperoning Endoplasmic Reticulumâ€“Associated Degradation (ERAD) and Protein Conformational Diseases. Cold Spring Harbor Perspectives in Biology, 2019, 11, a033928.	2.3	100

#	Article	IF	Citations
1432	Ceramide and Regulation of Vascular Tone. International Journal of Molecular Sciences, 2019, 20, 411.	1.8	55
1433	Structural Perspective on Revealing and Altering Molecular Functions of Genetic Variants Linked with Diseases. International Journal of Molecular Sciences, 2019, 20, 548.	1.8	20
1434	Animal Models in the Pathophysiology of Cystic Fibrosis. Frontiers in Pharmacology, 2018, 9, 1475.	1.6	77
1435	Defects in sarcolemma repair and skeletal muscle function after injury in a mouse model of Niemann-Pick type A/B disease. Skeletal Muscle, 2019, 9, 1.	1.9	21
1436	Pseudomonas aeruginosa Can Inhibit Growth of Streptococcal Species via Siderophore Production. Journal of Bacteriology, 2019, 201, .	1.0	15
1437	Next-generation sequencing for identifying a novel/de novo pathogenic variant in a Mexican patient with cystic fibrosis: a case report. BMC Medical Genomics, 2019, 12, 68.	0.7	1
1438	Î´-Tocopherol Effect on Endocytosis and Its Combination with Enzyme Replacement Therapy for Lysosomal Disorders: A New Type of Drug Interaction?. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 823-833.	1.3	6
1439	Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Research, 2019, 5, 00082-2019.	1.1	72
1440	Temperate Bacteriophages from Chronic Pseudomonas aeruginosa Lung Infections Show Disease-Specific Changes in Host Range and Modulate Antimicrobial Susceptibility. MSystems, 2019, 4, .	1.7	38
1441	Cystic Fibrosisâ€"Related Diabetes: Pathophysiology and Therapeutic Challenges. Clinical Medicine Insights: Endocrinology and Diabetes, 2019, 12, 117955141985177.	1.0	35
1442	Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 197-207.	2.3	34
1443	Acid Sphingomyelinase regulates the localization and trafficking of palmitoylated proteins. Biology Open, 2019, 8, .	0.6	4
1444	Neisseria meningitidis Type IV Pili Trigger Ca ²⁺ -Dependent Lysosomal Trafficking of the Acid Sphingomyelinase To Enhance Surface Ceramide Levels. Infection and Immunity, 2019, 87, .	1.0	17
1445	The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases. Antioxidants and Redox Signaling, 2019, 31, 954-993.	2.5	50
1446	Preclinical Modelling of PDA: Is Organoid the New Black?. International Journal of Molecular Sciences, 2019, 20, 2766.	1.8	14
1447	Profile of Aravinda Chakravarti. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10608-10610.	3.3	0
1448	Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens. International Journal of Molecular Sciences, 2019, 20, 1838.	1.8	55
1449	Filamentous bacteriophages are associated with chronic Pseudomonas lung infections and antibiotic resistance in cystic fibrosis. Science Translational Medicine, 2019, 11, .	5.8	80

#	Article	IF	Citations
1450	Agonists that stimulate secretion promote the recruitment of CFTR into membrane lipid microdomains. Journal of General Physiology, 2019, 151, 834-849.	0.9	21
1451	The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661984442.	1.0	19
1452	Genetic defects in human azoospermia. Basic and Clinical Andrology, 2019, 29, 4.	0.8	42
1453	CFTR interacts with Hsp90 and regulates the phosphorylation of AKT and ERK1/2 in colorectal cancer cells. FEBS Open Bio, 2019, 9, 1119-1127.	1.0	13
1454	Coalescence of RAGE in Lipid Rafts in Response to Cytolethal Distending Toxin-Induced Inflammation. Frontiers in Immunology, 2019, 10, 109.	2.2	14
1455	Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease. Genes, 2019, 10, 218.	1.0	48
1456	Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: The importance of side chain. Progress in Lipid Research, 2019, 74, 130-144.	5.3	29
1457	Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights. Genes, 2019, 10, 180.	1.0	14
1458	Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 329-339.	1.5	34
1459	CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool. Antibiotics, 2019, 8, 18.	1.5	48
1460	Approaches for probing and evaluating mammalian sphingolipid metabolism. Analytical Biochemistry, 2019, 575, 70-86.	1.1	13
1461	Liver Failure in a Chinese Cystic Fibrosis Child With Homozygous R553X Mutation. Frontiers in Pediatrics, 2019, 7, 36.	0.9	9
1462	Efficient Gene Editing at Major CFTR Mutation Loci. Molecular Therapy - Nucleic Acids, 2019, 16, 73-81.	2.3	60
1463	Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L71-L86.	1.3	24
1464	SLC9A3 Affects Vas Deferens Development and Associates with Taiwanese Congenital Bilateral Absence of the Vas Deferens. BioMed Research International, 2019, 2019, 1-10.	0.9	11
1465	Cathelicidin is a â€œfire alarmâ€ generating protective NLRP3-dependent airway epithelial cell inflammatory responses during infection with Pseudomonas aeruginosa. PLoS Pathogens, 2019, 15, e1007694.	2.1	35
1466	The CFTR gene variants in Japanese children with idiopathic pancreatitis. Human Genome Variation, 2019, 6, 17.	0.4	10
1467	Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model. Scientific Reports, 2019, 9, 1527.	1.6	97

#	Article	IF	Citations
1468	Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax, 2019, 74, 579-591.	2.7	38
1469	Is cellular senescence involved in cystic fibrosis?. Respiratory Research, 2019, 20, 32.	1.4	23
1470	Remodeling of O Antigen in Mucoid Pseudomonas aeruginosa via Transcriptional Repression of wzz2. MBio, 2019, 10, .	1.8	8
1471	Meta-analysis Reveals Potential Influence of Oxidative Stress on the Airway Microbiomes of Cystic Fibrosis Patients. Genomics, Proteomics and Bioinformatics, 2019, 17, 590-602.	3.0	4
1472	Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis. ERJ Open Research, 2019, 5, 00051-2019.	1.1	24
1473	Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients. Respiratory Research, 2019, 20, 290.	1.4	12
1474	Calcium-activated chloride channel regulator 1 (CLCA1): More than a regulator of chloride transport and mucus production. World Allergy Organization Journal, 2019, 12, 100077.	1.6	31
1475	Prognostic significance and molecular mechanisms of adenosine triphosphate-binding cassette subfamily C members in gastric cancer. Medicine (United States), 2019, 98, e18347.	0.4	17
1476	miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis. Frontiers in Immunology, 2019, 10, 2643.	2.2	11
1477	Editorial: Emerging Therapeutic Approaches for Cystic Fibrosis. Frontiers in Pharmacology, 2019, 10, 1440.	1.6	6
1478	Initial Regional Evaluation of Cystic Fibrosis Newborn Screening Program: Data from Mediterranean Coast of Turkey. Turkish Journal of Medical Sciences, 2019, 49, 1655-1661.	0.4	2
1479	The Neuroprotective Effect of Amitriptyline on Radiation-Induced Impairment of Hippocampal Neurogenesis. Dose-Response, 2019, 17, 155932581989591.	0.7	10
1480	Impairment of CFTR activity in cultured epithelial cells upregulates the expression and activity of LDH resulting in lactic acid hypersecretion. Cellular and Molecular Life Sciences, 2019, 76, 1579-1593.	2.4	5
1481	Targeting host lipid flows: Exploring new antiviral and antibiotic strategies. Cellular Microbiology, 2019, 21, e12996.	1.1	27
1482	Establishment of a High-Yield Recombinant Adeno-Associated Virus/Human Bocavirus Vector Production System Independent of Bocavirus Nonstructural Proteins. Human Gene Therapy, 2019, 30, 556-570.	1.4	14
1483	Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe ClassÂVI pathogenic mutation in cystic fibrosis. Journal of Physiology, 2019, 597, 543-560.	1.3	9
1484	Aquaporins in the lung. Pflugers Archiv European Journal of Physiology, 2019, 471, 519-532.	1.3	50
1485	Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure. Molecular Diagnosis and Therapy, 2019, 23, 263-279.	1.6	12

#	Article	IF	Citations
1486	Off the street phasing (OTSP): no hassle haplotype phasing for molecular PGD applications. Journal of Assisted Reproduction and Genetics, 2019, 36, 727-739.	1.2	2
1487	Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry. PLoS ONE, 2019, 14, e0210201.	1.1	11
1488	Cyclodextrins reduce the ability of Pseudomonas aeruginosa outer-membrane vesicles to reduce CFTR Cl^{â˜} secretion. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L206-L215.	1.3	17
1489	Ceramides, Autophagy, and Apoptosis Mechanisms of Ventilator-induced Lung Injury and Potential Therapeutic Targets. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 687-689.	2.5	3
1490	Tricyclic antidepressant amitriptyline inhibits autophagic flux and prevents tube formation in vascular endothelial cells. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 370-384.	1.2	9
1491	Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomics. Physiological Genomics, 2019, 51, 27-41.	1.0	14
1492	Protein Degradation and the Pathologic Basis of Disease. American Journal of Pathology, 2019, 189, 94-103.	1.9	66
1493	Direct-to-consumer carrier screening for cystic fibrosis via a hospital website: a 6-year evaluation. Journal of Community Genetics, 2019, 10, 249-257.	0.5	5
1494	The evolving landscape of expanded carrier screening: challenges and opportunities. Genetics in Medicine, 2019, 21, 790-797.	1.1	90
1495	Health-Related Quality of Life in Adolescents and Adults With Cystic Fibrosis: Physical and Mental Health Predictors. Respiratory Care, 2019, 64, 406-415.	0.8	40
1496	The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine,the, 2020, 8, 65-124.	5.2	573
1497	Discovering the chloride pathway in the CFTR channel. Cellular and Molecular Life Sciences, 2020, 77, 765-778.	2.4	14
1498	Positional effects of premature termination codons on the biochemical and biophysical properties of CFTR. Journal of Physiology, 2020, 598, 517-541.	1.3	15
1499	Iron and Sphingolipids as Common Players of (Mal)Adaptation to Hypoxia in Pulmonary Diseases. International Journal of Molecular Sciences, 2020, 21, 307.	1.8	17
1500	Transcriptome analysis and identification of genes associated with chicken sperm storage duration. Poultry Science, 2020, 99, 1199-1208.	1.5	23
1501	Lights and Shadows in the Use of Mesenchymal Stem Cells in Lung Inflammation, a Poorly Investigated Topic in Cystic Fibrosis. Cells, 2020, 9, 20.	1.8	16
1502	ABCF1 Regulates dsDNA-induced Immune Responses in Human Airway Epithelial Cells. Frontiers in Cellular and Infection Microbiology, 2020, 10, 487.	1.8	8
1503	The Role of Specialized Pro-Resolving Mediators in Cystic Fibrosis Airways Disease. Frontiers in Pharmacology, 2020, 11, 1290.	1.6	11

#	Article	IF	Citations
1504	Genomics and Transcriptomics: The Powerful Technologies in Precision Medicine . International Journal of General Medicine, 2020, Volume 13, 627-640.	0.8	19
1505	Detargeting Lentiviral-Mediated CFTR Expression in Airway Basal Cells Using miR-106b. Genes, 2020, 11, 1169.	1.0	4
1506	Cryo-EM as a powerful tool for drug discovery. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127524.	1.0	48
1507	Are cystic fibrosis mutation carriers a potentially highly vulnerable group to COVIDâ€19?. Journal of Cellular and Molecular Medicine, 2020, 24, 13542-13545.	1.6	7
1508	The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients. PLoS ONE, 2020, 15, e0235638.	1.1	11
1509	Genomic Diagnosis for Pediatric Disorders: Revolution and Evolution. Frontiers in Pediatrics, 2020, 8, 373.	0.9	30
1510	CFTR is a negative regulator of Î³Î´ T cell IFN-Î³ production and antitumor immunity. Cellular and Molecular Immunology, 2020, 18, 1934-1944.	4.8	5
1511	Advances in Development of mRNA-Based Therapeutics. Current Topics in Microbiology and Immunology, 2020, , 1.	0.7	6
1512	Amino Acid Transporter SLC6A14 (ATB0,+) â€“ A Target in Combined Anti-cancer Therapy. Frontiers in Cell and Developmental Biology, 2020, 8, 594464.	1.8	30
1513	First Wave of COVID-19 in French Patients with Cystic Fibrosis. Journal of Clinical Medicine, 2020, 9, 3624.	1.0	33
1514	Bile Acid Signal Molecules Associate Temporally with Respiratory Inflammation and Microbiome Signatures in Clinically Stable Cystic Fibrosis Patients. Microorganisms, 2020, 8, 1741.	1.6	13
1515	Sphingolipid Profiling Reveals Different Extent of Ceramide Accumulation in Bovine Retroperitoneal and Subcutaneous Adipose Tissues. Metabolites, 2020, 10, 473.	1.3	7
1516	Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis. Frontiers in Pharmacology, 2020, 11, 1098.	1.6	7
1517	Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Human Lung Microvascular Endothelial Cells Controls Oxidative Stress, Reactive Oxygen-Mediated Cell Signaling and Inflammatory Responses. Frontiers in Physiology, 2020, 11, 879.	1.3	14
1518	Gene Therapy in Rare Respiratory Diseases: What Have We Learned So Far?. Journal of Clinical Medicine, 2020, 9, 2577.	1.0	15
1519	Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma. Frontiers in Pharmacology, 2020, 11, 568993.	1.6	15
1520	Mass spectrometryâ€based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin. FEBS Letters, 2020, 594, 4134-4150.	1.3	21
1521	Cystic Fibrosis Diagnosed Using Indigenously Wrapped Sweating Technique: First Large-Scale Study Reporting Socio-Demographic, Clinical, and Laboratory Features among the Children in Bangladesh A Lower Middle Income Country. Global Pediatric Health, 2020, 7, 2333794X2096758.	0.3	4

#	Article	IF	Citations
1522	Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies. Frontiers in Pharmacology, 2020, 11, 1096.	1.6	30
1523	Costly Genes. PLoS Genetics, 2020, 16, e1008889.	1.5	1
1524	Comprehensive Host Cell-Based Screening Assays for Identification of Anti-Virulence Drugs Targeting Pseudomonas aeruginosa and Salmonella Typhimurium. Microorganisms, 2020, 8, 1096.	1.6	6
1525	Pendrin stimulates a chloride absorption pathway to increase CFTRâ€mediated chloride secretion from Cystic Fibrosis airway epithelia. FASEB BioAdvances, 2020, 2, 526-537.	1.3	5
1526	Simple binding of protein kinase A prior to phosphorylation allows CFTR anion channels to be opened by nucleotides. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21740-21746.	3.3	22
1527	Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis. Journal of Medicinal Chemistry, 2020, 63, 15773-15784.	2.9	18
1528	Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells. Cell Reports Medicine, 2020, 1, 100142.	3.3	142
1529	The first intracellular loop is essential for the catalytic cycle of the human ABCG2 multidrug resistance transporter. FEBS Letters, 2020, 594, 4059-4075.	1.3	4
1530	Clinical Interpretation and Management of Genetic Variants. JACC Basic To Translational Science, 2020, 5, 1029-1042.	1.9	23
1531	The true panel of cystic fibrosis mutations in the Sicilian population. BMC Medical Genetics, 2020, 21, 89.	2.1	3
1532	Synergistic interactions of cadmium-free quantum dots embedded in a photosensitised polymer surface: efficient killing of multidrug-resistant strains at low ambient light levels. Nanoscale, 2020, 12, 10609-10622.	2.8	6
1533	The CFTR Mutation c.3453G > C (D1152H) Confers an Anion Selectivity Defect in Primary Airway Tissue that Can be Rescued by Ivacaftor. Journal of Personalized Medicine, 2020, 10, 40.	1.1	25
1534	The Detection of Bile Acids in the Lungs of Paediatric Cystic Fibrosis Patients Is Associated with Altered Inflammatory Patterns. Diagnostics, 2020, 10, 282.	1.3	16
1535	CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2020, 22, 1288-1295.	1.1	39
1536	Allele-Specific Prevention of Nonsense-Mediated Decay in Cystic Fibrosis Using Homology-Independent Genome Editing. Molecular Therapy - Methods and Clinical Development, 2020, 17, 1118-1128.	1.8	33
1537	Quantitative phase imaging to study transmembrane water fluxes regulated by CFTR and AQP3 in living human airway epithelial CFBE cells and CHO cells. PLoS ONE, 2020, 15, e0233439.	1.1	6
1538	Performance of metabonomic serum analysis for diagnostics in paediatric tuberculosis. Scientific Reports, 2020, 10, 7302.	1.6	11
1539	Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells. Nucleic Acids Research, 2020, 48, 7454-7467.	6.5	26

#	Article	IF	Citations
1540	Identification of potential candidate genes and pathways in atrioventricular nodal reentry tachycardia by wholeâ€exome sequencing. Clinical and Translational Medicine, 2020, 10, 238-257.	1.7	10
1541	CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Frontiers in Pharmacology, 2019, 10, 1662.	1.6	287
1542	Changes in the Râ€region interactions depend on phosphorylation and contribute to PKA and PKC regulation of the cystic fibrosis transmembrane conductance regulator chloride channel. FASEB BioAdvances, 2020, 2, 33-48.	1.3	3
1543	Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition?. Nutrients, 2020, 12, 765.	1.7	8
1544	Update on SLC6A14 in lung and gastrointestinal physiology and physiopathology: focus on cystic fibrosis. Cellular and Molecular Life Sciences, 2020, 77, 3311-3323.	2.4	18
1545	CFTR Functions as a Tumor Suppressor and Is Regulated by DNA Methylation in Colorectal Cancer . Cancer Management and Research, 2020, Volume 12, 4261-4270.	0.9	18
1546	Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies. Pharmaceutics, 2020, 12, 616.	2.0	20
1547	Framing utility: Regulatory reform and genetic tests in the USA, 1989â€“2000. Social Science and Medicine, 2022, 304, 112924.	1.8	3
1548	iPSC-Derived Intestinal Organoids from Cystic Fibrosis Patients Acquire CFTR Activity upon TALEN-Mediated Repair of the p.F508del Mutation. Molecular Therapy - Methods and Clinical Development, 2020, 17, 858-870.	1.8	35
1549	The Squeaky Yeast Gets Greased: The Roles of Host Lipids in the Clearance of Pathogenic Fungi. Journal of Fungi (Basel, Switzerland), 2020, 6, 19.	1.5	1
1550	Small Molecule Anion Carriers Correct Abnormal Airway Surface Liquid Properties in Cystic Fibrosis Airway Epithelia. International Journal of Molecular Sciences, 2020, 21, 1488.	1.8	21
1551	Physiological Significance of Ion Transporters and Channels in the Stomach and Pathophysiological Relevance in Gastric Cancer. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-10.	0.5	10
1552	Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators. International Journal of Molecular Sciences, 2020, 21, 452.	1.8	31
1553	Disease-relevant mutations alter amino acid co-evolution networks in the second nucleotide binding domain of CFTR. PLoS ONE, 2020, 15, e0227668.	1.1	2
1554	Crosstalk Between Acid Sphingomyelinase and Inflammasome Signaling and Their Emerging Roles in Tissue Injury and Fibrosis. Frontiers in Cell and Developmental Biology, 2019, 7, 378.	1.8	17
1555	Drosophila as a model for studying cystic fibrosis pathophysiology of the gastrointestinal system. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10357-10367.	3.3	22
1556	Depletion of Host and Viral Sphingomyelin Impairs Influenza Virus Infection. Frontiers in Microbiology, 2020, 11, 612.	1.5	33
1557	Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. The Cochrane Library, 2020, 4, CD009529.	1.5	20

#	Article	IF	Citations
1558	Newborn Screening for Cystic Fibrosis in Russia: A Catalyst for Improved Care. International Journal of Neonatal Screening, 2020, 6, 34.	1.2	2
1559	Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis. Pharmaceuticals, 2020, 13, 75.	1.7	12
1560	Bridging the Gap between Scientific Advancement and Real-World Application: Pediatric Genetic Counseling for Common Syndromes and Single-Gene Disorders. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036640.	2.9	4
1561	Personalised medicine for non-classic cystic fibrosis resulting from rare CFTR mutations. European Respiratory Journal, 2020, 56, 2000062.	3.1	10
1562	Disease gene discovery in male infertility: past, present and future. Human Genetics, 2021, 140, 7-19.	1.8	50
1563	Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events. Journal of Cystic Fibrosis, 2021, 20, 228-233.	0.3	21
1564	Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes. Vox Sanguinis, 2021, 116, 141-154.	0.7	3
1565	Choline in cystic fibrosis: relations to pancreas insufficiency, enterohepatic cycle, PEMT and intestinal microbiota. European Journal of Nutrition, 2021, 60, 1737-1759.	1.8	18
1566	Geographic distribution of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Saudi Arabia. International Journal of Pediatrics and Adolescent Medicine, 2021, 8, 25-28.	0.5	7
1567	Interferon regulatory factor 8 regulates expression of acid ceramidase and infection susceptibility in cystic fibrosis. Journal of Biological Chemistry, 2021, 296, 100650.	1.6	3
1568	Defects in Protein Folding and/or Quality Control Cause Protein Aggregation in the EndoplasmicÂReticulum. Progress in Molecular and Subcellular Biology, 2021, 59, 115-143.	0.9	9
1569	The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue. Journal of Biological Chemistry, 2021, 296, 100598.	1.6	26
1570	Cellular and functional heterogeneity of the airway epithelium. Mucosal Immunology, 2021, 14, 978-990.	2.7	109
1571	F1099L-CFTR (c.3297C>G) has Impaired Channel Function and Associates with Mild Disease Phenotypes in Two Pediatric Patients. Life, 2021, 11, 131.	1.1	0
1572	Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells. STAR Protocols, 2021, 2, 100356.	0.5	7
1573	The first report on CFTR mutations of meconium ileus in cystic fibrosis population in Saudi Arabia. International Journal of Pediatrics and Adolescent Medicine, 2022, 9, 32-35.	0.5	1
1574	Immunoediting role for major vault protein in apoptotic signaling induced by bacterial N -acyl homoserine lactones. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	11
1575	Genetic testing for men with infertility: techniques and indications. Translational Andrology and Urology, 2021, 10, 1354-1364.	0.6	7

#	Article	IF	Citations
1576	New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation. Scientific Reports, 2021, 11, 6842.	1.6	9
1577	Cystic Fibrosis Lung Disease in the Aging Population. Frontiers in Pharmacology, 2021, 12, 601438.	1.6	9
1578	Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States. Pulmonary Therapy, 2021, 7, 281-293.	1.1	3
1580	Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease. International Journal of Molecular Sciences, 2021, 22, 5018.	1.8	15
1581	NLR family pyrin domain containing 3 (NLRP3) and caspase 1 (CASP1) modulation by intracellular Cl â€“ concentration. Immunology, 2021, 163, 493-511.	2.0	12
1582	Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis. Genes, 2021, 12, 803.	1.0	6
1583	Integrative chemogenomic analysis identifies small molecules that partially rescue Î”F508â€CFTR for cystic fibrosis. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 500-510.	1.3	3
1584	Tensin 1 (TNS1) is a modifier gene for low body mass index (BMI) in homozygous [F508del]CFTR patients. Physiological Reports, 2021, 9, e14886.	0.7	0
1585	Increased CFTR expression and function from an optimized lentiviral vector for cystic fibrosis gene therapy. Molecular Therapy - Methods and Clinical Development, 2021, 21, 94-106.	1.8	8
1586	Liver disease in cystic fibrosis patients in a tertiary care center in Saudi Arabia. International Journal of Pediatrics and Adolescent Medicine, 2022, 9, 78-82.	0.5	2
1587	History of the methodology of disease gene identification. American Journal of Medical Genetics, Part A, 2021, 185, 3266-3275.	0.7	5
1588	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1522-1532.	2.5	146
1589	Clinical outcomes of cystic fibrosis patients with hemoptysis treated with bronchial artery embolization. Jornal Brasileiro De Pneumologia, 2021, 47, e20200557.	0.4	1
1590	Advancing human disease research with fish evolutionary mutant models. Trends in Genetics, 2022, 38, 22-44.	2.9	23
1591	Healthcare resource utilization and costs among children with cystic fibrosis in the United States. Pediatric Pulmonology, 2021, 56, 2833-2844.	1.0	7
1592	Human Molecular Genetics and the long road to treating cystic fibrosis. Human Molecular Genetics, 2021, 30, R264-R273.	1.4	5
1593	Sphingomyelinase decreases transepithelial anion secretion in airway epithelial cells in part by inhibiting CFTRâ€mediated apical conductance. Physiological Reports, 2021, 9, e14928.	0.7	8
1594	Spns2 Transporter Contributes to the Accumulation of S1P in Cystic Fibrosis Human Bronchial Epithelial Cells. Biomedicines, 2021, 9, 1121.	1.4	3

#	Article	IF	Citations
1595	Seeing the forest through the trees: prioritising potentially functional interactions from Hi-C. Epigenetics and Chromatin, 2021, 14, 41.	1.8	3
1596	Disease-related blood-based differential methylation in cystic fibrosis and its representation in lung cancer revealed a regulatory locus in PKP3 in lung epithelial cells. Epigenetics, 2022, 17, 837-860.	1.3	1
1597	Association of cystic fibrosis transmembrane conductance regulator with epithelial sodium channel subunits carrying Liddleâ€™s syndrome mutations. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L308-L320.	1.3	2
1598	Role of inflammation and oxidative stress in tissue damage associated with cystic fibrosis: CAPE as a future therapeutic strategy. Molecular and Cellular Biochemistry, 2022, 477, 39-51.	1.4	10
1599	Sphingomyelinaseâ€Mediated Multitimescale Clustering of Ganglioside GM1 in Heterogeneous Lipid Membranes. Advanced Science, 2021, 8, 2101766.	5.6	5
1600	New Molecular Targets for Antidepressant Drugs. Pharmaceuticals, 2021, 14, 894.	1.7	22
1601	Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease. Breathe, 2021, 17, 210053.	0.6	8
1602	Functional stability of CFTR depends on tight binding of ATP at its degenerate ATPâ€binding site. Journal of Physiology, 2021, 599, 4625-4642.	1.3	9
1603	Mechanistic analysis and significance of sphingomyelinaseâ€mediated decreases in transepithelial CFTR currents in nHBEs. Physiological Reports, 2021, 9, e15023.	0.7	2
1604	The Gut-Lung Axis in Cystic Fibrosis. Journal of Bacteriology, 2021, 203, e0031121.	1.0	44
1605	A review of cystic fibrosis: Basic and clinical aspects. Animal Models and Experimental Medicine, 2021, 4, 220-232.	1.3	37
1606	NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis. Biomolecules, 2021, 11, 1417.	1.8	9
1607	Excitation ratiometric chloride sensing in a standalone yellow fluorescent protein is powered by the interplay between proton transfer and conformational reorganization. Chemical Science, 2021, 12, 11382-11393.	3.7	17
1608	Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). The Cochrane Library, 2020, 2020, CD010966.	1.5	27
1609	Poly(Lactic-co-Glycolic Acid) Nanoparticle Delivery of Peptide Nucleic Acids In Vivo. Methods in Molecular Biology, 2020, 2105, 261-281.	0.4	10
1610	Pharmacokinetics of Drugs in Cystic Fibrosis. , 1990, 9, 169-210.		51
1611	The Relationship Between Atopy and Cystic Fibrosis. , 1990, 9, 29-46.		7
1612	Severed Molecules Functionally Define the Boundaries of the Cystic Fibrosis Transmembrane Conductance Regulator's Nh2-Terminal Nucleotide Binding Domain. Journal of General Physiology, 2000, 116, 163-180.	0.9	73

#	Article	IF	Citations
1613	Functional inhibition or genetic deletion of acid sphingomyelinase bacteriostatically inhibits Anaplasma phagocytophilum infection in vivo. Pathogens and Disease, 2021, 79, .	0.8	5
1614	A Pathophysiological Model for COVID-19: Critical Importance of Transepithelial Sodium Transport upon Airway Infection. Function, 2020, 1, zqaa024.	1.1	24
1615	Agmatine accumulation by Pseudomonas aeruginosa clinical isolates confers antibiotic tolerance and dampens host inflammation. Journal of Medical Microbiology, 2019, 68, 446-455.	0.7	13
1616	Phosphorylation of protein kinase C sites in NBD1 and the R domain control CFTR channel activation by PKA. Journal of Physiology, 2003, 548, 39-52.	1.3	86
1617	Rare causes of osteoporosis. Clinical Cases in Mineral and Bone Metabolism, 2015, 12, 151-6.	1.0	36
1618	Association between transcript levels of the Pseudomonas aeruginosa regA, regB, and toxA genes in sputa of cystic fibrosis patients. Infection and Immunity, 1994, 62, 3506-3514.	1.0	13
1619	Burkholderia cepacia Produces a Hemolysin That Is Capable of Inducing Apoptosis and Degranulation of Mammalian Phagocytes. Infection and Immunity, 1998, 66, 2033-2039.	1.0	95
1620	Glucose Stimulates Phagocytosis of UnopsonizedPseudomonas aeruginosaby Cultivated Human Alveolar Macrophages. Infection and Immunity, 1999, 67, 16-21.	1.0	12
1621	Pseudomonas aeruginosa Quorum-Sensing Signal Molecule N -(3-Oxododecanoyl)-<scp>l</scp> -Homoserine Lactone Inhibits Expression of P2Y Receptors in Cystic Fibrosis Tracheal Gland Cells. Infection and Immunity, 1999, 67, 5076-5082.	1.0	49
1622	Pulmonary Outcome in Cystic Fibrosis Is Influenced Primarily by Mucoid Pseudomonas aeruginosa Infection and Immune Status and Only Modestly by Genotype. Infection and Immunity, 1999, 67, 4744-4750.	1.0	135
1623	GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus. Journal of Virology, 1992, 66, 1635-1640.	1.5	150
1624	Influence of Cell Polarity on Retrovirus-Mediated Gene Transfer to Differentiated Human Airway Epithelia. Journal of Virology, 1998, 72, 9818-9826.	1.5	94
1625	Microbial clues lead to a diagnosis of cystic fibrosis in late adulthood. BMJ Case Reports, 2020, 13, e233470.	0.2	2
1626	Active cascade testing for carriers of cystic fibrosis gene. BMJ: British Medical Journal, 1994, 308, 1462-1467.	2.4	87
1627	Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience. BMJ: British Medical Journal, 1994, 308, 1469-1472.	2.4	75
1628	Innovation in the pharmaceutical industry. BMJ: British Medical Journal, 1994, 309, 422-3.	2.4	7
1629	Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. BMJ: British Medical Journal, 1995, 310, 353-357.	2.4	80
1630	Lesson of the Week: Cystic fibrosis presenting as hyponatraemic heat exhaustion. BMJ: British Medical Journal, 1995, 310, 579-580.	2.4	44

#	Article	IF	Citations
1631	Optimal polymerase chain reaction amplification for preimplantation diagnosis in cystic fibrosis ((Delta)F508). BMJ: British Medical Journal, 1995, 311, 536-540.	2.4	10
1632	Cost effectiveness of antenatal screening for cystic fibrosis. BMJ: British Medical Journal, 1995, 311, 1460-1460.	2.4	55
1633	The new genetics: The new genetics in clinical practice. BMJ: British Medical Journal, 1998, 316, 618-620.	2.4	185
1634	Evaluating performance in sweat testing in medical biochemistry laboratories in Croatia. Biochemia Medica, 2017, 27, 122-130.	1.2	6
1635	Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators. JCI Insight, 2018, 3, .	2.3	86
1636	Lentiviral-mediated phenotypic correction of cystic fibrosis pigs. JCI Insight, 2016, 1, .	2.3	73
1637	Nasospheroids permit measurements of CFTR-dependent fluid transport. JCI Insight, 2017, 2, .	2.3	40
1638	Thymosin Î±-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia. JCI Insight, 2018, 3, .	2.3	23
1639	Na-K-2Cl cotransporter gene expression and function during enterocyte differentiation. Modulation of Cl- secretory capacity by butyrate.. Journal of Clinical Investigation, 1998, 101, 2072-2079.	3.9	65
1640	The core polypeptide of cystic fibrosis tracheal mucin contains a tandem repeat structure. Evidence for a common mucin in airway and gastrointestinal tissue.. Journal of Clinical Investigation, 1990, 86, 1921-1927.	3.9	62
1641	Localization of the cystic fibrosis transmembrane conductance regulator in pancreas.. Journal of Clinical Investigation, 1991, 88, 712-716.	3.9	268
1642	Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel.. Journal of Clinical Investigation, 1991, 88, 1422-1431.	3.9	229
1643	Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis.. Journal of Clinical Investigation, 1991, 88, 1880-1885.	3.9	122
1644	Localization of cystic fibrosis transmembrane conductance regulator in chloride secretory epithelia.. Journal of Clinical Investigation, 1992, 89, 339-349.	3.9	230
1645	Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line.. Journal of Clinical Investigation, 1992, 89, 1478-1484.	3.9	455
1646	Only three mutations account for almost all defective alleles causing adenine phosphoribosyltransferase deficiency in Japanese patients.. Journal of Clinical Investigation, 1992, 90, 130-135.	3.9	49
1647	Localization of cystic fibrosis transmembrane conductance regulator mRNA in human fetal lung tissue by in situ hybridization.. Journal of Clinical Investigation, 1992, 90, 619-625.	3.9	52
1648	Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis.. Journal of Clinical Investigation, 1992, 90, 785-790.	3.9	118

#	Article	IF	Citations
1649	Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor.. Journal of Clinical Investigation, 1992, 90, 1296-1301.	3.9	284
1650	In vivo retroviral gene transfer into human bronchial epithelia of xenografts.. Journal of Clinical Investigation, 1992, 90, 2598-2607.	3.9	81
1651	Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer.. Journal of Clinical Investigation, 1993, 91, 225-234.	3.9	197
1652	Regulation of membrane chloride currents in rat bile duct epithelial cells.. Journal of Clinical Investigation, 1993, 91, 319-328.	3.9	177
1653	Antisense oligodeoxynucleotide to the cystic fibrosis transmembrane conductance regulator inhibits cyclic AMP-activated but not calcium-activated cell volume reduction in a human pancreatic duct cell line.. Journal of Clinical Investigation, 1993, 91, 1253-1257.	3.9	20
1654	Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells.. Journal of Clinical Investigation, 1993, 92, 1875-1880.	3.9	320
1655	Nonsense mutation R1162X of the cystic fibrosis transmembrane conductance regulator gene does not reduce messenger RNA expression in nasal epithelial tissue.. Journal of Clinical Investigation, 1993, 92, 2683-2687.	3.9	21
1656	Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization.. Journal of Clinical Investigation, 1994, 93, 347-354.	3.9	236
1657	Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype.. Journal of Clinical Investigation, 1994, 93, 461-466.	3.9	128
1658	Taurine modulation of hypochlorous acid-induced lung epithelial cell injury in vitro. Role of anion transport.. Journal of Clinical Investigation, 1994, 93, 606-614.	3.9	79
1659	Expression of the cystic fibrosis gene in adult human lung.. Journal of Clinical Investigation, 1994, 93, 737-749.	3.9	234
1660	Defective fluid transport by cystic fibrosis airway epithelia.. Journal of Clinical Investigation, 1994, 93, 1307-1311.	3.9	74
1661	Similar levels of mRNA from the W1282X and the delta F508 cystic fibrosis alleles, in nasal epithelial cells.. Journal of Clinical Investigation, 1994, 93, 1502-1507.	3.9	26
1662	Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs.. Journal of Clinical Investigation, 1994, 93, 2224-2229.	3.9	120
1663	Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding.. Journal of Clinical Investigation, 1994, 94, 228-236.	3.9	75
1664	Identification of mutations in the putative ATP-binding domain of the adrenoleukodystrophy gene.. Journal of Clinical Investigation, 1994, 94, 516-520.	3.9	62
1665	Localization and functional characterization of rat kidney-specific chloride channel, ClC-K1.. Journal of Clinical Investigation, 1995, 95, 104-113.	3.9	184
1666	Expression and localization of the cystic fibrosis transmembrane conductance regulator mRNA and its protein in rat brain.. Journal of Clinical Investigation, 1995, 96, 646-652.	3.9	55

#	Article	IF	Citations
1667	CFTR and differentiation markers expression in non-CF and delta F 508 homozygous CF nasal epithelium.. Journal of Clinical Investigation, 1995, 96, 1601-1611.	3.9	98
1668	A mouse model for the delta F508 allele of cystic fibrosis.. Journal of Clinical Investigation, 1995, 96, 2051-2064.	3.9	270
1669	Gene therapy for cystic fibrosis: challenges and future directions.. Journal of Clinical Investigation, 1995, 96, 2547-2554.	3.9	81
1670	Genotypic analysis of respiratory mucous sulfation defects in cystic fibrosis.. Journal of Clinical Investigation, 1995, 96, 2997-3004.	3.9	97
1671	Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition.. Journal of Clinical Investigation, 1996, 98, 513-520.	3.9	53
1672	A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo.. Journal of Clinical Investigation, 1996, 98, 1304-1312.	3.9	132
1673	Structural cues involved in endoplasmic reticulum degradation of G85E and G91R mutant cystic fibrosis transmembrane conductance regulator.. Journal of Clinical Investigation, 1997, 100, 1079-1088.	3.9	65
1674	Lung disease in mice with cystic fibrosis.. Journal of Clinical Investigation, 1997, 100, 3060-3069.	3.9	156
1675	Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Î”F508 homozygous twins and siblings. Journal of Clinical Investigation, 2001, 108, 1705-1715.	3.9	135
1676	Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation. Journal of Clinical Investigation, 2020, 130, 2041-2053.	3.9	44
1677	Defective TNF-Î±â€“mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. Journal of Clinical Investigation, 2003, 111, 197-208.	3.9	200
1678	Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis. Journal of Clinical Investigation, 2002, 110, 1591-1597.	3.9	40
1679	Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells.. Journal of Clinical Investigation, 1998, 102, 1200-1207.	3.9	229
1680	Factors affecting statistical power in the detection of genetic association. Journal of Clinical Investigation, 2005, 115, 1408-1418.	3.9	118
1681	Chloride channel diseases resulting from impaired transepithelial transport or vesicular function. Journal of Clinical Investigation, 2005, 115, 2039-2046.	3.9	112
1682	CFTR is required for PKA-regulated ATP sensitivity of Kir1.1 potassium channels in mouse kidney. Journal of Clinical Investigation, 2006, 116, 797-807.	3.9	61
1683	The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways.. Journal of Clinical Investigation, 1998, 102, 15-21.	3.9	191
1684	Roles for tumor necrosis factor receptor p55 and sphingomyelinase in repairing the cutaneous permeability barrier. Journal of Clinical Investigation, 1999, 104, 1761-1770.	3.9	160

#	Article	IF	Citations
1685	Defective regulation of gap junctional coupling in cystic fibrosis pancreatic duct cells. Journal of Clinical Investigation, 1999, 103, 1677-1684.	3.9	44
1686	Î”F508 CFTR protein expression in tissues from patients with cystic fibrosis. Journal of Clinical Investigation, 1999, 103, 1379-1389.	3.9	237
1687	The innate immune system in cystic fibrosis lung disease. Journal of Clinical Investigation, 1999, 103, 303-307.	3.9	184
1688	Novel pharmacologic therapies for cystic fibrosis. Journal of Clinical Investigation, 1999, 103, 447-452.	3.9	85
1689	Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation.. Journal of Clinical Investigation, 1998, 101, 487-496.	3.9	356
1690	A PDZ-interacting domain in CFTR is an apical membrane polarization signal. Journal of Clinical Investigation, 1999, 104, 1353-1361.	3.9	259
1691	Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. Journal of Clinical Investigation, 1999, 104, 1245-1255.	3.9	211
1692	SNPing away at innate immunity. Journal of Clinical Investigation, 1999, 104, 369-370.	3.9	18
1693	Vasoactive intestinal peptide, forskolin, and genistein increase apical CFTR trafficking in the rectal gland of the spiny dogfish, Squalus acanthias. Acute regulation of CFTR trafficking in an intact epithelium.. Journal of Clinical Investigation, 1998, 101, 737-745.	3.9	88
1694	Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. Journal of Clinical Investigation, 1999, 104, R55-R62.	3.9	150
1695	Insights from human genetic studies of lung and organ fibrosis. Journal of Clinical Investigation, 2018, 128, 36-44.	3.9	31
1696	Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase. Journal of Clinical Investigation, 2000, 105, 1711-1721.	3.9	199
1697	Clinically approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia. Journal of Clinical Investigation, 2019, 129, 3448-3463.	3.9	27
1698	First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers. ERJ Open Research, 2021, 7, 00447-2020.	1.1	6
1699	The Role of Computed Tomography in Monitoring Patients with Cystic Fibrosis. Polski Przeglad Radiologii I Medycyny Nuklearnej, 2016, 81, 141-145.	1.0	4
1700	Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR. Drugs of Today, 2016, 52, 229.	0.7	18
1701	Loss of SLC9A3 decreases CFTR protein and causes obstructed azoospermia in mice. PLoS Genetics, 2017, 13, e1006715.	1.5	37
1702	Involvement of the Cdc42 Pathway in CFTR Post-Translational Turnover and in Its Plasma Membrane Stability in Airway Epithelial Cells. PLoS ONE, 2015, 10, e0118943.	1.1	11

#	Article	IF	Citations
1703	Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA. PLoS ONE, 2015, 10, e0136396.	1.1	5
1704	Statins Attenuate Helicobacter pylori CagA Translocation and Reduce Incidence of Gastric Cancer: In Vitro and Population-Based Case-Control Studies. PLoS ONE, 2016, 11, e0146432.	1.1	39
1705	Investigating CFTR and KCa3.1 Protein/Protein Interactions. PLoS ONE, 2016, 11, e0153665.	1.1	11
1706	Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis. PLoS ONE, 2016, 11, e0155882.	1.1	12
1707	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. PLoS ONE, 2016, 11, e0163615.	1.1	23
1708	Evaporimeter and Bubble-Imaging Measures of Sweat Gland Secretion Rates. PLoS ONE, 2016, 11, e0165254.	1.1	16
1709	A High Level of Soluble CD40L Is Associated with P. aeruginosa Infection in Patients with Cystic Fibrosis. PLoS ONE, 2016, 11, e0168819.	1.1	3
1710	Longitudinal sampling of the lung microbiota in individuals with cystic fibrosis. PLoS ONE, 2017, 12, e0172811.	1.1	64
1711	Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS ONE, 2017, 12, e0174463.	1.1	65
1712	Cas9/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA. PLoS ONE, 2017, 12, e0184009.	1.1	71
1713	Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies. Molecules and Cells, 2015, 38, 482-495.	1.0	37
1714	Defective CFTR- Î²-catenin interaction promotes NF-ÎºB nuclear translocation and intestinal inflammation in cystic fibrosis. Oncotarget, 2016, 7, 64030-64042.	0.8	38
1715	Ca2+ signaling in HCO3â^' secretion and protection of upper GI tract. Oncotarget, 2017, 8, 102681-102689.	0.8	6
1716	Na+ homeostasis by epithelial Na+ channel (ENaC) and Nax channel (Nax): cooperation of ENaC and Nax. Annals of Translational Medicine, 2016, 4, S11-S11.	0.7	10
1717	A Postgenomic Perspective on Molecular Cytogenetics. Current Genomics, 2018, 19, 227-239.	0.7	22
1718	Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target. Current Drug Targets, 2016, 17, 1535-1544.	1.0	20
1719	Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response. Current Neuropharmacology, 2020, 18, 301-318.	1.4	7
1720	Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis. Open Respiratory Medicine Journal, 2015, 9, 30-36.	1.3	19

#	Article	IF	Citations
1721	A Survey of the Common Mutations and IVS8-Tn Polymorphism of Cystic Fibrosis Transmembrane Conductance Regulator Gene in Infertile Men with Nonobstructive Azoospermia and CBAVD in Iranian Population. Iranian Biomedical Journal, 2019, 23, 92-98.	0.4	4
1722	Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. World Journal of Gastroenterology, 2007, 13, 5217.	1.4	30
1723	Genetic and phenotypic heterogeneity in tropical calcific pancreatitis. World Journal of Gastroenterology, 2014, 20, 17314.	1.4	28
1724	Role of ion channels in gastrointestinal cancer. World Journal of Gastroenterology, 2019, 25, 5732-5772.	1.4	122
1725	New and old tools to evaluate new antimicrobial peptides. AIMS Microbiology, 2018, 4, 522-540.	1.0	18
1726	Two Qatari siblings with cystic fibrosis and apparent mineralocorticoid excess. Annals of Thoracic Medicine, 2015, 10, 69-72.	0.7	7
1727	Cystic fibrosis revisited. Journal of Postgraduate Medicine, 2019, 65, 193-196.	0.2	8
1728	Human induced pluripotent stem cells for monogenic disease modelling and therapy. World Journal of Stem Cells, 2016, 8, 118.	1.3	27
1729	Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis. World Journal of Clinical Pediatrics, 2017, 6, 132.	0.6	19
1730	Allele frequency for Cystic fibrosis in Indians vis-a/-vis global populations. Bioinformation, 2015, 11, 348-352.	0.2	6
1731	Novel CFTR Mutations in Two Iranian Families with Severe Cystic Fibrosis. Iranian Biomedical Journal, 2016, 20, 201-6.	0.4	3
1732	Obligate coupling of CFTR pore opening to tight nucleotide-binding domain dimerization. ELife, 2016, 5, .	2.8	26
1733	Asymmetry of movements in CFTR's two ATP sites during pore opening serves their distinct functions. ELife, 2017, 6, .	2.8	27
1734	Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations. ELife, 2019, 8, .	2.8	24
1735	In silico analysis on the functional and structural impact of Rad50 mutations involved in DNA strand break repair. PeerJ, 2020, 8, e9197.	0.9	8
1736	A Letter in Reply : A Novel Cystic Fibrosis Gene Mutation C.4242+1G>C in an Omani Patient. Oman Medical Journal, 2022, 37, e345.	0.3	0
1737	A small molecule CFTR potentiator restores ATPâ€dependent channel gating to the cystic fibrosis mutant G551Dâ€CFTR. British Journal of Pharmacology, 2022, 179, 1319-1337.	2.7	7
1738	The molecular evolution of function in the CFTR chloride channel. Journal of General Physiology, 2021, 153, .	0.9	10

#	Article	IF	Citations
1739	Insights of CRISPR-Cas systems in stem cells: progress in regenerative medicine. Molecular Biology Reports, 2022, 49, 657-673.	1.0	4
1740	The acid sphingomyelinase/ceramide system in COVID-19. Molecular Psychiatry, 2022, 27, 307-314.	4.1	71
1741	Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis. American Journal of Gastroenterology, 2021, 116, 2446-2454.	0.2	22
1742	Biobanking of human gut organoids for translational research. Experimental and Molecular Medicine, 2021, 53, 1451-1458.	3.2	21
1743	Targeting PDZ domains as potential treatment for viral infections, neurodegeneration and cancer. Biology Direct, 2021, 16, 15.	1.9	12
1744	The Distribution and Role of the CFTR Protein in the Intracellular Compartments. Membranes, 2021, 11, 804.	1.4	11
1745	Basic Aspects of Cystic Fibrosis. , 1990, 9, 1-28.		5
1746	Molecular analysis of the multidrug transporter. , 1994, , 33-62.		6
1747	Porosome in Cystic Fibrosis. Discoveries, 2014, 2, e24.	1.5	2
1748	Introduction of Francis S. Collins. Journal of Clinical Investigation, 2015, 125, 3321-3327.	3.9	0
1749	The Necessity for In Vivo Functional Analysis in Human Medical Genetics.. Medical Research Archives, 2015, 2, .	0.1	1
1750	REPRODUCIBLE AND SHAREABLE QUANTIFICATIONS OF PATHOGENICITY. , 2016, , .		2
1751	c.753_754delAG, a novel CFTR mutation found in a Chinese patient with cystic fibrosis: A case report and review of the literature. World Journal of Clinical Cases, 2019, 7, 2110-2119.	0.3	2
1752	Analysis of multiple gene co-expression networks to discover interactions favoring CFTR biogenesis and Î”F508-CFTR rescue. BMC Medical Genomics, 2021, 14, 258.	0.7	2
1753	Gene therapy for cystic fibrosis: new tools for precision medicine. Journal of Translational Medicine, 2021, 19, 452.	1.8	23
1754	The Interplay between the Unfolded Protein Response, Inflammation and Infection in Cystic Fibrosis. Cells, 2021, 10, 2980.	1.8	12
1755	Role of Non-Coding RNAs in Post-Transcriptional Regulation of Lung Diseases. Frontiers in Genetics, 2021, 12, 767348.	1.1	11
1756	Cystic fibrosis gene mutations and polymorphisms in Saudi men with infertility. Annals of Saudi Medicine, 2020, 40, 321-329.	0.5	2

#	Article	IF	Citations
1757	Alternative treatment for secretory diarrhea revealed in a new class of CFTR inhibitors. Journal of Clinical Investigation, 2002, 110, 1599-1601.	3.9	11
1758	The sodium/glucose cotransporters as potential therapeutic targets for CF lung diseases revealed by human lung organoid swelling assay. Molecular Therapy - Methods and Clinical Development, 2022, 24, 11-19.	1.8	10
1759	A Comprehensive Review on the Interplay between Neisseria spp. and Host Sphingolipid Metabolites. Cells, 2021, 10, 3201.	1.8	5
1760	Heme Peroxidases at Unperturbed and Inflamed Mucous Surfaces. Antioxidants, 2021, 10, 1805.	2.2	11
1761	Ivacaftor in Omani children with cystic fibrosis caused by p.Ser549Arg CFTR mutation. International Journal of Pediatrics and Adolescent Medicine, 2022, 9, 104-107.	0.5	0
1762	CFTR limits Fâ€actin formation and promotes morphological alignment with flow in human lung microvascular endothelial cells. Physiological Reports, 2021, 9, e15128.	0.7	1
1764	Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs. Journal of Cell Science, 2022, 135, .	1.2	9
1765	What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics?. Nutrients, 2022, 14, 480.	1.7	27
1766	From karyotypes to precision genomics in 9p deletion and duplication syndromes. Human Genetics and Genomics Advances, 2022, 3, 100081.	1.0	9
1767	Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	16
1768	The Role of Sphingolipid Signaling in Oxidative Lung Injury and Pathogenesis of Bronchopulmonary Dysplasia. International Journal of Molecular Sciences, 2022, 23, 1254.	1.8	12
1769	Editorial: Functional Characterization and Pharmaceutical Targets in Common and Rare CFTR Dysfunctions. Frontiers in Physiology, 2021, 12, 830285.	1.3	0
1770	Discovery of a dual-action small molecule that improves neuropathological features of Alzheimerâ€™s disease mice. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	12
1771	Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A. Cells, 2022, 11, 136.	1.8	11
1772	Clinical Phenotypes of Cystic Fibrosis Carriers. Annual Review of Medicine, 2022, 73, 563-574.	5.0	17
1773	Synthesis and bioactivity of readily hydrolysable novel cationic lipids for potential lung delivery application of mRNAs. Chemistry and Physics of Lipids, 2022, 243, 105178.	1.5	10
1774	Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 91-104.	0.4	8
1775	Congenital Bilateral Absence of the Vas Deferens. Frontiers in Genetics, 2022, 13, 775123.	1.1	8

#	Article	IF	Citations
1776	Novel CFTR modulator combinations maximise rescue of G85E and N1303K in rectal organoids. ERJ Open Research, 2022, 8, 00716-2021.	1.1	17
1777	Mucosal Immunity in Cystic Fibrosis. Journal of Immunology, 2021, 207, 2901-2912.	0.4	8
1778	Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers. Journal of Clinical Medicine, 2022, 11, 1283.	1.0	5
1779	CFTR interactome mapping using the mammalian membrane twoâ€hybrid highâ€throughput screening system. Molecular Systems Biology, 2022, 18, e10629.	3.2	13
1780	Nutrition in Cystic Fibrosisâ€”Some Notes on the Fat Recommendations. Nutrients, 2022, 14, 853.	1.7	9
1781	Administration of an Acidic Sphingomyelinase (ASMase) Inhibitor, Imipramine, Reduces Hypoglycemia-Induced Hippocampal Neuronal Death. Cells, 2022, 11, 667.	1.8	8
1782	Neutrophil dysfunction in the pathogenesis of cystic fibrosis. Blood, 2022, 139, 2622-2631.	0.6	17
1783	CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011â€“2018. ERJ Open Research, 2022, 8, 00724-2021.	1.1	18
1784	Xylitol as a Hydrophilization Moiety for a Biocatalytically Synthesized Ibuprofen Prodrug. International Journal of Molecular Sciences, 2022, 23, 2026.	1.8	7
1785	The structural basis for regulation of the glutathione transporter Ycf1 by regulatory domain phosphorylation. Nature Communications, 2022, 13, 1278.	5.8	18
1786	Structural Comparative Modeling of Multi-Domain F508del CFTR. Biomolecules, 2022, 12, 471.	1.8	10
1787	Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study. Translational Psychiatry, 2022, 12, 90.	2.4	23
1788	Comprehensive analysis of recessive carrier status using exome and genome sequencing data in 1543 Southern Chinese. Npj Genomic Medicine, 2022, 7, 23.	1.7	6
1789	SLC6A14 Impacts Cystic Fibrosis Lung Disease Severity via mTOR and Epithelial Repair Modulation. Frontiers in Molecular Biosciences, 2022, 9, 850261.	1.6	3
1790	The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis. International Journal of Molecular Sciences, 2022, 23, 3513.	1.8	23
1791	The role of microRNAs in COVID-19 with a focus on miR-200c. Journal of Circulating Biomarkers, 2022, 11, 14-23.	0.8	7
1792	Cystic fibrosis transmembrane conductance regulator prevents ischemia/reperfusion induced intestinal apoptosis via inhibiting PI3K/AKT/NF-ÎºB pathway. World Journal of Gastroenterology, 2022, 28, 918-932.	1.4	1
1793	Acid Sphingomyelinase Is a Modulator of Contextual Fear. International Journal of Molecular Sciences, 2022, 23, 3398.	1.8	1

#	Article	IF	Citations
1794	A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators. Pediatric Pulmonology, 2022, 57, 1253-1261.	1.0	13
1795	The NSAID glafenine rescues class 2 CFTR mutants via cyclooxygenase 2 inhibition of the arachidonic acid pathway. Scientific Reports, 2022, 12, 4595.	1.6	6
1796	The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs. International Journal of Molecular Sciences, 2022, 23, 3175.	1.8	19
1797	Seamless Gene Correction in the Human Cystic Fibrosis Transmembrane Conductance Regulator Locus by Vector Replacement and Vector Insertion Events. Frontiers in Genome Editing, 2022, 4, 843885.	2.7	0
1798	Safety of chronic hypertonic bicarbonate inhalation in a cigarette smoke-induced airway irritation guinea pig model. BMC Pulmonary Medicine, 2022, 22, 131.	0.8	0
1799	The Effect of Elexacaftor/Tezacaftor/Ivacaftor on Hospitalizations and Intravenous Antibiotic Use. , 2022, 26, .		5
1800	Translating in vitro CFTR rescue into small molecule correctors for cystic fibrosis using the Library of Integrated Networkâ€based Cellular Signatures drug discovery platform. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 240-251.	1.3	4
1801	Nutritional status and lung function in children with pancreatic-sufficient cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 769-776.	0.3	11
1802	The Role of Gut Microbiota and Genetic Susceptibility in the Pathogenesis of Pancreatitis. Gut and Liver, 2021, , .	1.4	6
1803	Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy. Breathe, 2021, 17, 210112.	0.6	10
1804	Revisiting CFTR Interactions: Old Partners and New Players. International Journal of Molecular Sciences, 2021, 22, 13196.	1.8	11
1805	Clinical complications in children with false-negative results in cystic fibrosis newborn screening. Jornal De Pediatria, 2022, 98, 419-424.	0.9	5
1806	Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: an unprecedented property of antimicrobial peptides. Cellular and Molecular Life Sciences, 2022, 79, 1.	2.4	4
1807	A disorder clinically resembling cystic fibrosis caused by biallelic variants in the AGR2 gene. Journal of Medical Genetics, 2022, 59, 993-1001.	1.5	5
1808	Most Short Children with Cystic Fibrosis Do Not Catch Up by Adulthood. Nutrients, 2021, 13, 4414.	1.7	8
1809	Immunoglobulin A Mucosal Immunity and Altered Respiratory Epithelium in Cystic Fibrosis. Cells, 2021, 10, 3603.	1.8	9
1810	Infection and immunity toPseudomonas. Clinical Reviews in Allergy, 1991, 9, 47-74.	1.0	12
1811	Established and novel human translational models to advance cystic fibrosis research, drug discovery, and optimize CFTR-targeting therapeutics. Current Opinion in Pharmacology, 2022, 64, 102210.	1.7	6

#	Article	IF	Citations
1812	Alterations of mucosa-attached microbiome and epithelial cell numbers in the cystic fibrosis small intestine with implications for intestinal disease. Scientific Reports, 2022, 12, 6593.	1.6	10
1814	Muc5b Contributes to Mucus Abnormality in Rat Models of Cystic Fibrosis. Frontiers in Physiology, 2022, 13, 884166.	1.3	4
1815	Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions that Promotes Disease Persistence. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 253-265.	1.4	18
1816	From genes to modules, from cells toâ€‰ecosystems. Molecular Systems Biology, 2022, 18, e10726.	3.2	4
1817	Diet quality in cystic fibrosis â€“ associations with patient reported outcome measures and enablers and barriers to eating a healthy diet: A protocol paper for a mixed methods study. HRB Open Research, 0, 5, 33.	0.3	1
1818	Exploring YAP1-centered networks linking dysfunctional CFTR to epithelialâ€“mesenchymal transition. Life Science Alliance, 2022, 5, e202101326.	1.3	6
1819	Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs. Molecular Therapy - Nucleic Acids, 2022, 28, 685-701.	2.3	29
1820	The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis. Orphanet Journal of Rare Diseases, 2022, 17, 188.	1.2	24
1821	Translational Research in Cystic Fibrosis: From Bench to Beside. Frontiers in Pediatrics, 2022, 10, .	0.9	3
1822	Nanomechanics combined with HDX reveals allosteric drug binding sites of CFTR NBD1. Computational and Structural Biotechnology Journal, 2022, 20, 2587-2599.	1.9	1
1823	Treatment With LAU-7b Complements CFTR Modulator Therapy by Improving Lung Physiology and Normalizing Lipid Imbalance Associated With CF Lung Disease. Frontiers in Pharmacology, 0, 13, .	1.6	0
1824	Increased sputum lactate during oral glucose tolerance test in cystic fibrosis. Apmis, 0, , .	0.9	1
1825	Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score. Frontiers in Pharmacology, 0, 13, .	1.6	33
1826	The Impact of Air Pollution on the Course of Cystic Fibrosis: A Review. Frontiers in Physiology, 2022, 13, .	1.3	3
1827	The human ATPâ€binding cassette (ABC) transporter superfamily. Human Mutation, 2022, 43, 1162-1182.	1.1	45
1828	Prevalence and Characteristics of Cystic Fibrosis in Omani Children over Two Decades: A Multi-center Cross-sectional Study. Oman Medical Journal, 0, , .	0.3	0
1829	Recombinant Adeno-Associated Virus-Mediated Editing of the G551D Cystic Fibrosis Transmembrane Conductance Regulator Mutation in Ferret Airway Basal Cells. Human Gene Therapy, 2022, 33, 1023-1036.	1.4	8
1830	Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists. Health Science Reports, 2022, 5, .	0.6	1

#	Article	IF	Citations
1831	Molecular mechanisms of cystic fibrosis â€“ how mutations lead to misfunction and guide therapy. Bioscience Reports, 2022, 42, .	1.1	9
1832	Acid sphingomyelinase/ceramide system in schizophrenia: implications for therapeutic intervention as a potential novel target. Translational Psychiatry, 2022, 12, .	2.4	8
1833	Pharmacological Responses of the G542X-CFTR to CFTR Modulators. Frontiers in Molecular Biosciences, 0, 9, .	1.6	1
1834	Involvement of Ceramide Signalling in Radiation-Induced Tumour Vascular Effects and Vascular-Targeted Therapy. International Journal of Molecular Sciences, 2022, 23, 6671.	1.8	11
1835	Analysis of the genotypic profile and its relationship with the clinical manifestations in people with cystic fibrosis: study from a rare disease registry. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	5
1836	CF Patientsâ€™ Airway Epithelium and Sex Contribute to Biosynthesis Defects of Pro-Resolving Lipids. Frontiers in Immunology, 0, 13, .	2.2	6
1837	One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies. Cells, 2022, 11, 1868.	1.8	12
1838	The Use of Artificial Sputum Media to Enhance Investigation and Subsequent Treatment of Cystic Fibrosis Bacterial Infections. Microorganisms, 2022, 10, 1269.	1.6	10
1839	Bilateral Pseudomonas aeruginosa keratitis as presenting feature in an infant of cystic fibrosis. Indian Journal of Ophthalmology, 2022, 70, 2641.	0.5	0
1840	A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1239-1247.	2.5	13
1841	The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR Modulation: A Mini Review. Frontiers in Pediatrics, 0, 10, .	0.9	13
1842	Role of Caveolin-1 in Sepsis â€“ A Mini-Review. Frontiers in Immunology, 0, 13, .	2.2	4
1843	A Splice Switch in SIGIRR Causes a Defect of IL-37-Dependent Anti-Inflammatory Activity in Cystic Fibrosis Airway Epithelial Cells. International Journal of Molecular Sciences, 2022, 23, 7748.	1.8	1
1844	Auxological and Endocrinological Features in Children and Adolescents with Cystic Fibrosis. Journal of Clinical Medicine, 2022, 11, 4041.	1.0	2
1845	Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1361-1369.	2.5	50
1846	Inimitable Impacts of Ceramides on Lipid Rafts Formed in Artificial and Natural Cell Membranes. Membranes, 2022, 12, 727.	1.4	13
1847	Going the Extra Mile: Why Clinical Research in Cystic Fibrosis Must Include Children. Children, 2022, 9, 1080.	0.6	3
1848	A multimodal iPSC platform for cystic fibrosis drug testing. Nature Communications, 2022, 13, .	5.8	12

#	Article	IF	Citations
1849	Congenital etiologies of exocrine pancreatic insufficiency. Frontiers in Pediatrics, 0, 10, .	0.9	4
1850	PHLPP1 regulates CFTR activity and lumen expansion through AMPK. Development (Cambridge), 2022, 149, .	1.2	1
1851	Antibiotherapy in Children with Cystic Fibrosisâ€"An Extensive Review. Children, 2022, 9, 1258.	0.6	5
1852	Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia. Life Science Alliance, 2022, 5, e202101320.	1.3	18
1853	Differential CFTR-Interactome Proximity Labeling Procedures Identify Enrichment in Multiple SLC Transporters. International Journal of Molecular Sciences, 2022, 23, 8937.	1.8	6
1854	Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis. Journal of Personalized Medicine, 2022, 12, 1321.	1.1	15
1855	Combined Treatment of Bronchial Epithelial Calu-3 Cells with Peptide Nucleic Acids Targeting miR-145-5p and miR-101-3p: Synergistic Enhancement of the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene. International Journal of Molecular Sciences, 2022, 23, 9348.	1.8	8
1856	ATP-Binding Cassette Transporters: Snap-on Complexes?. Sub-Cellular Biochemistry, 2022, , 35-82.	1.0	1
1857	Multicenter Surveillance of Cystic Fibrosis in Korean Children. Allergy, Asthma and Immunology Research, 2022, 14, 494.	1.1	2
1858	Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 817-825.	0.6	5
1859	Mechano-Sensing Channel PIEZO2 Enhances Invasive Phenotype in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 9909.	1.8	8
1860	Stress induces major depressive disorder by a neutral sphingomyelinase 2-mediated accumulation of ceramide-enriched exosomes in the blood plasma. Journal of Molecular Medicine, 2022, 100, 1493-1508.	1.7	10
1861	Ultrastructural Characterization of Human Bronchial Epithelial Cells during SARS-CoV-2 Infection: Morphological Comparison of Wild-Type and CFTR-Modified Cells. International Journal of Molecular Sciences, 2022, 23, 9724.	1.8	3
1862	Pregnancy Outcomes of Non-Visualization of the Fetal Gallbladder from a Chinese Tertiary Single Centre and Literature Review. Children, 2022, 9, 1288.	0.6	0
1863	How sphingolipids affect T cells in the resolution of inflammation. Frontiers in Pharmacology, 0, 13, .	1.6	6
1864	Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia. International Journal of Molecular Sciences, 2022, 23, 11396.	1.8	5
1865	Integrated Analysis of Gut Microbiome and Lipid Metabolism in Mice Infected with Carbapenem-Resistant Enterobacteriaceae. Metabolites, 2022, 12, 892.	1.3	0
1866	Single-Cell RNA Sequencing Reveals New Basic and Translational Insights in the Cystic Fibrosis Lung. American Journal of Respiratory Cell and Molecular Biology, 2023, 68, 131-139.	1.4	3

#	Article	IF	Citations
1867	Molecular structures reveal synergistic rescue of Î”508 CFTR by Trikafta modulators. Science, 2022, 378, 284-290.	6.0	65
1868	Cftr deletion in mouse epithelial and immune cells differentially influence the intestinal microbiota. Communications Biology, 2022, 5, .	2.0	3
1870	Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis. Journal of Cystic Fibrosis, 2023, 22, 266-274.	0.3	16
1871	Neuronal Ganglioside and Glycosphingolipid (GSL) Metabolism and Disease. Advances in Neurobiology, 2023, , 333-390.	1.3	6
1872	Gene therapy for cystic fibrosis: Challenges and prospects. Frontiers in Pharmacology, 0, 13, .	1.6	12
1873	Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies. Saudi Pharmaceutical Journal, 2022, 30, 1736-1747.	1.2	2
1874	Drug Repurposing for Cystic Fibrosis: Identification of Drugs That Induce CFTR-Independent Fluid Secretion in Nasal Organoids. International Journal of Molecular Sciences, 2022, 23, 12657.	1.8	6
1875	High-quality read-based phasing of cystic fibrosis cohort informs genetic understanding of disease modification. Human Genetics and Genomics Advances, 2023, 4, 100156.	1.0	0
1876	Clinical characteristics and outcomes of incident cases of COVID-19 in unvaccinated adult cystic fibrosis patients in southern Brazil: a prospective cohort study conducted during the first year of the COVID-19 pandemic. Jornal Brasileiro De Pneumologia, 0, , e20220265.	0.4	1
1877	Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes. International Journal of Molecular Sciences, 2022, 23, 14205.	1.8	7
1878	Essential Fatty Acid Deficiency in Cystic Fibrosis Disease Progression: Role of Genotype and Sex. Nutrients, 2022, 14, 4666.	1.7	2
1879	Congenital absence of the vas deferens with hypospadias or without hypospadias: Phenotypic findings and genetic considerations. Frontiers in Genetics, 0, 13, .	1.1	0
1880	Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage. Frontiers in Immunology, 0, 13, .	2.2	3
1881	The pan-genome of Aspergillus fumigatus provides a high-resolution view of its population structure revealing high levels of lineage-specific diversity driven by recombination. PLoS Biology, 2022, 20, e3001890.	2.6	21
1882	Association between phenotypic and genotypic characteristics and disease severity in individuals with cystic fibrosis. Revista Paulista De Pediatria, 0, 41, .	0.4	0
1883	Evaluation of the quality of life and associated factors of a group of children and adolescents with cystic fibrosis in the northern region of Portugal: a cross-sectional pilot study. Porto Biomedical Journal, 2022, 7, e194.	0.4	0
1884	Obstructive sleep apnea and nocturnal hypoxemia in adult patients with cystic fibrosis. BMC Pulmonary Medicine, 2022, 22, .	0.8	2
1885	New TMA (4,6,4â€²-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease. International Journal of Molecular Sciences, 2022, 23, 14483.	1.8	1

#	Article	IF	Citations
1886	Patient-derived cell models for personalized medicine approaches in cystic fibrosis. Journal of Cystic Fibrosis, 2023, 22, S32-S38.	0.3	7
1887	Translational Bioinformatics for Human Reproductive Biology Research: Examples, Opportunities and Challenges for a Future Reproductive Medicine. International Journal of Molecular Sciences, 2023, 24, 4.	1.8	3
1888	Cystic fibrosis rabbits develop spontaneous hepatobiliary lesions and CF-associated liver disease (CFLD)-like phenotypes. , 2023, 2, .		1
1889	Alteration in glucocorticoids secretion and metabolism in patients affected by cystic fibrosis. Frontiers in Endocrinology, 0, 13, .	1.5	2
1890	Zinc Laurate Protects against Intestinal Barrier Dysfunction and Inflammation Induced by ETEC in a Mice Model. Nutrients, 2023, 15, 54.	1.7	2
1891	Gut Dysbiosis in Children with Cystic Fibrosis: Development, Features and the Role of Gutâ€“Lung Axis on Disease Progression. Microorganisms, 2023, 11, 9.	1.6	2
1892	Effects of Exercise Training on Peripheral Muscle Strength in Children and Adolescents with Cystic Fibrosis: A Meta-Analysis. Healthcare (Switzerland), 2022, 10, 2520.	1.0	0
1893	Additive Potentiation of R334W-CFTR Function by Novel Small Molecules. Journal of Personalized Medicine, 2023, 13, 102.	1.1	4
1894	Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics. Cells, 2023, 12, 199.	1.8	35
1895	The COPD-Associated Polymorphism Impairs the CFTR Function to Suppress Excessive IL-8 Production upon Environmental Pathogen Exposure. International Journal of Molecular Sciences, 2023, 24, 2305.	1.8	1
1896	Menthone Exerts its Antimicrobial Activity Against Methicillin Resistant Staphylococcus aureus by Affecting Cell Membrane Properties and Lipid Profile. Drug Design, Development and Therapy, 0, Volume 17, 219-236.	2.0	4
1897	The STING/TBK1/IRF3/IFN type I pathway is defective in cystic fibrosis. Frontiers in Immunology, 0, 14, .	2.2	0
1898	Lower Expression of CFTR Is Associated with Higher Mortality in a Meta-Analysis of Individuals with Colorectal Cancer. Cancers, 2023, 15, 989.	1.7	1
1899	Changes in Essential Fatty Acids and Ileal Genes Associated with Metabolizing Enzymes and Fatty Acid Transporters in Rodent Models of Cystic Fibrosis. International Journal of Molecular Sciences, 2023, 24, 7194.	1.8	0
1900	Immunosuppression reduces rAAV2.5T neutralizing antibodies that limit efficacy following repeat dosing to ferret lungs. Molecular Therapy - Methods and Clinical Development, 2023, 29, 70-80.	1.8	5
1901	Optimization of CFTR gating through the evolution of its extracellular loops. Journal of General Physiology, 2023, 155, .	0.9	3
1903	Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease. Genes, 2023, 14, 449.	1.0	7
1904	Pregnancy in Cystic Fibrosisâ€”Past, Present, and Future. Journal of Clinical Medicine, 2023, 12, 1468.	1.0	1

#	Article	IF	Citations
1905	In Utero Mapping and Development Role of CFTR in Lung and Gastrointestinal Tract of Cystic Fibrosis Patients. ACS Pharmacology and Translational Science, 2023, 6, 355-360.	2.5	2
1906	Impact of extracellular vesicles on the pathogenesis, diagnosis, and potential therapy in cardiopulmonary disease. Frontiers in Pharmacology, 0, 14, .	1.6	1
1907	Modeling of Respiratory Diseases Evolving with Fibrosis from Organoids Derived from Human Pluripotent Stem Cells. International Journal of Molecular Sciences, 2023, 24, 4413.	1.8	0
1908	Cystic Fibrosis Bone Disease: The Interplay between CFTR Dysfunction and Chronic Inflammation. Biomolecules, 2023, 13, 425.	1.8	2
1909	Stenotrophomonas maltophilia pneumonia in critical COVID-19 patients. Scientific Reports, 2023, 13, .	1.6	7
1910	Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators. International Journal of Molecular Sciences, 2023, 24, 5010.	1.8	5
1911	Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals, 2023, 16, 410.	1.7	17
1912	Personalized medicine: Function of CFTR variant p.Arg334Trp is rescued by currently available CFTR modulators. Frontiers in Molecular Biosciences, 0, 10, .	1.6	1
1913	Drug Hypersensitivity Reactions in Patients with Cystic Fibrosis: Potential Value of the Lymphocyte Toxicity Assay to Assess Risk. Molecular Diagnosis and Therapy, 2023, 27, 395-403.	1.6	1
1914	CFTR function, pathology and pharmacology at single-molecule resolution. Nature, 2023, 616, 606-614.	13.7	17
1915	Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients. European Respiratory Journal, 2023, 61, 2202009.	3.1	0
1916	Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy. Archives of Gynecology and Obstetrics, 2024, 309, 9-15.	0.8	1
1917	Experiences and perceptions of receiving and prescribing rehabilitation in adults with cystic fibrosis undergoing lung transplantation. Chronic Respiratory Disease, 2023, 20, 147997312211392.	1.0	0
1918	Cystic Fibrosis Screen Positive, Inconclusive Diagnosis Genotypes in the Cystic Fibrosis Registry. Annals of the American Thoracic Society, 2023, 20, 512-513.	1.5	0
1919	Quorum-Sensing Signaling Molecule 2-Aminoacetophenone Mediates the Persistence of Pseudomonas aeruginosa in Macrophages by Interference with Autophagy through Epigenetic Regulation of Lipid Biosynthesis. MBio, 2023, 14, .	1.8	4
1920	Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nature Biotechnology, 2023, 41, 1410-1415.	9.4	54
1921	The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2023, 324, L756-L770.	1.3	4
1922	Sphingolipids in thyroid eye disease. Frontiers in Endocrinology, 0, 14, .	1.5	1

#	Article	IF	Citations
1925	New Therapeutic Options in Pulmonal Diseases: Sphingolipids and Modulation of Sphingolipid Metabolism. Handbook of Experimental Pharmacology, 2023, , .	0.9	0